**CURRICULUM VITAE**

**RICHARD T. SILVER, M.D.**

**Office Addresses**

Weill Cornell Medicine

520 East 70th Street, 3rd Floor

New York, NY 10021

Telephone: (646) 962-2700

**Education**

Cornell University Medical College, M.D., 1953

Cornell University, A.B., 1950

**Medical Training**

Resident in Medicine (Hematology), The New York Hospital‑Cornell Medical Center, 1957‑1958

Assistant Resident in Medicine, The New York‑Cornell Medical Center, 1956‑1957

Clinical Associate, General Medicine Branch, National Cancer Institute, National Institutes of Health, 1954‑1956

Intern in Medicine, The New York Hospital‑Cornell Medical Center, 1953‑1954

**Academic Appointments**

Clinical Advisor, Laboratory of Biomedical Engineering, Cornell College of Engineering, Cornell University, 2010

Professor of Medicine, Cornell University Medical College, 2002-present

Clinical Professor of Medicine, Cornell University Medical College, 1973-2002

Associate Clinical Professor of Medicine, Cornell University Medical College, 1967‑1973

Assistant Clinical Professor of Medicine, Cornell University Medical College, 1962‑1967

Instructor in Medicine, Cornell University Medical College, 1958‑1962

Visiting Fulbright Lecturer, University of Bahia School of Medicine, Bahia, Brazil,1958‑1959

Assistant in Medicine, Cornell University Medical College, 1956‑1958

**Hospital Appointments**

Director, Leukemia and Myeloproliferative Center, New York Presbyterian Hospital, 2002‑present

Attending Physician, New York Presbyterian Hospital, 1973‑present

Associate Attending Physician, New York Presbyterian Hospital, 1967‑1973

Assistant Attending Physician, New York Presbyterian Hospital, 1964‑1967

Assistant Visiting Physician 2nd (Cornell) Med. Div., Bellevue Hospital 1963‑1966

Physician to Outpatients, New York Presbyterian Hospital, 1958‑1964

**Board Certification**

Diplomate, Medical Oncology, American Board of Internal Medicine, 1973

Fellow, American College of Physicians, 1965

Diplomate, American Board of Internal Medicine, 1962

Licensure, New York State, 1954

Diplomate, National Board of Medical Examiners, 1953

**Awards and Honors**

European Leukemia Net Merit Award, XVI European Leukemia Net Symposium, Mannheim, Germany. February 2019

Levine Cancer Institute Outstanding Achievement Award, 4th Annual Levine Cancer Institute Hematology Symposium, Charlotte, NC. October 2018

Myeloproliferative Neoplasms (MPN) Heroes Award, 56th American Society of Hematology Meeting and Exposition, San Francisco, California. December 2014

Dedication, Richard T. Silver, M.D. Myeloproliferative Neoplasm Center at Weill Cornell Medical College, New York, New York, Weill Cornell Medical College, February 2014

Lifetime Achievement Award in the field of Hematology, Israel Society of Hematology and Blood Transfusion and the University of Texas MD Anderson Cancer Center, September 2013

Lifetime Achievement Award, The SASS Foundation for Medical Research, Inc., 2012

The Weill Cornell Medical College Alumni Association Special Achievement Award, 2012

Lifetime of Academic Achievement, Dedication and Service to Weill Cornell Medical College (WCMC), 2011

Distinguished Emeritus member, American Society of Hematology, 2010

Lifetime achievement award for pioneering work in clinical hematology and as Founder and Medical Director of the Cancer Research & Treatment Fund (CR&T), 2008

Timothy Gee Award for Outstanding Clinician, Teacher, Mentor, Humanist presented by Sass & Strauss Foundation, May 19, 2001

Richard T. Silver Distinguished Professorship in Hematology & Medical Oncology at Weill Medical College of Cornell University, 2001

Pasmantier Award of the New York Cancer Society and Fund for Blood and Cancer Research for Outstanding Accomplishment and Distinguished Service to Clinical Medicine and Medical Oncology, June 1999

Richard T. Silver Distinguished Visiting Professorship,1998

New York State Society of Medical Oncologists and Hematologists Award of Appreciation for Service as President 1991-2000

Cornell University Medical College Award of Appreciation, 1976

Big Pi Award for Outstanding Civic Achievement, 1975

Visiting Fulbright Lecturer, University of Bahia School of Medicine, Brazil, 1958‑1959

New York State Scholarship for Professional Study of Medicine, 1950-1953

**Lifetime**

**Special Appointments and Assignments**

**The New York Presbyterian Hospital-Weill Cornell Medical Center**

Departmental of Medicine Activities

Fellow Selection Committee, Division of Hematology, 2004-present

Intern Selection Committee, Department of Medicine, 2000-2005

Member, Committee on Computerized Laboratory Medicine, 1981-1983

Advisory Committee for Selection of Departmental Chairman, 1981

Member, Dean's Committee on Oncology Education, 1979-1983

Member, Admissions Review Committee, 1966-67; 1979-1981

Coordinator, Clinicopathological Conference, 1963-1973

Divisional Activities (Hematology-Oncology)

Director, Leukemia and Myeloproliferative Center, 2002- present

Chairperson, Hematology-Oncology Tumor Board, 1990-1993

Director, Section of Clinical Oncology Chemotherapy Research, 1983- present

Program Director, Oncology Training Program, 1973-1983

Principal Investigator, Clin. Chemotherapy Program in Cancer Control, 1973-1980

Chief, Oncology Service, Div. of Hematology-Oncology, 1976-83

Principal Investigator, Cancer and Leukemia Group B, 1965-1997

Director, Chemotherapy Service, Div. of Hematology-Oncology, 1964-1976

**Cornell University**

Life Member Cornell University Council, 2003-present

Council Committee on Student and Academic Services, 1995-present

The President's Circle, 1993 to present

Member, Cornell University Council, 1987-1992; 1993-present

Alumni Trustee Nominating Committee, 1983-1988

The Tower Club, 1980-present; Caduceus Society, 1980-present

Vice President, Cornell University Alumni Association, 1980

**Cornell University Medical College**

Clinical Advisor, College of Biomedical Engineering, Cornell University, 2010

Senior Advisor, Cornell Medical College Alumni Association, 1976-present

Trustee, Cornell Medical College Alumni Council, 1976-1980

President, Cornell Medical College Alumni Association, 1973-1976

Vice-President, Cornell Medical College Alumni Association, 1972-1973

Editor, Cornell Medical College Alumni Quarterly, 1962-1969

Associate Editor, Cornell Medical College Alumni Quarterly, 1960-1962

**National Institutes of Health, National Cancer Institute**

Review Board Memberships

External Site Review, Cancer Therapy Evaluation Section, June, (MD Anderson), 2003

Consultant, Cancer Chemotherapy Investigative Review Board (Site Visit to Southwest Oncology Group) 1980

Member, Clinical Trials Committee, 1979‑1981

Member, Combined Modality Committee of the Division of Cancer Treatment, 1977‑1979

Special Site Visitor, Medicine A, Roswell Park Memorial Institute, July, 1976

**Polycythemia Vera National Study Group**

Member, Polycythemia Vera National Study Group, 1967‑1979

Co‑Chairman, Morphology Committee, Polycythemia Vera National Study Group, 1967‑1979

**Cancer and Leukemia Group B**

Chairman, Nominating Committee, 1991

Member, Committee on Community Cancer Centers, 1991

Member, Membership Committee, 1985‑1989

Group Vice Chairman, 1976‑1981

Member, Executive Committee, 1976‑1985

Chairman, Publications Committee, 1976‑1981

Chairman, Chronic Leukemia Committee, 1965‑1976

Principle Investigator, NYH‑Cornell, 1963‑1997

Member, 1957 to present

**International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes Chair and Convener, 2001- present**

Congress 1, New York, October 2001

Congress 2, New York, October 2003

Congress 3, Washington, DC, November, 2005

Congress 4, New York, November, 2007

Congress 5, New York, November, 2009

Congress 6, New York, November, 2011

Congress 7, New York, November, 2013

Congress 8, New York, November, 2015

Congress 9, New York, November, 2016

Congress 10, New York, November, 2017

**American Society of Clinical Oncology**

Member, Committee on Public Affairs, 1981‑1983

Chairman, Program Committee, 1977

Member, Committee on Clinical Practice, 1976

**American Society of Hematology**

Emeritus status, 2009.

Session Chairman, Myeloproliferative Diseases, Annual Meeting, 2006

Meet-the-Expert Session, Polycythemia Vera, Annual Meeting, 2006.

Development Committee, 2002 - 2006

**International Society of Hematology**

Invited Chair and Speaker: “XVII Meeting of the International Society of Haematology – European and African Division”, Graz, Austria, September, 2003

Invited Chair and Speaker: Current Concepts and Treatment of the Myeloproliferative Diseases, Seoul, Korea, 2002

Invited Chair and Speaker: Treatment of the Myeloproliferative Disease, Durban South Africa, 1999

Invited Lecturer, "Thrombocytosis Refractory to Hydroxyurea in Chronic Myeloid Leukemia (CML) Responds to Anagrelide," London, England, August, 1992

Invited Lecturer, "Chronic Leukemia," "Refractory Anemias," XX Congress, Buenos Aires, 1984

Member, International Advisory Committee, XX Congress, Buenos Aires, 1984

Invited Lecturer, "Agnogenic Myeloid Metaplasia," XVIII Congress, Montreal, 1980

Chairman, Bone Marrow Biopsy Workshop, XV Congress, Jerusalem, 1974

**New York State Society of Medical Oncologists and Hematologists**

Cancer Advisory Committee, American Society of Hematology, 1997-2001

Special Advisory Policy Committee for Medical Oncology Issues, Empire Blue Cross/Blue Shield, 1993-1996

Cancer Advisory Committee, Medicare, New York State, 1993-1998

President, 1991 ‑ 2000

Member, Executive Committee, 1991‑present

**European LeukemiaNet**

Principal Representative, Weill Cornell Medical College, 2012-present

Member, Guidelines Committee for Chronic Myeloid Leukemia, Appointed July 1, 2004–Present

**International Working Group (IWG) for Myelofibrosis Research and Treatment (MRT)**

Member, 2006 – present

International Myeloproliferative Disease Research Consortium (NIH), 2001-present

Founding Member

Principal Investigator for Weill Cornell Medical Center

**Chronic Myeloid Leukemia (CML) Life after stopping Tyrosine Kinase Inhibitors (LAST) Study Group**

Member, 2014 – present

**PUBLICATIONS**

**Books**

1. Silver RT: Morphology of the blood and marrow in clinical practice. Grune and Stratton, Inc., New York, NY, 1970.
2. Silver RT, Lauper RD, Jarowski CI: A synopsis of cancer chemotherapy. Dun-Donnelley Publishing Corp., New York, 1977.
3. Silver RT, Editor: Clinical Topics in Cancer: Diagnosis and Treatment, LeJacq Publishing Co., 1982.
4. Silver RT and Tefferi A. Myeloproliferative Disorders. Silver RT and Tefferi A (eds). Informa Healthcare, New York, 2007.
5. Silver RT: Polycythemia vera and other polycythemia syndromes. In: Ansell SM (ed): Rare Hematological Malignancies. Springer Science and Business Media LLC, 2008

**Chapters**

1. Cortes JE, Silver RT, and Kantarjian H: Chronic Leukemia – 30: Leukemia Central Desktop, CMHG Author, July 18, 2011.
2. Cortes JE, Silver RT, and Kantarjian H: Chronic myeloid leukemia. In: Cancer Management: A Multidisciplinary Approach. 2009. pp.1-16. 11th Edition.
3. Silver RT: The Blast Phase of Chronic Myeloid Leukemia. In: Best Pract Res Clin Hematol. 2009.
4. Silver RT. Polycythemia vera and other polycythemia syndromes. In: Rare Hematological Malignancies. Ansell SM (ed)Springer Science and Business Media LLC, 2008, Chapter 1, pp. 1-27
5. Sirhan S, Silver RT. Management of Polycythemia Vera. In: Myeloproliferative Disorders. Silver RT and Tefferi A (eds). Informa Healthcare, New York, 2007, p. 87.
6. Silver RT and Tefferi A. Biology and Management. In: Myeloproliferative Disorders. Silver RT and Tefferi (eds). Informa Healthcare, New York, 2007.
7. Cortes J, Silver RT, Kantarjian H: Chronic Myeloid Leukemia. In: Cancer Medicine 7 (eds) Holland-Frei; Kufe D, Pollock R, Weichselbaum R, Bast R; BC Decker Inc. Hamilton, London, Chapter 114, pp. 1761-1771.
8. Cortes J, Silver RT, Kantarjian H: Chronic Myelogenous Leukemia. Cancer Management: A Multidisciplinary Approach, 10th edition, Pazdur R, Coia L, Hoskins WJ, and Wagman LD (Eds), CMP Healthcare Media, 2007 – 2008, pp. 789-804.
9. Silver RT: Clinical Features and Making the Diagnosis. Chronic Myeloproliferative Diseases in Clinical Malignant Hematology, Sekeres M, Kalaycio ME, Bolwell BJ (Eds), McGraw Hill, 2007, pp 461-467.
10. Cortes JE, Silver RT, and Kanarjian H: Chronic Myelogenous Leukemia. Cancer Management: A Multidisciplinary Approach. 10th edition, Pazdur R, Coia L, Hoskins WJ, and Wagman LD (Eds), CMP United Business Media, New York, 2006, Chapter 33, Section 34 pp. 1-11.
11. Cortes J, Silver RT, Kantarjian H: Chronic Myeloid Leukemia. Holland-Frei Cancer Medicinee.7, D. Kufe, R. Pollock, R. Weichselbaum, R. Bast, Jr., J. Holland and E. Frei, III (Eds), Chapter 114, pp. 1761-1771, BC Decker Inc., Hamilton, London, 2006.
12. Cortes JE, Silver RT, and Kanarjian H: Chronic Myelogenous Leukemia. Cancer Management: A Multidisciplinary Approach, 9th edition, Pazdur R, Coia L, Hoskins WJ, and Wagman LD (Eds), CMP United Business Media, New York, NY, pp. 797-810, 2005.
13. Silver RT: Chronic Myeloid Leukemia, Holland-Frei Cancer Medicinee.6, edited by: D. Kufe, R. Pollock, R. Weichselbaum, R. Bast, Jr., J. Holland and E. Frei, III, BC Decker Inc., Hamilton, London, 2003, pp. 2117.
14. Silver RT, Frei E: Chronic Myeloid Leukemia, Clinical Practice of Hematology and Oncology. B. Furie, P. Cassileth, M. Atkins, RJ. Mayer (Eds). W.B. Saunders Co., Philadelphia, PA, 2003, pp. 671.
15. Silver RT: Chronic Myeloid Leukemia. Cancer Management: A Multidisciplinary Approach handbook, 6th edition, Jorge E. Cortes, Hagop Kantarjian (Eds), PPR, Inc., 2002, pp. 709-720
16. Silver RT: Evidence-based guidelines for the treatment of chronic-phase chronic myeloid leukemia. Chronic Myeloid Leukemia, Carello, Daley, Eaves, Goldman & Hellmann (Eds), Martin Dunitz Ltd., 2001, pp. 225-237
17. Carella AM, Daley GQ, Siler, RT, Goldman JM, Hehlmann R: Chronic Myeloid Leukemia-Biology and Treatment. Martin Dunitz Ltd., UK, 2001, pp. 225-237.
18. Silver RT: Polycythemia. Saunders Manual of Medical Practice, Edition 2. Ed. R. E. Rakel (Eds), W. B. Saunders Co., 2000, pp. 797-799.
19. Silver RT: Chronic myeloid leukemia. Conn’s Current Therapy, 1999 Edition. Robert E. Rakel (Ed), W.B. Saunders Co., 1999, pp.426-428.
20. Silver RT: Chronic Myeloid Leukemia: Practice Guidelines. Trends in Onco-Hematology, Volume 6, 60, December 1998. Selected reports from the 40th annual meeting of Miami, USA.
21. Lichtin AE, Woolf SH, Silver RT, Hehlmann R. Chronic Myeloid Leukemia—ASH Practice Guideline and Beyond. American Society of Hematology Education Program Book,1998, pp. 433-453.
22. Silver RT: Polycythemia Vera and Other Polycythemia Syndromes. Current Diagnosis, 9th Edition; W.B. Saunders Co., 1997. pp. 505-509.
23. Silver RT: Chronic myeloid leukemia. Cancer Medicine, 4th edition, Holland, Bast Morton, et al (Eds), Williams & Wilkins, 1997, pp. 2651-2661.
24. Silver RT: The Myeloproliferative Disorders and their Treatment with interferon Alfa. Molecular Biology of Hematopoiesis, 1996, pp.571-576.
25. Talpaz M. Giles F, Goldman JM, Silver RT, Tura S: Current perspective on the management of chronic myelogenous leukemia. Monograph, (Proceedings of a Consensus Roundtable, 9/23/95, Washington, D.C.), Publishers, Scienta Healthcare Education, Sept. 1996.
26. Silver RT: The anemia of malignancy; issues and treatment. Monograph, Publishers, Ortho Biotech, June, 1995.
27. Silver RT: Polycythemia Vera. In: Conn's Current Therapy, R.E. Rakel (Ed), W.B. Saunders Company, 1995, pp. 387-389.
28. Silver RT (Guest Editor): New approaches to the treatment of cancer-related anemia. Monograph, Seminars in Oncology, 21(2)suppl.3:April, 1994.
29. Silver RT: Chronic myeloid leukemia. In: Conn's Current Therapy, R.E. Rakel (Ed), W.B. Saunders Company, 1994, pp. 404-407.
30. Silver RT: Chronic myeloid leukemia. In: Cancer Medicine, Third Edition, John Spahr, Jr. (Ed), Lea & Febiger, 1993, pp. 1934 1942.
31. Silver RT: Agnogenic myeloid metaplasia. In: Current Diagnosis, Rex Conn (Ed), W.B. Saunders Co, 1991, pp. 581 583.
32. Stenzel KH, Wang J, Walle A, Suthanthiran M, Silver RT, Novogrodsky A: Adoptive immunotherapy for renal adenocarcinoma: Use of oxidizing mitogen treated mononuclear leukocytes and continuous infusion of interleukin 2. In: Progress in Regional Cancer Therapy, R. Jakesz/H. Rainer (Eds), Springer Verlag, Berlin Heidelberg, 1990, pp. 304 309.
33. Silver RT: The chronic leukemias. In: Conn Current Therapy, R.E. Rakel (Ed), W.B. Saunders Company, 1986, pp. 330 336.
34. Silver RT, Lauper RD, Jarowski CI: A Synopsis of Cancer Chemotherapy. Yorke Medical Books, 2nd edition, 1986.
35. Silver RT: Leukemoid reactions, pp. 917; myeloproliferative disorders, pp. 943; Agnogenic myeloid metaplasia. In: Cecil, Textbook of Medicine, J.D. Wyngaarden, L.H. Smith (Eds), W.B. Saunders Co., Philadelphia, 1982.
36. Silver RT, Lauper RD, Jarowski CI: Compendium of antineoplastic agents. In: Cornell Medical Update, L.A. Wallis (Ed), Yorke Medical Books, Dun-Donnelley Publishing Corp., 1978, pp. 99-135.
37. Silver RT, Lauper RD, Jarowski CI: Recent advances in cancer chemotherapy. In: Cornell Medical Update, L.A. Wallis (Ed), Yorke Medical Books, Dun-Donnelley Publishing Corp., 1978, pp. 90-98.
38. Pasmantier MW, Coleman M, Silver RT, Birnbaum SJ: Endometrial cervical and vulva cancer. In: Randomized Trials in Cancer: A Critical Review by Sites, M.J. Staquet (Ed), Raven Press, 1978.
39. Silver RT: The chronic leukemias. In: Current Therapy, H.F. Conn (Ed), W.B. Saunders Co., 1976, pp. 311-316.
40. Silver RT: Treatment of the chronic leukemias. In: Clinical Cancer Chemotherapy, E.M. Greenspan (Ed), Raven Press, New York, 1975.
41. Silver RT: Chronic lymphocytic leukemia: Proposed guidelines for protocol studies. In: Cancer Therapy: Prognostic Factors and Criteria of Response. M.J. Staquet, Raven Press, New York, 1975.
42. Silver RT: Myeloproliferative disorders. In: Textbook of Medicine, Beeson and McDermott (Eds), W.B. Saunders Co., Philadelphia, 1975, pp. 1497-98.
43. Silver RT: Leukemoid reactions. In: Textbook of medicine, Beeson and McDermott (Eds), W.B. Saunders Co., Philadelphia, 1975, pp. 1484-85.
44. Coleman M, Silver RT: Chemotherapy of plasma cell myeloma and related disorders. In: antibiotics and Chemotherapy, H.S. Grenzach, R.W. Brockman, F.E. Hahn (Eds), Basel W, Karger S: Vol. 18, Chapt. 4, 1973, pp. 103-106.
45. Silver RT: Polycythemia. In: Difficult Problems in Internal Medicine, J.E. Barondess (Ed), Williams and Wilkins Press, 1971, pp. 442.

**Articles**

1. RICHARD T. SILVER and Spencer Krichevsky. Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera: limitations
2. of erythrocyte values. Haematologica 2019;104.
3. Silver RT. Abstracted Remarks made at the fellows Graduation at Brooklyn Methodist Hospital, Division of Hematology and Medical Oncology. Ascensus Journal of Humanities – Weill Cornell Medicine. August 2018; (7)130
4. Atallah E, Schiffer CA, Weinfurt KP, Zhang MJ, Radich JP, Oehler VG, Pinilla-Ibarz J, Deininger MWN, Lin L, Larson RA, Mauro MJ, Moore JO, Ritchie EK, Shah NP, SILVER RT, Wadleigh M, Cortes J, Thompson J, Guhl J, Horowitz MM, Flynn KE. Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. BMC Cancer. 2018 Apr 2;18(1):359. doi: 10.1186/s12885-018-4273-1.
5. Tiziano Barbui, Ayalew Tefferi, Alessandro Vannucchi, Francesco Passamonti, RICHARD SILVER, Ronald Hoffman, Srdan Verstovsek, Ruben Mesa, MD, Jean-Jacques Kiladjian, Rüdiger Hehlmann, Andreas Reiter, Francisco Cervantes, Claire Harrison, Mary-Frances McMullin, Hans Hasselbalch, Steffen Koschmieder, Monia Marchetti, Andrea Bacigalupo, Guido Finazzi, Nicolaus Kroeger, Martin Griesshammer, Gunnar Birgegard, and Giovanni Barosi. Philadelphia Chromosome – Negative Classical Myeloproliferative Neoplasms: Revised Management Recommendations from European LeukemiaNet.
6. Passamonti F, Mora B, Giorgino T, Rumi E, Maffioli M, Rambaldi A, Domenica C, Komrokji, RS, Gotlib, J, Kiladjian JJ, Cervantes F, Devos T, Palandri FP, De Stefano V, Ruggeri M, SILVER RT, Benevolo G, Albano F, Cavalloni C, Barraco D, Merli M, Pietra D, Casalone R, Barbui T, Rotunno G, Cazzola M, Vannucchi A.Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. Haematologica 2018
7. Mora B, Giorgino T, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Barraco D, Pietra D, Barbui T, Rotunno G, Vannucchi AM, Passamonti F. Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. Leuk Res. 2018 Jun;69:100-102.
8. Mora B, Giorgino T, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, SILVER RT, Benevolo G, Albano F, Cavalloni C, Stasia A, Merli M, Pietra D, Bussini A, Barbui T, Rotunno G, Cazzola M, Vannucchi AM, Passamonti F. Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. 2018.
9. Tiziano Barbui, Ayalew Tefferi, Alessandro Vannucchi, Francesco Passamonti, RICHARD SILVER, Ronald Hoffman, Srdan Verstovsek, Ruben Mesa, MD, Jean-Jacques Kiladjian, Rüdiger Hehlmann, Andreas Reiter, Francisco Cervantes, Claire Harrison, Mary-Frances McMullin, Hans Hasselbalch, Steffen Koschmieder, Monia Marchetti, Andrea Bacigalupo, Guido Finazzi, Nicolaus Kroeger, Martin Griesshammer, Gunnar Birgegard, and Giovanni Barosi. Philadelphia Chromosome – Negative Classical Myeloproliferative Neoplasms: Revised Management Recommendations from European LeukemiaNet. 2018
10. Passamonti F, Mora B, Giorgino T, Rumi E, Maffioli M, Rambaldi A, Domenica C, Komrokji, RS, Gotlib, J, Kiladjian JJ, Cervantes F, Devos T, Palandri FP, De Stefano V, Ruggeri M, SILVER RT, Benevolo G, Albano F, Cavalloni C, Barraco D, Merli M, Pietra D, Casalone R, Barbui T, Rotunno G, Cazzola M, Vannucchi A.Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. Haematologica 2018
11. SILVER RT, Barel A, Lascu E, Ritchie EK, Roboz GJ, Christos P, Orazi A, Hassane D, Tam W & Cross NCP: The Effect of Initial Molecular Profile on Response to Recombinant Interferon Alpha (rIFNα) Treatment in Early Myelofibrosis. Cancer Jul 15, 2017
12. Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, SILVER RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Jones M, Kornacki D, Sun K, Kantarjian H; COMFORT-I investigators. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. Feb 22, 2017
13. SILVER RT, Krichevsky S, Gjoni S, Cross NC. Evaluation of serum erythropoietin values as defined by 2016 World Health Organization criteria for the diagnosis of polycythemia vera. Leuk Lymphoma. 2017
14. Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu RV, Zachee P, Jourdan E, Winton E, SILVER RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Lager J, Shun Z, Mesa R. A phase II open-label study of the Janus Kinase-2 inhibitor fedratinib in myelofibrosis patients previously treated with ruxolitinib. Lancet Haematol. 2017
15. SILVER RT, Barel AC, Lascu E, Ritchie EK, Roboz GJ, Christos PJ, Orazi A, Hassane DC, Tam W, Cross NCP. The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis. Cancer. 2017
16. Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, SILVER RT, Benevolo G, Albano F, Caramazza D, Merli M, Pietra D, Casalone R, Rotunno G, Barbui T, Cazzola M, Vannucchi AM. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia. 2017
17. Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu RV, Zachee P, Jourdan E, Winton E, SILVER RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Lager J, Shun Z, Mesa RA. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol. 2017
18. Hans Michael Kvasnicka, Attilio Orazi, Juergen Thiele, Giovanni Barosi, Carlos E. Bueso-Ramos, Alessandro M. Vannucchi, Robert P. Hasserjian, Jean-Jacques Kiladjian, Umberto Gianelli, RICHARD SILVER, Tariq I. Mugha. European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia. Am J Hematol. 2017
19. Margolskee E, Krichevsky S, Orazi A, SILVER RT. Evaluation of bone marrow morphology is essential for assessing disease status in recombinant interferon alpha-treated polycythemia vera patients. Haematologica. 2017
20. Hans Michael Kvasnicka, Attilio Orazi, Juergen Thiele, Giovanni Barosi, Carlos E. Bueso-Ramos, Alessandro M. Vannucchi, Robert P. Hasserjian, Jean-Jacques Kiladjian, Umberto Gianelli, Richard Silver, Tariq I. Mugha. European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia. Am J Hematol. 2017 Oct;92(10):1062-1067. doi: 10.1002/ajh.24837. Epub 2017 Jul 29.
21. Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu RV, Zachee P, Jourdan E, Winton E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Lager J, Shun Z, Mesa RA.
22. Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Caramazza D, Merli M, Pietra D, Casalone R, Rotunno G, Barbui T, Cazzola M, Vannucchi AM. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia. 2017 May 31. leu.2017.169.
23. Silver RT, Barel AC, Lascu E, Ritchie EK, Roboz GJ, Christos PJ, Orazi A, Hassane DC, Tam W, Cross NCP. The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis. Cancer. 2017 Jul 15;123(14):2680-2687
24. Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu RV, Zachee P, Jourdan E, Winton E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Lager J, Shun Z, Mesa R. A phase II open-label study of the Janus Kinase-2 inhibitor fedratinib in myelofibrosis patients previously treated with ruxolitinib. Lancet Haematol. 2017 May;4(5):225-236.
25. Silver RT, Krichevsky S, Gjoni S, Cross NC. Evaluation of serum erythropoietin values as defined by 2016 World Health Organization criteria for the diagnosis of polycythemia vera. Leuk Lymphoma. 2017:1-2. doi: 10.1080/10428194.2017
26. Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Jones M, Kornacki D, Sun K, Kantarjian H; COMFORT-I investigators. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. 2017 Feb 22; 10(1):55.
27. Silver RT, Barel A, Lascu E, Ritchie EK, Roboz GJ, Christos P, Orazi A, Hassane D, Tam W & Cross NCP: The Effect of Initial Molecular Profile on Response to Recombinant Interferon Alpha (rIFNα) Treatment in Early Myelofibrosis. Cancer 2017 Jul 15;123(14):2680-2687
28. Margolskee E, Krichevsky S, Orazi A, Silver RT. Evaluation of bone marrow morphology is essential for assessing disease status in recombinant interferon alpha-treated polycythemia vera patients. Haematologica. 2017; 102(3):e97-e99
29. Hehlmann R, Saussele S, Voskanyan A., SILVER RT. Management of CML-blast crisis. Best Pract Res Clin Haematol. 2016
30. SILVER RT, Hasselbalch HC. Optimal therapy for polycythemia vera and essential thrombocythemia: Preferred use of interferon therapy based on phase 2 trials. Hematology. 2016
31. Koschmieder S, Mughal TI, Hasselbalch HC, Barosi G, Valent P, Kiladjian JJ, Jeryczynski G, Gisslinger H, Jutzi JS, Pahl HL, Hehlmann R, Vannucchi AM, Cervantes F, SILVER RT, Barbui T. Myeloproliferative neoplasms and inflammation: Whether to target the malignant clone or the inflammatory process or both. Leukemia. 2016
32. Jones GH, Carrier MA, SILVER RT, Kantarjian H. Strategies that delay or prevent the timely availability of affordable generic drugs in the United States. Blood. 2016
33. Hehlmann R, Saussele S, Voskanyan A., SILVER RT. Management of CML-blast crisis. Best Pract Res Clin Haematol. 2016; 29(3):295-307
34. SILVER RT, Hasselbalch HC. Optimal therapy for polycythemia vera and essential thrombocythemia: Preferred use of interferon therapy based on phase 2 trials. Hematology. 2016 21(7):387-91.
35. Gergis U, Kuriakose E, Shore T, Mayer S, Mark T, Pearse R, Schuster M, Feldman E, Roboz G, Ritchie E, Scandura J, Wang H, Zhou XK, SILVER RT, van Besien K. Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment. Clin Lymphoma Myeloma Leuk. 2016 May;16(5):297-303
36. Padula WV, Larson RA, Dusetzina SB, Apperley JF, Hehlmann R, Baccarani M, Eigendorff E, Guilhot J, Guilhot F, Hehlmann R, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Saussele S, Schiffer CA, SILVER RT, Simonsson B, Conti RM. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States. J Natl Cancer Inst. 2016 Mar 4;108(7).
37. Koschmieder S, Mughal TI, Hasselbalch HC, Barosi G, Valent P, Kiladjian JJ, Jeryczynski G, Gisslinger H, Jutzi JS, Pahl HL, Hehlmann R, Vannucchi AM, Cervantes F, SILVER RT, Barbui T. Myeloproliferative neoplasms and inflammation: Whether to target the malignant clone or the inflammatory process or both. Leukemia. 2016 30(5):1018-24
38. Jones GH, Carrier MA, SILVER RT, Kantarjian H. Strategies that delay or prevent the timely availability of affordable generic drugs in the United States. Blood. 2016 127(11):1398-402
39. Pizzi M, SILVER RT, Barel A, Orazi A. Recombinant interferon-α in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response. Mod Pathol. 2015 28(10): 1315-23
40. Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC Jr, Bennett JM, Benz EJ Jr, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ Jr, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, SILVER RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA.. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc. 2015 90(8):996-1000
41. Hasselbalch HC, SILVER RT. Interferon in polycythemia vera and related neoplasms. Can it become the treatment of choice without a randomized trial? Expert Rev Hematol. 2015 8(4):439-45.
42. SILVER, RT, Gjoni S: The Hematocrit Value in Polycythemia Vera: Caveat Utilitor. Leuk Lymphoma. 2015 56(5):1540-1
43. Saussele S, SILVER RT: Management of chronic myeloid leukemia in blast crisis. Ann Hematol. 2015 94 Suppl 2:159-65
44. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, SILVER RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Raza A, Vaddi K, Sun W, Peng W, Sandor V, Kantarjian H. Three-year efficacy, overall survival, and safety of ruxolitinib therapy in patients with myelofibrosis from the COMFORT-I study. Haematologica. 2015 100(4):479-88
45. Barosi G, Tefferi A, Besses C, Birgegard G, Cervantes F, Finazzi G, Gisslinger H, Griesshammer M, Harrison C, Hehlmann R, Hermouet S, Kiladjian JJ, Kröger N, Mesa R, Mc Mullin MF, Pardanani A, Passamonti F, Samuelsson J, Vannucchi AM, Reiter A, SILVER RT, Verstovsek S, Tognoni G, Barbui T: Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT). Leukemia. 2015 29(1):20-6
46. Santisakultarm TP, Paduano CQ, Stokol T, Southard TL, Nishimura N, Skoda RC, Olbricht WL, Schafer AI, SILVER RT, Schaffer CB: Stalled Cerebral Capillary Blood Flow in Mouse Models of Essential Thrombocythemia and Polycythemia Vera Revealed by In Vivo Two-Photon Imaging.J Thromb Haemost. 2014 12(12):2120-30
47. SILVER RT: Life, genes and death in Ph- MPNs. Blood. 2014 124(16):2471-2
48. Mesa RA, Kiladjian JJ, Verstovsek S, Al-Ali HK, Gotlib JR, Gisslinger H, Levy RS, Siulnik A, Gupta V, Khan M, Dipersio JF, McQuitty M, Catalano JV, Hunter DS, Knoops L, Deininger M, Cervantes F, Miller C, Vannucchi AM, SILVER RT, Barbui T, Talpaz M, Barosi G, Winton EF, Mendeson E, Harvey JH, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Sun W, Sandor V, Kantarjian HM, Harrison C. Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica. 2014;99(2):292-8
49. Kantarjian HM, SILVER RT, Komrokji RS, Mesa RA Tacke R, Harrison CN: Ruxolitinib for Myelofibrosis – An Update of Its Clinical. Clin Lymphoma Myeloma Leuk. 2013;13(6): 638-45
50. Kuriakose ET, Lascu E, Wang YL, Gjoni S, Cross NCP, Baumann R, Tam K, Scherk E, Longman RS, SILVER RT: The JAK2V617F Mutation Seen in Myeloproliferative Neoplasms (MPNs) Occurs in Patients with Inflammatory Bowel Disease: Implications of a Pilot Study. Int J Clin Med. 2013. 4: 10-15
51. SILVER RT: All Interferons the Same for Therapy in Polycythemia Vera (PV)?. Clin Lymphoma Myeloma Leuk. 2013 Suppl 2:S305-6.
52. Kuriakose ET, Gjoni S, Wang YL, Baumann R, Jones AV, Cross NCP, SILVER RT: JAK2V617F allele burden is reduced by busulfan therapy: A new observation using an old drug. Hematol. 2013. 98(11):135-171
53. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, Dipersio JF, Catalano JV, Deininger MW, Miller CB, SILVER RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM.: Efficacy, safety and survival with ruxolitinib treatment in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013. 98(12):1865-71
54. SILVER RT, Chow W, Orazi A, Arles SP, Goldsmith SJ: Evaluation of WHO Criteria for Diagnosis of Polycythemia Vera: A Prospective Analysis. Blood. 2013 122(11):1881-1886
55. Mesa RA, SILVER RT, Verstovsek S, Mascarenhas J, Kessler C, Rondelli D, Goldberg J, Marchioli R, Demakos E, Silverman L, Hoffman R.: Single agent Bevacizumab for myelofibrosis: results of the Myeloproliferative disorders-Research Consortium Trial. Haematol. 2013 98(9):1421-3
56. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes FC, Clark RE, Cortes JE, Guilhot F, Hansen HH, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FZ, Martinell G, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saussele S, Schiffer C, SILVER RT, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R: European LeukemiaNet Recommendations for the Management of Chronic Myeloid Leukemia, Blood 2013 122(6):872-84
57. Kantarjian, Hagop, SILVER, RT, et al: The Price of Drugs for Chronic Myeloid Leukemia (CML); A Reflection of the Unsustainable Prices of Cancer Drugs: From the Persepective of a Large Group of CMl Experts. Blood. 2013; 121(22):4439-42.
58. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, Dipersio JF, Catalano JV, Deininger M, Miller C, SILVER RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM: The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. Br J Haematol. 2013; 161(4):508-16.
59. Mesa RA, Gotlib J, Gupta V, Catalano JV, Deininger MW, Shields AL, Miller CB, SILVER RT, et al: Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial. J Clin Oncol. 2013; 31(10):1285-92
60. SILVER RT, Kiladjian JJ, Hasselbalch HC. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Rev Hematol. 2013 6(1):49-58
61. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, SILVER RT, et al: A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012; 366(9):799-807.
62. Santisakultarm TP, Cornelius NR, Nishimura N, Schafer AI, Silver RT, Doerschuk PC, et al: In vivo two-photon excited fluorescence microscopy reveals cardiac- and respiration-dependent pulsatile blood flow in cortical blood vessels in mice. Am J Physiol Heart Circ Physiol. 2012;302(7):H1367-77
63. Kuriakose E, Vandris K, Wang YL, Chow W, Jones AV, Christos P, Cross NC, Silver RT: Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera. Haematologica. 2012; 97(4):538-542.
64. Silver RT, Bourla MH, Vandris K, Fruchtman S, Spivak JL, Feldman EJ, Salvado AJ.: Treatment of polycythemia vera with imatinib mesylate. Leuk Res. 2012; 36(2):156-62.
65. Fleischman AG, Aichberger KJ, Luty SB, Bumm TG, Petersen CL, Doratotaj S, Silver RT, et al.: TNFalpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood. 2011;118(24):6392-6398
66. Spivak JL, Silver RT: The Treatment of essential thrombocytosis revisited. Blood. 2011; 118(4): 1179-1180.
67. Hasselbalch HC, Kiladjian JJ, Silver RT: Interferon alfa in the treatment of Philadelphia-Negative Chronic Myeloproliferative Neoplasms. J Clin Oncol. 2011; 29(18):564-565.
68. Silver RT, Vandris K, and Goldman J: Recombinant interferon alpha may retard progression of early primary myelofibrosis: a preliminary report. Blood, 2011; 117(24):6669-6672.
69. Spivak JL, Silver RT: How I treat essential thrombocythemia. Letter to the Editor. Blood. 2011; 117(5):1472-1482.
70. Silver, RT: Predictive Value of In Vitro Mutation Data to Guide Second-Generation Tyrosine Kinase Inhibitor Selection: Ready for Prime Time? Oncologist, 2011; 16(5) 554-558.
71. Silver RT, Vandris K, Wang YL, Adriano F, Jones AV, Christos PJ and Cross NCP: JAK2V617F allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy. Leuk Res. 2011; 35 :(2), 177-182.
72. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, Kiladjian JJ, Kroger N, Mesa R, McMul lin MF, Pardanani A, Passamonti F, Vannucchi A, Reiter A, Silver RT, Verstovsek S, and Tefferi A. Philadelphia –Negative classical myeloproliferative neoplasms: Critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011; 29(6):761-770.
73. Tefferi A, Abdel-wahb O, Cervantes F, Crispino JD, Finazzi G, Girodon F, Gisslinger H, Gotlib J, Kiladjian J-J, Levine RL, Licht JD, Mullaly A, Odenike T, Pardani A, Silver RT, Solary E, Mughal T. Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th international post-American Society of Hematology Symposium, Blood Cancer Journal 2011, e7
74. Najfield V, Tirpodi J, Scalise A, Silverman LR, Silver RT, Fruchtman S, Hoffman R. Jumping translocations of the long arms of chromosome 1 in myeloid malignancies is associated with a high risk of transformation to acute myeloid leukemia. Br J Haematol. 2010, (3): 288-291.
75. Salie R, Silver RT. Uncommon or delayed adverse events associated with imatinib treatment for chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2010; 10(5): 331-335.
76. Jones AV, Cambell P, Beer P, Schnittger S, Vannucchi A, Zoi K, Percy M, McMullin MF, Scott L, Tapper W, Silver RT, Oscier, Harrison Cn, Grailert H, Kisialiou A, Strike P, Chase AJ, Green A and Cross Nicholas CP. The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. Blood. 2010 ;( 115):4517-4523.
77. Shah NP, Kim D-W, Kantarjian H, Rousselot P, Dorlhiac-Llacer PE, Enrico A, Vela-Ojeda J, Silver RT, Khoury HJ, Muller MC, Lambert A, Matloub Y, Hocchaus A. Potent, transient inhibition of BCR-ABL with dasatinib 100mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica. 2010, 95(2): 232-240.
78. Silver R. The Blast Phase of Chronic Myeloid Leukemia. Best Pract Res Clin Hematol. 2009, 22(3):387-394.
79. Baccarani M, Cortes J, Pane F, Dietzger N, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonson B, Silver R, Goldman J and Hehlmann R. Chronic Myeloid Leukemia: An update of Concepts and Management Recommendations of European LeukemiaNet. J Clin Oncol. 2009, 27 (35): 6041-6051.
80. Silver RT, Vandris K.: Recombinant interferon alpha (rIFN alpha-2b) may retard progression of early primary myelofibrosis. Leukemia. 2009; 23 (7): 1366-1369.
81. Silver RT, Cortes J, Waltzman R, Mone M, and Kantarjian H.: Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia long-term follow-up of the ST15710102 and 0109 trials. Letter to the Editor. Haematologica. 2009; 94 (5): 743-744.
82. Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL, Cario H, Pahl HL, Collins A, Reiter A, Grand F and Cross NC. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet. 2009; 41(4) 446-449.
83. Silver RT. Polycythemia vera and other polycythemia syndromes. Cancer Treat Res. 2008; 142:1-27.
84. Spivak JL, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood. 2008; 112(2):231-9. Epub 2008.
85. Shah NP, Kantarjian HM, Kim DW, Réa D, Dorlhiac-Llacer PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ, Charbonnier A, Khoroshko N, Paquette RL, Deininger M, Collins RH, Otero I, Hughes T, Bleickardt E, Strauss L, Francis S, Hochhaus A. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008; 26(19):3204-3212.
86. Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, Niederwieser D, Stone RM, Dombret H, Larson RA, Roy L, Hughes T, Müller MC, Ezzeddine R, Countouriotis AM, Kantarjian HM. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008; 22(6):1200-1206.
87. Wang YL, Vandris K, Jones A, Cross NC, Christos P, Adriano F, Silver RT. JAK2 Mutations are present in all cases of polycythemia vera. Leukemia. 2008; 22(6):1289. Epub 2007.
88. Mughal T, Cortes J, Cross NC, Donato N, Hantschel O, Jabbour E, Kantarjian H, Melo JV, Skorski T, Silver RT, Goldman JM. Chronic myeloid leukemia--some topical issues. Leukemia. 2007; 21(7):1347-1352. Epub 2007.
89. Mesa RA, Verstovsek S, Cervantes F, Barosi G, Reilly JT, Dupriez B, Levine R, Le Bousse-Kerdiles MC, Wadleigh M, Campbell PJ, Silver RT, Vannucchi AM, Deeg HJ, Gisslinger H, Thomas D, Odenike O, Solberg LA, Gotlib J, Hexner E, Nimer SD, Kantarjian H, Orazi A, Vardiman JW, Thiele J, Tefferi A; International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res. 2007; 31(6):737-740. Epub 2007.
90. Xiong Z, Liu E, Yan Y, Silver RT, Yang F, Chen IH, Hodge I, Verstovsek S,

Segura FJ, Wang H, Prchal J, Yang X-F. A Novel Unconventional Antigen MPD5 Elicits Anti-Tumor Immune Responses in Subset of Patients with Polycythemia

Vera. International Journal of Immunopathology and Pharmacology. 2007; 2:373 - 375.

1. Mughal T, Cortes J, Cross NC, Donato N, Hantschel O, Jabbour E, Kantarjian H, Melo JV, Skorski T, Silver RT, Goldman JM. Chronic Myeloid Leukemia – some topical issues. Leukemia. 2007; 1(7):1347-1352
2. Silver RT. Update on the Treatment of Polycythemia Vera with Recombinant Interferon Alfa or Imatinib Mesylate. Current Hematologic Malignancy Rep. 2007; 2:43-46.
3. Chen Q, Lu P, Jones AV, Cross NCP, Silver RT, Wang YL. Amplification refractory mutation system (ARMS), a highly sensitive and simple PCR assay for the detection of JAK2V617F mutation in chronic myeloproliferative disorders. J Molecular Diagnostics. 2007; 9(2):272-276.
4. Peerschke EI, Silver RT, Weksler BB, Yin W, Bernhardt B, Varon D. Examination of platelet function in whole blood under dynamic flow conditions with the cone and plate(let) analyzer: effect of erythrocytosis and thrombocytosis. Am J Clin Pathol. 2007; 127(3):422-428.
5. Hochhaus A, Kantarjian H, Baccarani M, Lipton J, Apperley J, Druker B, Facon T, Goldberg S, Cervantes F, Niederweisser D, Silver RT et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007; 109(6):2303-2309.
6. Xiong Z, Yan Y, Lieu E, Silver RT, Verstoversek S, Yang F, Wang H, Prchal J, Yang XF. Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera. Clin Immunol. 2007; 122:279-287.
7. Silver RT, Bennett JM, Deininger M, et al. The third international congress on myeloproliferative and myelodysplastic syndromes. Leuk Res. 2007; 31(1):11-17.
8. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Silver RT, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355(23):2408-2417
9. Drucker BJ, Guilhot F, O’Brien SG, Gathmann M, Kantarjian H, Gattermann N, Deininger MWN, Silver RT, et al. Five-year follow-up of Imatinib therapy for newly diagnosed chronic myeloid leukemia in chronic-phase shows sustained responses and high overall survival. N Engl J Med. 2006; 355(23):2408-2417.
10. Bumm TGP, Elsea C, Corbin AS, Loriaux M, Sherbenou D, Wood L, Deininger J, Silver RT, Drucker BJ, Deininger MW. Characterization of murine JAK2V617F positive myeloproliferative disease. Cancer Res. 2006; 66(23):1156-1165.
11. Verstovsek S, Silver RT, Cross NCP, Tefferi A. JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less? Leukemia. 2006; 20(11):2067.
12. Xiong Z, Liu E, Yan Y, Silver RT, Yang F, Chen IH, Chen Y, Verstovsek S, Wang H, Prchal J, Yang XF. An unconventional antigen translated by a novel internal ribosome entry site elicits anti-tumor humoral immune reactions in a subset of patients with Polycythemia vera. Journal of Immunology. 2006; 177:4907-4916.
13. Tefferi A, Mesa R, Silver RT, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia: On behalf of the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 2006; 108(5):1497-1503.
14. Silver, R.T. The Budd-Chiari Syndrome and V617 Mutation in JAK2. New Engl J Med. 2006; 355(7):737; author reply 738.
15. Spivak JL, Moliterno AR, Silver RT. Case 15-2006: the Budd-Chiari syndrome and V617F mutation in JAK2. N Engl J Med. 2006 Aug 17; 355(7):737-738.
16. Shore T, Silver RT, et al. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy. Biol Blood Marrow Transplant. 2006 Aug; 12(8):868-775.
17. Silver, RT: Long-term effects of the treatment of polycythemia vera (PV) with recombinant interferon-alpha (rIFN). Cancer. 2006 Aug 1; 107(3):451-458.
18. Baccarani M, Saglio G, Goldman J, Silver RT, et al. Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006; 108:1809-1820.
19. Silver RT. Treatment of Polycythemia Vera. Semins Thromb Hemost. 2006 Jun; 32(4):437-442.
20. Jones AV, Silver RT, Waghorn K, et al. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood. 2006 Apr; 107(8):3339-3341.
21. Silver RT. The ABCs of myelofibrosis. Blood. 2005; 106:2598-2599.
22. Jones VJ, Kreil S, Zoi K, Silver RT, Reiter A, Cross CP, et al. Widespread occurrence of the JAK2V617F mutation in chronic myeloproliferative disorders. Blood. 2005; 106:2162-2188.
23. Silver RT: Treatment of polycythemia vera with recombinant interferon α (rIFNα) or imatinib mesylate. Current Hematology Rep. 2005; 4(3):235-237.
24. Silver RT: Current treatment of myelofibrosis. Current Advances in Hematology & Oncology. 2005; (4):269-270.
25. Silver RT: Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia. Leukemia. 2004; 19(1):39-43.
26. Peerschke EI, Silver RT, Weksler B, et al. Ex vivo evaluation of erythrocytosis-enhanced platelet thrombus formation using the cone and plate(let) analyzer: effect of platelet antagonists. Br J Haematol. 2004 Oct; 127(2):195-203.
27. Silver RT, Bennett JM, Deininger M, et al: Meeting Report: The Second International Congress On Myeloproliferative and Myelodysplastic Syndromes. Leukemia Research. 2004 Sep; 28(9):979-985.
28. Spivak JL, Silver RT: Imatinib mesylate in polycythemia vera. Blood. 2004; 103(8):3241.
29. Farag SS, Ruppert AS, Silver, et al: Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study. Int J Oncol. 2004; Jul 25(1):143-151.
30. Silver RT: Myelofibrosis: Thalidomide Finds a New Disease. Mayo Clinic Proceedings. 2004 Jul; 79(7):857-858.
31. Michallet M, Maloisel F, Silver RT, et al: Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study. Leukemia. 2004; 18(2):309-315.
32. Feldman E, Najfeld V, Silver RT, et al: The emergence of Ph-, trisomy –8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate. Exp Hematol. 2003; 31(8):702-707.
33. Silver RT: Chronic Myeloid Leukemia. Hematology/Oncology Clinics of North America. 2003; 17:1159-1173.
34. Silver RT: Imatinib Mesylate (Gleevec TM) Reduces Phlebotomy Requirements in Polycythemia Vera. Leukemia. 2003; 17:1186-1187.
35. Silver RT: A Hope For The Future. Cancer Invest. 2003; 21(3):486.
36. O’Brien, Guihot F, Silver RT, et al: Imatinib Compared with Interferon and Low Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. New Engl J Med. 2003; 348(11):994-1004.
37. Strife, A, Wisniewski, D, Silver RT, et al: Direct Evidence That Bcr-Abl Tyrosine Kinase Activity Disrupts Normal Synergistic Interactions Between Kit Ligand and Cytokines in Primary Primitive Progenitor Cells. Molecular Cancer Research. 2003; 1,(3):176-185.
38. Silver, RT, Peterson BL, Szatrowski TP, et al: Treatment of the Chronic Phase of Chronic Myeloid Leukemia with an Intermittent Schedule of Recombinant Interferon Alfa-2b and Cytarabine: Results from CALGB Study 9013. Leukemia & Lymphoma. 2003; 44 (1):39-48.
39. Ottmann OG, Druker BJ, Silver RT, et al: A Phase 2 Study of Imatinib in Patients with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoid Leukemias. Blood. 2002; 100:(6)1965-1971.
40. Lesser ML, DeWald GW, Silver RT, et al: Correlation of Three Methods of Measuring Cytogenetic Response in Chronic Myelocytic Leukemia. Cancer Genetics and Cytogenetics. 2002; 137 :(2)79-84.
41. Silver RT, Treatment of Polycythemia Vera with Recombinant Interferon. Int J Hematol. 2002; 76 Suppl 2:294-295.
42. Roboz GJ, Bayer RL, Silver RT, et al: Efficacy and Safety of Gemtuzumab Ozogamicin in Patients with Poor-prognosis Acute Myeloid Leukemia. Leukemia & Lymphoma. 2002; 43:1-5.
43. Talpaz M, Silver RT, Druker BJ, et al: Imatinib Induces Durable Hematologic & Cytogenetic Responses in Patients with Accelerated Phase Chronic Myeloid Leukemia: Results of a Phase 2 Study. Blood. 2002; 99:1928-1937.
44. Sirulink A, Silver RT, Najfeld V. Marked ploidy and BCR-ABL gene amplification in vivo in a patient treated with STI-571. Leukemia. 2001; 15(11):1795-1797. No abstract available.
45. Cameron CL, Cella D, Herndon JE, Kornblith A, Zuckerman E, Henderson E, Weiss RB, Cooper MR, Silver RT, Leone L, Canellos GP, Peterson BA, Holland JC. Persistent symptoms among Survivors of Hodgkin’s Disease: An Explanatory Model Based on Classical conditioning.” Health Psychology. MS#98-187R1. 2001; 20(1):71-75.
46. Hensley ML, Pederson B, Silver RT, Larson RA, Schiffer CA and Szatrowski TP. Risk Factors for Severe Neuropsychiatric Toxicity in Patients Receiving Interferon Alfa-2b and Low-Dose Cytarabine for Chronic Myelogenous Leukemia: Analysis of Cancer and Leukemia Group B 9013. J Clin Oncol. 2000; 18:1301-1308.
47. Michaels JJ, Barbui T, Finazzi G, Fuchtman SM, Kutti J, Rain JD, Silver RT, Tefferi A and Thiele J: Diagnosis and Treatment of Polycythemia Vera and Possible Future Study Designs of the PVSG. Leukemia and Lymphoma. 2000; 36:39.
48. Engelhardt M, Mackenzie K, Drulinsky P, Silver RT, Moore MA: Telomerase Activity and Telomere Length in Acute and Chronic Leukemia, Pre- and Post-ex Vivo Culture. Cancer Res. 2000 Feb 1; 60(3):610-617.
49. Budd GT, Atiba J, Silver RT, Palmer G, Armstrong S, Otto K, Presant C. Phase I/II trial of human recombinant granulocyte-colony-stimulating factor (filgrastim) and escalating doses of cyclophosphamide, mitoxantrone, and 5-FU in the treatment of advanced breast cancer. J Cancer Res Clin Oncol. 1999 Aug-Sep; 125(8-9):500-504.
50. DeWald GW, Wyatt WA, Silver RT: Atypical BCR and ABL D-Fish Patterns in Chronic Myeloid Leukemia & their Possible Role in Therapy. Leukemia & Lymphoma. 1999; 34(5)481-491.
51. Silver RT, Woolf SH, Hehlmann R, Appelbaum FR: Anderson J, Bennett C, Goldman JM, Guilhot F, Kantarjian HM, Lichtin AE, Talpaz M, Tura S: An Evidenced-Based Analysis of the Effect of Busulfan, Hydroxyurea, Interferon, and Allogeneic Bone marrow Transplantation in Treating the Chronic Phase of Chronic Myeloid Leukemia: Developed for the American Society of Hematology. Blood. 1999; 94 (5):1517-1536.
52. Silver RT: Chronic Myeloid Leukemia: Practice Guidelines, Trends in Onco-Hematology (selected reports from the 40th annual meeting of the American Society of Hematology) 1998 Dec; 6(4):60.
53. Michiels JJ, Kutti J, Stark P, Bazzan M, Gugliotta L, Marchioli R, Griesshammer M, Van Genderen PJJ, Briere J, Barbui T, Berlin NI, Pearson TC, Green AC, Fruchtmann SM, Silver RT, et al: Diagnosis, Pathogenesis and Treatment of the Myeloproliferative Disorders Essential Thrombocythemia, Polycythemia Vera and Idiopathic Myelofibrosis. (Proceedings of the Rotterdam MPD-Workshop March 13-14, 1998) (EWG.MPD) The Netherlands Journal of Medicine. 1999; 54:46-62.
54. Buño I, Wyatt WA, Zinsmeister AR, Dietz-Band J, Silver RT, Dewald G: A Special Fluorescent In Situ Hybridization Technique to Study Peripheral Blood and Assess the Effectiveness of Interferon Therapy in Chronic Myeloid Leukemia. Blood. 1998; 92(7):2315-2321.
55. Dewald GW, Wyatt A, Juneau AL, Carlson RO, Zinsmeister AR, Jalal SM, Spurbeck JL, Silver RT: Highly Sensitive Fluorescence In Situ Hybridization Method to Detect Double BCR/ABL Fusion and Monitor Response to Therapy in Chronic Myeloid Leukemia. Blood. 1998; 91:(9)3357-3365.
56. Kornblith AB, Herndon II JE, Zuckerman E, Cella DF, Cherin E, Wolchok S, Weiss RB, Diehl LF, Henderson E, Cooper MR, Schiffer C, Canellos GP, Mayer RJ, Silver RT, Schilling A, Peterson BA, Greenberg D & Holland JC for the Cancer and Leukemia Group B: Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. Ann of Oncol. 1998; 9:297-306.
57. Stock W, Westbrook CA, Bercedis P, Arthur DC, Szatrowski TP, Silver RT, et al: Value of Molecular Monitoring During the Treatment of Chronic Myeloid Leukemia: A Cancer and Leukemia Group B Study. J Clin Oncol. 1997; 15(1)26-36.
58. Silver RT: Interferon Alpha: Effects of Long-Term Treatment for Polycythemia Vera. Seminars in Hematology. 1997; 34 (1); 40-50.
59. Perloff M, Norton L, Korzun AH, Wood WC, Carey RW, Gottlieb A, Aust JC, Bank A, Silver RT, et al. Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study. J Clin Oncol. 1996 May; 14(5):1589-1598.
60. Coleman M, Silver RT: Recombinant alpha-2b-interferon in therapy of previously untreated hairy cell leukemia: long-term follow-up results of study by Cancer and Leukemia Group B. Leukemia. (England). 1995; 9(7):1116-1120.
61. Henry DH, Brooks BJ Jr, Case DC Jr, Fishkin E, Jacobson R, Keller AM, Kugler J, Moore J, Silver RT, et al. Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy. Cancer J Sci Am. 1995 Nov-Dec; 1(4):252-260.
62. Abdelaal AF, Silver RT, Macera MJ, Verma RS: Characterization of chromosome 11 with a complex inversion and deletion in an AML (M2) using fluorescence in situ hybridization. Acta Haematol. 1995; 94:152-155.
63. Silver RT: Hydroxyurea and sickle cell crisis. N Eng J Med. (Letter to the Editor). 1995; 333(15):1008-1009.
64. Rai KR, Davey F, Peterson B, Schiffer C, Silver RT, et al: Recombinant alpha-2b-interferon in therapy of previously untreated hairy-cell leukemia: long term follow-up results of study by Cancer & Leukemia Group B. Leukemia. 1995; 9(7):1116-1120.
65. Fleming RA, Capizzi RL, Rosner GL, Oliver LK, Smith SJ, Schiffer CA, Silver RT, et al: Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: A Cancer and Leukemia Group B study. Can Chemo Pharmacol. 1995; 36:425-430.
66. Neubauer A, Dodge RK, George SL, Davey FR, Silver RT, Schiffer CA, Mayer RJ, Ball ED, Wurster-Hill D, Bloodfield CD, Liu ET: Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood. 1994; 83(6):1603-1611.
67. Ozer H, Anderson JR, Peterson BA, Budman DR, Cooper R., Kennedy BJ, Silver RT, Henderson ES, Duggan DB, Barcos M, Bloomfield CD, Gottlieb AJ: Combination trial of subcutaneous recombinant 2b interferon and oral cyclophosphamide in follicular low grade non Hodgkin's lymphoma. Med & Ped Oncol. 1994; 22:228- 235.
68. Christodoulidou F, Silver RT, Macera MJ and Verma RS: Unusual Clonal Evolution During Blast Crisis of Chronic Myeloid Leukemia. European Journal of Cancer. 1994; 30A(7): p. 1041.
69. Sandler DP, Shore DL, Anderson JR, Davey FR, Arthur D, Mayer RJ, Silver RT, Weiss RB, Moore JO, Schiffer CA, Wurster Hill DH, McIntyre OR, Bloomfield CD: Cigarette smoking and risk of acute leukemia: Associations with morphology and cytogenetic abnormalities in bone marrow. JNCI. 1993; 85(24):1994-2003.
70. Silver RT: Interferon a2b: A new treatment for polycythemia vera. Ann intern Med. 1993; 119(11):1091-1092.
71. Case DC Jr., Bukowski RM, Carey RW, Fishkin EH, Henry DH, Jacobson RJ, Jones SE, Keller AM, Kugler JW, Nichols R, Salmon SE, Silver RT, et al: Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. JNCI. 1993; 85(10):801-806.
72. Leemhuis T, Leibowitz D, Cox G, Silver R, Srour EF, Tricot G, Hoffman R: Identification of BCR/ABL negative primitive hematopoietic progenitor cells within chronic myeloid leukemia marrow. Blood. 1993; 81(3):801-807.
73. Christodoulidou F, Silver RT, Macera MJ, Verma RS: Disappearance of a highly unusual clone, 46,XY,del(7)(p12),t(9;22)(q34;q11), in chronic myeloid leukemia after treatment with recombinant interferon and cytosine arabinoside. Cancer Genet Cytogenet. 1992; 64:174-177.
74. Kornblith AB, Anderson J, Cella DF, Tross S, Zuckerman MA, Cherin E, Henderson E, Weiss RB, Cooper MR, Silver RT, Leone L, Canellos GP, Gottlieb A, Holland JC: Hodgkin's disease survivors at increased risk for problems in psychosocial adaptation. Cancer. 1992; 70(8):2214-2224.
75. Janov AJ, Anderson J, Cella DF, Zuckerman E, Kornblith AB, Holland JC, Kantor AF, Li FP, Silver RT, et al: Pregnancy outcome in survivors of advanced Hodgkin's disease. Cancer. 1992; 70(3):688-692.
76. Kaufmann T, Nisce LZ, Silver RT: Lymphomatoid papulosis: Case report of a patient managed with radiation therapy and review of the literature. Am J Clin Oncol. 1992; 15(5):412-416.
77. Silver RT, Karanas A, Dear KB, Weil M, Brunner K, Haurani F, Holland JF: Attempted Prevention of Blast Crisis in Chronic Myeloid Leukemia by the Use of Pulsed Doses of Cytarabine and Lomustine. Leukemia & Lymphoma. 1992; 7:63-68.
78. Silver RT: Chronic myeloid leukemia. Current Opinion in Oncology. 1992; 4:66- 72.
79. Silverstein MN, Petitt RM, Solberg LA, Jr, Rosenblum B, Silver RT, et al: Anagrelide A therapy for thrombocythemic states: Experience in 577 patients. Anagrelide Study Group. AJM. 1992; 92:69-76.
80. Ellison RR, Mick R, Cuttner J, Schiffer CA, Silver RT, Henderson ES, Woliver T, Royston I, Davey FR, Glicksman AS, et al: The effects of post induction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: A prospective randomized clinical trial by Cancer and Leukemia Group B. J Clin Oncol. 1991; 9(11):2002-2015.
81. Puccio CA, Mittelman A, Lichtman SM, Silver RT, Budman DR, Ahmed T, Feldman EJ, Coleman M, Arnold PM, Arlin ZA, Chun HG: A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia. JCO. 1991; 9:1562-1569.
82. Grossman A, Silver RT, et al: Densitometric analysis of southern blot autoradiographs and its application to monitoring patients with chronic myeloid leukemia. Leukemia. 1991; 5(7):540-547.
83. Silver RT: Recombinant interferon alpha in the treatment of polycythemia vera. Blood. 1991; 77:2790-2091.
84. Silver RT, Case DC Jr, Wheeler RH, Miller TP, Stein RS, Stuart JJ, Peterson BA, Rivkin SE, Golomb HM, Costanzi JJ, Erslev AJ, Reisman A, Dugan M: Multicenter clinical trial of mitoxantrone in non Hodgkin's lymphoma and Hodgkin's disease. JCO. 1991; 9:754-761.
85. Budman DR, Korzun AH, Aisner J, Younger J, Silver R, Costanza M, Rice MA, Wood W: A feasibility study of intensive CAF as outpatient adjuvant therapy for stage II breast cancer in a cooperative group:CALGB 8443. Cancer Invest. 1990; 8(6):571-575.
86. Arlin ZA, Silver RT, Bennett JM: Blastic phase of chronic myeloid leukemia (blCML): A proposal for standardization of diagnostic and response criteria. Leukemia. 1990; 4:755-757.
87. Silver RT: A new treatment for polycythemia vera: recombinant interferon alfa. Blood. (Rapid Communication). 1990; 76(4):664-665.
88. Silver RT: Interferon in the treatment of myeloproliferative diseases. Sem in Hematol. 1990; 27(3):6-14.
89. Kornblith AB, Anderson J, Cella DF, Tross S, Zuckerman E, Cherin E, Henderson ES, Weiss RB, Cooper MR, Silver RT, Leone L, Canellos GP, Gottlieb A, Holland JC: Quality of life assessment of Hodgkin's disease survivors: A model for cooperative clinical trials. Oncology. 1990; 4(5):93-101.
90. Silver RT: Chronic myeloid leukemia: A perspective of the clinical and biologic issues of the chronic phase. Hematol/Oncol Clin NA. 1990; 4:319-335.
91. Silver RT, Benn P, Verma RS, Coleman M, Soper L, Gutfriend A: Recombinant gamma interferon has activity in chronic myeloid leukemia. Am J Clin Oncol. 1990; 13:49-54.
92. Stenzel KH, Wang J, Walle M, Suthanthiram M, Silver RT and Novogrodsky A: Adoptive immunotherapy for renal adenocarcinoma: Use of oxidizing mitogen-treated mononuclear leukocytes and continuous infusion of interleukin-2. Progress In Regional Cancer Therapy. 1990; 304-309.
93. Grossman A, Silver RT, Arlin Z, Coleman M, Camposano E, Gascon P, Benn PA. Fine mapping of chromosome 22 breakpoints within the breakpoint cluster region (bcr) implies a role for bcr exon 3 in determining disease duration in chronic myeloid leukemia. Am J Hum Genet. 1989 Nov; 45(5):729-738.
94. Gilbert HS, Silver RT: Intron A (interferon alfa 2b, recombinant) in the management of myeloproliferative disorders. Monograph #11, Publishers Schering Plough International, September, 1989.
95. Wang JCL, Walle A, Novogrodsky A, Suthanthiran M, Silver RT, Bander NH, Rubin AL, Stenzel KH: A phase II clinical trial of adoptive immunotherapy for advanced renal cell carcinoma using mitogen activated autologous leukocytes and continuous infusion interleukin 2. J Clin Oncol. 1989; 7:1885-1891.
96. Benn PA, Soper LA, Eisenberg A, Silver R, Bernhardt B: Use of immunoglobulin gene rearrangement to stage disease severity in chronic lymphocytic leukemia. J Tumor Marker Oncology. 1988; 3:93-99.
97. Eisenberg A, Silver R, Soper L, Arlin Z, Coleman M, Bernhardt B, Benn P: The location of breakpoints within the breakpoint cluster region (bcr) of chromosome 22 in chronic myeloid leukemia. Leukemia. 1988; 2:642-647.
98. Weinstein ME, Grossman A, Perle MA, Wilmot L, Verma RS, Silver RT, Arlin Z, Allen SL, Amorosi E, Waintraub SE, Shapiro LR, Benn PA: The karyotype of Philadelphia chromosome negative, bcr rearrangement positive chronic myeloid leukemia. Cancer Genet Cytogenet. 1988; 35:223-229.
99. Verma RS, Macera MJ, Silver RT, Coleman M: Origin of near haploidy in malignant hematopoietic cells. Leukemia Research. 1988; 12:941-950.
100. Botti AC, Silver RT, Macera MJ, Benn P, Verma RS: A new translocation involving chromosomes 8 and 9 in a Philadelphia negative chronic myelogenous leukemia. Cancer Genet Cytogene. 1988; 35:51-54.
101. Benn PA, Eisenberg A, Soper LA, Weinstein M, Silver RT, et al: Rearrangement of the breakpoint cluster region (bcr) of chromosome 22 as a diagnostic marker for chronic myeloid leukemia. J Tumor Marker Onc. 1988; 3(1):101-105.
102. Silver RT: Recombinant interferon alpha for treatment of polycythemia vera. Lancet (Letter to the Editor). 1988; 13:403.
103. Verma RS, Thomas S, Coleman M, Silver RT: Spatial relationship of chromosomes 9 and 22 at metaphase in patients with chronic myelogenous leukemia (CML). In J Cancer. 1988; 41:829-831.
104. Soper L, Bernhardt B, Eisenberg A, Cacciapaglia B, Bennett L, Sanda A, Baird M, Silver RT, Benn P: Clonal immunoglobulin gene rearrangements in chronic lymphocytic leukemia: A correlative study. Am J Hem. 1988; 27:257-264.
105. Coleman M, Armitage JO, Gaynor M, McDermott D, Weisenburger DD, Adler K, Beshevkin M, Silver RT, Reisman AM, Pasmantier MW: The COP BLAM programs: Evolving chemotherapy concepts in large cell lymphoma. Seminars in Hematology. 1988; 25(2):23-33.
106. Shustik C, Mick R, Silver RT, Sawitsky A, Rai K, Shapiro L: Treatment of early chronic lymphocytic leukemia: Intermittent chlorambucil versus observation. Hemat. Onc. 1988, 6:7-12.
107. Silver RT, Mick R, Degnan TJ, Holland JF, Cavelli F: Attempted prevention of blast crisis in chronic myeloid leukemia by the use of pulsed doses of cytosine arabinoside and cis chloronitrosurea during the course of busulfan maintained remission. Cancer Investigation. 1988; 6(3):253-260.
108. Wang J, Walle A, Gordon B, Novogrodsky A, Suthanthiran M, Rubin A, Morrison H, Silver RT, Stenzel KH: Adoptive immunotherapy for stage IV renal cell carcinoma:A novel protocol utilizing periodate and interleukin e activated autologous leukocytes and continuous infusions of low dose interleukin 2. Amer Jour Med. 1987; 83(6):1016-1023.
109. Benn P, Soper L, Eisenberg A, Silver RT, Coleman M, Cacciapaglia B, Bennett L, Baird M, Silverstein M, Berger C, Bernhardt B: Utility of molecular genetic analysis of bcr rearrangement in the diagnosis of chronic myeloid leukemia. Cancer Genet Cytogenet. 1987; 29(1):1-7.
110. Silver RT, Mick R, Cooper R, et al: A comparative study of dibromomannitol and busulfan in the treatment of chronic myeloid leukemia. A study of Cancer and Leukemia Group B. Cancer. 1987; 60:1442-1448.
111. Mayer RJ, Schiffer CA, Peterson BA, Budman DR, Silver RT, et al: Intensive Postremission Therapy in Adults With Acute Nonlymphocytic Leukemia Using Various Dose Schedules of ara C: A Progress Report from the CALGB. Seminars in Oncology. 1987; 14(2):25-31.
112. Coleman M, Gerstein G, Topilow A, Lebowicz J, Bernhardt B, Chiarieri D, Silver RT, Pasmantier MW: Advances in chemotherapy for large cell lymphoma. Seminars in Hematology. 1987; 24:8-20.
113. Verma RS, Thomas S, Coleman M, Silver RT, Dosik H. Length polymorphisms of the human Y chromosome in patients with chronic myelogenous leukemia. Cancer Genet Cytogenet. 1987 Feb; 24(2):295-297.
114. Verma RS, Rodriquez J, Babu A, Chemitiganti S, Coleman M, Silver RT, Dosik H: Role of heterochromatin during preferential 9q;22q translocation in chronic myelogenous leukemia. Canadian Journal of Genetics and Cytology. 1986; 28(6): 998-1002.
115. Silver RT, Gale RP: Chronic Myeloid Leukemia. Amer. J. Med. 1986; 80 (6):1137-1148.
116. Verma RS, Thomas S, Coleman M, Silver RT, Dosik H: Position of the Y Chromosome at somatic metaphase in patients with chronic myelogenous leukemia (CML). Experientia. 1986; 42(4):440-441.
117. Silver, RT: Refractory Anemias, Pre Leukemia and Myelodysplasias. Rev. Hosp. Clin. Fac. Med. S. Paulo. 1985; 40(6):266-269.
118. Coleman M, Pasmantier MW, Silver RT: Hac-cytoxan chemotherapy for ovarian carcinoma. Alternating chemotherapy with intensification. Cancer. 1985; 55:40-45.
119. Arlin Z, Silver RT, Cassileth P, Armentrout S, Gams R, et al: Phase I-11 Trial of mitoxantrone in acute leukemia: An interim report. Investigational New Drugs. 1985; 2:213-217.
120. Pasmantier MW, Coleman M, Silver RT, Ballard PW: Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, 5-FU; CHAMP-5) for ovarian carcinoma: Alternating sequences of combination regimens. Cancer Treatment Rep. 1985; 69:689-693.
121. Wood WC, Weiss RB, Tormey DC, Holland JF, Henry PH, Leone LA, Fafla S, Silver RT, et al: A randomized trial of CMF vs. CMFVP as adjuvant chemotherapy in women with node-positive stage II breast cancer: A CALGB study. World J Surg. 1985; 9(5):714-718.
122. Mayer RJ, Schiffer CA, Peterson BA, Silver RT, et al: Intensive postremission therapy in adults with acute nonlymphocytic leukemia with Ara-C by continuous infusion or bolus administration: preliminary results of a CALGB Phase I Study. Sem in Oncol. 1985; 12(2), suppl 3:84-90.
123. Silver RT, Case D, Jones S, Gams R, et al: Novantrone mitoxantrone in the treatment of non-Hodgkin's lymphoma. (Lederle Cooperative Group) Proc 14th Internat Congress of Chemotherapy. 1985 June; pgs. 23-28.
124. Pasmantier MW, Coleman M, Silver RT, Mamaril AP, Quiguyan CC, Galindo A Jr. Treatment of advanced endometrial carcinoma with doxorubicin and cisplatin: effects on both untreated and previously treated patients. Cancer Treat Rep. 1985 May; 69(5):539-542.
125. Arlin ZA, Silver RT, et al: Further evaluation of mitoxantrone in acute leukemia. Advances in Cancer Chemotherapy. The Current Status of Novantrone. 1985; pp. 91-94.
126. Gams RA, Keller J, Case DC Jr., Jones SE, Stein RS, Stuart JJ, Silver RT, et al: Novantrone in malignant lymphoma. Advances in Cancer Chemotherapy, The Current Status of Novantrone. 1985; pgs. 75-77.
127. Henderson IC, Wolff SN, Allegra JC, Woodcock T, Silver RT, et al: A randomized trial comparing mitoxantrone and doxorubicin inpatients with metastatic breast cancer. Advances in Cancer Chemoatherapy, The Current Status of Novantrone, 1985; pgs. 45-53.
128. Henderson IC, Wolff S, Allegra J, Silver RT, et al: A randomized trial of novantrone versus adriamycin for metastatic breast cancer. Advances in Cancer Chemotherapy, The Current Status of Novantrone, 1985.
129. Chemitiganti S, Verma RS, Silver RT, Coleman M, Dosik H: Unusual translocations involving chromosomes 12;22 and 9;12 in a case of chronic myelogenous leukemia. Cancer Genetics and Cytogenetics. 1985; 14:61-65.
130. Arlin ZA, Silver RT, et al: Phase I-II trial of mitooxantrone in acute leukemia. Cancer Treatment Reports. 1985; 69(1):61-64.
131. Landesman R, Silver RT: Cytoreductive surgery. Obst & Gyn (Letter). 1984; 64(1):148-149.
132. Gottlieb AJ, Weinberg V, Ellison RR, Henderson ES, Terebelo H, Fafla S, Cuttner J, Silver RT, et al: Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: A prospective randomized trial by CALGB. Blood. 1984; 64(1):267-274.
133. Tormey DC, Weinberg VE, Leone LA, Glidewell OJ, Perloff M, Kennedy BJ, Cortes E, Silver RT, et al: A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer: A CALGB study. Amer J Clin Oncol. Cancer Clinical Trials. 1984; 7:231-239.
134. Brower MS, Coleman M, Pasmantier MW, Silver RT, et al: Treatment of advanced ovarian carcinoma with hexamethylmelamine, doxorubicin and cis-platinum (HAC): Results in both untreated and previously treated patients. Med & Ped Oncol. 1984; 12:17-24.
135. Green M, Horton C, Spaulding M, Silver RT, Berenberg J, Kennedy BJ, Pajak TF, Comis R. Four-drug combination chemotherapy (methotrexate, cyclophosphamide, hexamethylmelamine, and CCNU) for non-small cell bronchogenic carcinoma: a Cancer and Leukemia Group B study. J Clin Oncol. 1983 Sep; 1(9):559-565.
136. Pasmantier MW, Coleman M, Silver RT, et al: Administration of a complex chemotherapy regimen: Inpatient versus outpatient treatment. Med & Ped Oncol. 1983; 11:333-335.
137. Paciucci PA, Ohnuma T, Cuttner J, Silver RT, Holland JF: Mitoxantrone in patients with acute leukemia in relapse. Cancer Res. 1983; 43:3919-3922.
138. Paciucci PA Ohnuma T, Cuttner J, Silver RT, Holland JF: Mitoxantrone in acute lymphoblastic leukemia. Cancer Treatment Reviews. 1983; 10(B):65-68.
139. Silver RT, Douglas RG, editors: Combined clinical basic science seminar: Nutrition and cancer by Dr. Rivlin. Amer J Med. 1983; 75:843-854.
140. Silver RT, Douglas RG: Endocytosis by the mononuclear phagocyte system and antoimmune disease. Amer J Med. 1983; 74:481-493.
141. Tormey DC, Weinberg VE, Holland JF, Weiss RB, Glidewell OJ, Perloff M, Falkson G, Falkson HC, Henry PH, Leone LA, Fafla S, Ginsberg SA, Silver RT, et al: A randomized trial of five and three-drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer. A CALGB study. J Clin Oncol. 1983; 1(2):138-145.
142. Hollister D Jr, Silver RT, Gordon B, ColemanM: Continuous infusion vincristine and bleomycin with high dose methotrexate for resistant non-Hodgkin's lymphoma. Cancer. 1982; 50:1690-1694.
143. Cornwell GG III, Pajak TF, Kochwa S, McIntyre OR, Glowienka LP, Brunner K, Rafla S, Silver RT, et al: Comparison of oral melphan, CCNU and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. A CALGB study. Cancer. 1982; 50:1669-1675.
144. Yates J, Glidewell O, Wiernik P, Cooper MR, Steinberg D, Dosik H, Silver RT, et al: Cytostine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: A CALGB study. Blood. 1982; 60(2):454-462.
145. Pelus L, Saletan S, Silver RT, Moore M: Expression of IA antigens on normal and chronic myeloid leukemic human granulocyte-macrophage colony-forming cells (CFU-GM) is associated with the regulation of cell proliferation by prostaglandin E. Blood. 1982; 59(2):284-292.
146. Laurence J, Coleman M, Allen S, Silver RT, Pasmantier M: Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen. Ann Int Med. 1982; 97:190-195.
147. Rai K, Holland J, Glidewell O, Weinberg V, Brunner, Silver RT, et al: Treatment of acute myelocytic leukemia. A CALGB study. Blood. 1981; 58(6):1203-1212.
148. Brandstetter RD, Silver RT, Verma TK: Multiple (five) primary malignancies in one patient. Southern Med J. 1981; 74(5):641-642.
149. Donavan PB, Landaw SA, Cresch C, Silver RT, et al: Resistance to therapy of acute leukemia developing in the course of polycythemia vera. Nouv Rev Fr Hematol. 1981; 23(4):187-192.
150. Brandstetter RD, Silver RT, Verma TK: Multiple (five) primary malignancies in one patient. Southern Med J. 1981; 74(5):641-642.
151. Donavan PB, Landaw SA, Cresch C, Silver RT, et al: Resistance to therapy of acute leukemia developing in the course of polycythemia vera. Nouv Rev Fr Hematol. 1981; 23(4):187-192.
152. Cooper MR, Pajak TF, Nissen NI, Stutzman L, Brunner K, Cuttner J, Falkson G, Grunwald H, Bank A, Leone L, Seligman BR, Silver RT, et al. A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's disease. Cancer. 1980 Aug 15; 46(4):654-662.
153. Nissen NI, Pajak TF, Leone LA, Bloomfield CD, Silver RT, et al: Clinical trial of VP 16-213 i.v. twice weekly in advanced neoplastic disease. A CALGB study. Cancer. 1980; 45:232-235.
154. Wolf DJ, Silver RT, Coleman M: Waldenstron's macroglobullinemia – a review. The Medical Journal of the New York Hospital-Cornell Medical Center 1980; 1:24-30.
155. Silver RT: The Dying Patient. Cornell Alumni News: 1980; pgs. 27-29.
156. Silver RT: The dying patient: A clinician's view. Am J Med. 1980; 68:374-375.
157. Coleman M, Silver RT, Pajak TF, et al: Combination chemotherapy for terminal-phase chronic granulocytic leukemia: CALGB studies. Blood. 1980; 55:22-36.
158. Pinkel D, Silver RT, Simone JV, Van Eys J: Exploring current leukemia therapies. Patient Care. 1979; 13:54-78.
159. Wiernik PH, Glidewell O, Silver RT: A comparative trial of daunorubicin, cytosine arabinoside and thioquanine, and a combination of the three agents for the treatment of acute myelocytic leukemia. Med & Ped Oncol. 1979; 6:261-277.
160. Rowley JD, Resnick GD, Whitman SL, Senterfit L, Silver RT: Variant Ph1 translocation in chronic myeloid leukemia. Blood. 1979; 54:294.
161. Hayes DM, Pajak TF, Rege V, Silver RT, et al: Combination chemotherapy for non-Hodgkin's lymphomas: A ten year follow-up CALGB study. Med & Ped. 1979; 6:23-38.
162. Henderson ES, Scharlau C, Cooper MR, Haurani FI, Silver RT, et al. Combination chemotherapy and radiotherapy for acute lymphocytic leukemia in adults: results of CALGB protocol 7113. Leuk Res. 1979; 3(6):395-407.
163. Sawitsky A, Rai K, Silver R: Mediastinal irradiation for chronic lymphocytic leukemia. In: Yearbook of Medicine, Edited by David E. Rogers, M.D., et al. 1978; pp 237.
164. Silver RT, Sawitsky A, Rai K, Holland JF, Glidewell O: Guidelines for protocol studies in chronic lymphocytic leukemia. A CALGB study. Am J Hematol. 1978; 4:343-358.
165. Wolf DJ, Silver RT, Coleman M: Splenectomy in chronic myeloid leukemia: A review. Ann Intern Med. 1978 Nov; 89(5 Pt1):684-689.
166. Wolf DJ, Silver RT, Coleman M: Factors associated with prolonged survival in chronic myeloid leukemia. Cancer. 1978 Oct; 42(4):1957-1963.
167. Brogadir S, Fialk MA, Coleman M, Vinciguerra V, Degnan T, Pasmantier M, Silver RT: Morbidity of staging laparotomy in Hodgkin's disease. Am J Med. 1978; 64:429-433.
168. Maurice P, Glidewell O, Jacquillat C, silver RT, Et al: Comparison of methyl-CCNU and CCNU in patients with advanced forms of Hodgkin's disease, lymphosarcoma, and reticulum cell sarcoma. Cancer. 1978 May; 41(5):1658-1663.
169. Jarowski CI, Fialk MA, Murray HW, Gottlieb GJ, Coleman M, Steinberg CR, Silver RT: Fever, rash and muscle tenderness: A distinctive clinical presentation of disseminated candidiasis. Arch Int Med. 1978; 138:544-546.
170. Sawitsky A, Rai KR, Glidewell O, Silver RT: Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. A CALGB study. Blood. 1977 Dec; 50(6):1049-1059.
171. Pasmantier MW, Coleman M, Silver RT, Birnbaum SJ: Endometrial, cervical and vulva cancer. Randomized trials in cancer: A critical review by sites edited by Maurice J. Staquet, Raven Press, NY, 1977.
172. Pasmantier MW, Coleman M, Kennedy BJ, Eagan R, Carolla R, Weiss R, Leone L, Silver RT: Piperazinedione in metastatic renal carcinoma. Cancer Treatment Rep. 1977; 61:1731.
173. Turman S, Coleman M, Silver RT, Pasmantier M: High dose methotrexate with citrovorum factor in adult resistant lymphoma. Cancer. 1977; 40:2823.
174. Silver RT, Young RC, Holland JF: Some new aspects of modern cancer chemotherapy. Am J Med. 1977 Nov; 63(5):772-787.
175. Fialk MA, Coleman M, Grant MD, Pasmantier MW, Silver RT: Case report: Splenectomy in patients with Hodgkin's disease and marrow hypoplasia. Am J Med Sci. 1977 Jul-Aug; 274(1):87-91.
176. Pasmantier MW, Coleman M, Silver RT: Value of biopsy in diagnosis of primary lymphosarcoma of marrow. Arch Int Med. 1977; 137:52-54.
177. Vinciguerra V, Coleman M, Jarowski CI, Degnan TJ, Silver RT: A new combination chemotherapy for resistant Hodgkin's disease. JAMA. 1977; 237:33-35.
178. Sawitsky A, Rai KR, Aral I, Silver RT, et al: Mediastinal irradiation for chronic lymphocytic leukemia. Am J Med. 1976 Dec; 61(6):892-896.
179. Coleman M, Lightdale CJ, Vinciguerra VP, Degnan TJ, Goldstone MJ, Horowitz ST, Winawer SJ, Silver RT: Peritoneoscopy in Hodgkin's disease: Confirmation of results by laparotomy. JAMA. 1976; 236:2634-2636.
180. Pasmantier MW, Coleman M, Silver RT: Chemotherapy of non-Hodgkin's lymphoma. Med Clin North Am. 1976 Sep; 60(5):1043-1052.
181. Silver RT, Coleman M: Chronic leukemia in adults. Continuing Education for the Family Physician. 1976; 4:28-35.
182. Carey RW, Ribas-Mundo M, Ellison RR, Glidewell O, Lee ST, Cuttner J, Levy RN, Silver RT, et al: Comparative study of cytosine arabinoside therapy alone and combined with thioguanine, mercaptopurine, or daunorubicin in acute myelocytic leukemia. Cancer. 1975; 36:1560.
183. Cuttner J, Wasserman LR, Martz G, Sonntag RW, Kyle RA, Silver RT, et al: The use of low-dose prednisone and melphalan in the treatment of poor risk patients with multiple myeloma. Med and Ped Oncol. 1975; 1(3):207-16.
184. Ellis JT, Silver RT, Coleman, Geller SA: The bone marrow in polycythemia vera. Sem in Hematol. 1975 Oct; 12(4):433-44.
185. Kyle RA, Seligman BR, Wallace HJ Jr, Silver RT, Glidewell O, Holland JF. Mutiple myeloma resistant to melphalan (NSC-8806) treated with cyclophosphamide (NSC-26271), prednisone (NSC-10023), and chloroquine (NSC-187208). Cancer Chemother Rep. 1975 May-Jun; 59(3):557-62.
186. Drout D, Moore A, Rothman H, Silver RT, Eisnmenger W: Acute hemolytic episodes 37 years apart. N Engl J Med. 1975 Jan 23; 292(4):213.
187. Pasmantier MW, Coleman M, Silver RT. Diagnosis of plasma cell myeloma. Am Fam Physician. 1975 Jan; 11(1):76-81.
188. Sharer LR, Barondess JA, Silver RT, Gray GF: Association of Hodgkin's disease and Gaucher's disease. Arch Pathol. 1974 Dec; 98(6):376-8.
189. Coleman M, Silver RT. The chemotherapy of plasma cell myeloma and related disorders. Antibiot Chemother. 1974; 18:112-47.
190. Silver RT, Stutzman L, Glidewell O, et al: Multiple chemotherapeutic agents for Hodgkin's disease. A CALGB study. JAMA. 1973; 225:1202.
191. Costa G, Engle RL, Schilling A, Silver RT, et al: Melphalan and prednisone: An effective combination for the treatment of multiple myeloma. A CALGB study. Am J Med. 1973; 54:589.
192. Silver RT, Nisce L, Hoogstraten B, et al: Combination chemotherapy-radiotherapy for stage III Hodgkin's disease. A CALGB study. Arch Int Med. 1973; 131:424I.
193. Cucin RL, Coleman M, Eckardt JJ, Silver RT: The diagnosis of miliary tuberculosis: utility of peripheral blood abnormalities, bone marrow and liver needle biopsy. J Chron Dis. 1973 Jun; 26(6):335-61.
194. Vinciguerra V, Silver RT: The importance of bone marrow biopsy in the staging of patients with lymphosarcoma. Blood. 1973 Jun; 41(6):913-20.
195. Smith J, Pasmantier M, Silver RT, et al: Selective versus routine laparotomy in the staging of Hodgkin's disease. JAMA. 1973 May 14; 224(7):1026-8.
196. Kyle RA, Costa G, Cooper MR, Ogawa M, Silver RT, et al: Evaluation of aniline mustard in patients with multiple myeloma. Cancer Research. 1973 May; 33(5):956-60.
197. Well M, Glidewell OJ, Jacquilat C, Levy R, Silver RT, et al: Daunorubicin in the therapy of acute granulocytic leukemia. Cancer Res. 1973 May; 33(5):921-8.
198. Ellison RR, Hoogstraten B, Holland JF, Silver RT, et al: Intermittent therapy with 6-mercaptopurine (NSC-755) and methotrexate (NSC-740) given intravenously to adults with acute leukemia. Cancer Chemotherapy Rep, part I. 1972 Aug; 56(4):535-42.
199. Silver RT: Ineffectiveness of fluoride therapy in multiple myeloma. A CALGB study. N Engl J Med. 1972; 285:1283.
200. Ohnuma T, Rosner R, Levy RN, Cuttner J, Moon JH, Silver RT, et al: Treatment of adult leukemia with L-asparaginase (NSC-109229). Cancer Chemotherapy Rep. 1971 Jun; 55(3):269-75.
201. Fratantoni JC, Silver RT: Autoimmune hemolytic anemia and Gaucher cells. Proc Amer Soc Hematol. 1970; 13:312.
202. Webb DI, Ubogy G, Silver RT: Importance of bone marrow biopsy in the clinical staging of Hodgkin's disease. Cancer. 1970 Aug; 26(2):313-7.
203. Silver RT: Treatment of chronic lymphocytic leukemia. Sem in Hematol. 1969 Oct; 6(4):344-56.
204. Hoogstraten B, Silver RT, et al: Combination chemotherapy in lymphosarcoma and reticulum cell sarcoma. Blood. 1969; 33:370.
205. Levin WC, Griffith K, Huguley CM, Silver RT, Karanas A, et al: Proposed guidelines for protocol studies: Chronic lymphocytic leukemia. Cancer Chemotherapy Report. 1968; 1:41.
206. Ellison RR, Holland JF, Weil M, Silver RT, et al: Arabinoside cytosine: a useful agent in the treatment of acute leukemia in adults. Blood. 1968 Oct; 32(4):507-23.
207. Karanas A, Silver RT: Characteristics of the terminal phase of chronic granulocytic leukemia. Blood. 1968 Sep; 32(3):445-59.
208. Webb DI, Silver RT: Hodgkin's disease: Value of bone marrow biopsy. N Engl J Med. 1968 Jul 4; 279(1):46.
209. Carbone PP, Spurr C, Silver RT, et al: Management of patients with malignant lymphoma. A comparative study with cyclophosphamide and vinca alkaloids. Cancer Res. 1968; 28:811.
210. Kyle RA, Carbone PP, Lynch JJ, Owens AH, Costa G, Silver RT, Cuttner J, et al: Evaluation of tryptophan mustard in patients with plasmacytic myeloma. Cancer Res. 1967 Mar; 27(3):510-5.
211. Silver RT, Keuhnelian J, Jenkins DE Jr, Engle RL Jr, Marshall VF: Influence of testosterone on the development of bone marrow at sites of transplanted bladder mucosa. Invest Urol. 1967 Jan; 4(4):314-20.
212. Karanas A, Silver RT: Natural history of the terminal phase of chronic granulocytic leukemia. Proc Amer Assoc Cancer Res. 1966; 7:65.
213. Nachman RL, Horowitz HL, Silver RT: Platelet amino acids in essential thrombocytosis. Blood. 1966 May; 27(5):715-21.
214. Silver RT: Bone marrow biopsy. Medical Digest. 1966; 825:50.
215. Silver RT: Bone marrow aspiration and biopsy. GP. 1965 Mar; 31:100-6.
216. Silver RT, Jenkins D, Engle RL: Use of testosterone and busulfan in the treatment of myelofibrosis with myeloid metaplasia. Blood. 1964 Mar; 23:341-353.
217. Silver RT: Infection, fever and host resistance in neoplastic diseases. J Chron Dis. 1963 Jul; 16:677-701.
218. Pedreira L, Engle RL, Silver RT: Studies of the plasma proteins in pregnancy using starch zone electrophoresis. Clin Chim Acta. 1962 Sep; 7:710-3.
219. Silver RT, Haber J, Kellner A: Blood group studies of jungle Indians of Mato Grosso. Transfusion. 1962 Mar-Apr; 2:110-4.
220. Silver RT: Medical adventures in the Upper Xingu. Cornell University Medical College Alumni Bulletin. Winter 1968; pp. 3-8. Also: Bibl Haematol. 1962; 13:167-9.
221. Silver RT, Utz J, Fahey J, Frei E: The nature of the antibody response in acute leukemia. Modern Med. 1961; 29:100.
222. Silver RT, Pedreira L, Korngold L, Engle RL: Studies of the serum protein abnormalities in kala azar. Proc Soc for Experimental Biol and Med. 1961; 106:365.
223. Silver RT, Kellner A, Haber J: Evidence for a new allele in the Kidd blood group system. Nature. 1960 May 7; 186:481.
224. Silver RT, Utz J, Fahey J, Frei E: The nature of the antibody response in acute leukemia. J Lab & Clin Med. 1960; 56:634.
225. Silver RT: Sojourn in Brazil, Cornell Alumni Bulletin, 1959.
226. Ellison RR, Silver RT, Engle RL Jr: Comparative study of 6-chloropurine and 6-mercaptopurine in acute leukemia in adults. Ann Intern Med. 1959 Aug; 51:322-38.
227. Frei E, Holland J, Schneiderman M, Pinkel D, Selkirk G, Freireich E, Silver RT, Gol L, Regelson W: A comparative study of the regimens of combination chemotherapy in acute leukemia. Blood. 1958 Dec; 13(12):1126-48.
228. Watkin D, Silver RT: Nitrogen, mineral, uric acid and basal metabolism in a case of adult acute leukemia with extensive osteolytic bone disease. Am J Med. 1958 Apr; 24(4):638-47.
229. Silver RT, Utz J, Frei E, McCollough N: Fever, infection and host resistance in acute leukemia. Am J Med 1958 Jan; 24(1):25-39.
230. Silver RT, Beal G, Schneiderman H, McCullough NB: The role of the mature neutrophil in bacterial infections in acute leukemia. Blood. 1957 Sep; 12(9):814-21.
231. Wells CE, Silver RT: The neurologic manifestations of the acute leukemias: a clinical study. Ann Int Med. 1957 Mar; 46(3):439-49.
232. Wells CE, Silver RT: The neurologic manifestations of the acute leukemias: a clinical study. Pediatric Current in Nutrition and Medicine. 1957; 6:22.

**Abstracts and Presentations**

1. Fedratinib (FEDR) in myelofibrosis (MF) patients previously treated with ruxolitinib (RUX): A reanalysis of the JAKARTA-2 study. C. Brownstein, Claire Harrison, N. Schaap, Jean-Jacques Kiladjian, Pierre Zachee, Eric Jourdan, Harry Schouten, S. Zweegman, M. Talpaz, Rueben Mesa, Sjardan Verstovsek, Francesco Passamonti, Alessandro Vannucchi, RICHARD T SILVER, T. Gerike, Nicholas, Combates, Rachel Strother. ASCO Annual Meeting. Chicago, Illinois, May 31-June 4, 2019
2. How I Treat Polycythemia Vera After Hydroxyurea Failure (2018). RICHARD T. SILVER. 60th ASH Annual Meeting & Exposition Hematology Symposium. San Diego, CA, December 1-4, 2018
3. The Diagnosis of Polycythemia Vera. RICHARD T. SILVER. 11th International Congress on Myeloproliferative Neoplasms. New York, NY, October 25-26, 2018
4. How I Treat Polycythemia Vera in 2018. RICHARD T. SILVER. 4th Annual Levine Cancer Institute Hematology Symposium. Charlotte, NC, October 20, 2018
5. Distinguishing Essential Thrombocythemia JAK2V617F from Polycythemia Vera:

Clinical and Biological Relevance. RICHARD T. SILVER and Spencer Krichevsky. Dublin, Ireland, May 15, 2018

1. Myeloproliferative neoplasms – Clinical. EHA-3957. Gender Effect On

Phenotype And Genotype In Patients With Post-Polycythemia Vera And Post-Essential Thrombocythemia Myelofibrosis: Results From The MYSEC Project. Daniela Barraco, Barbara Mora, Toni Giorgino, Paola Guglielmelli, Elisa Rumi, Margherita Maffioli, Alessandro Rambaldi, Marianna Caramella, Rami Komrokj, Jason Gotlib, Jean Jacques Kiladjian, Francisco Cervantes,Timothy Devos, Francesca Palandri, Valerio De Stefano, Marco Ruggeri, RICHARD T. SILVER, Giulia Benevolo, Francesco Albano, Michele Merli, Daniela Pietra, Tiziano Barbui, Giada Rotunno, Mario Cazzola, Alessandro Maria Vannucchi, Passamonti Francesco. 23rd Congress of the European Hematology Association Stockholm, Sweden; June 14-17, 2017.

1. Pulmonary Hypertension Independently Shortens Survival of Patients with

Myeloproliferative Neoplasms. Jiwon Kim, MD, Spencer Krichevsky, BS, Neil K

Mehta, MD, Sara Rodriguez-Diego, MD, Meridith P Pollie, BS, RICHARD T.

SILVER, MD, Andrew I Schafer ... ASH 59th Annual Meeting and Exposition,

Atlanta, GA December 7 – 13, 2017

1. Incidence of Infections and Second Cancers in Philadelphia Chromosome-

Negative Patients with Myeloproliferative Neoplasms Treated with Ruxolitinib. Ellen

K Ritchie, MD, Spencer Krichevsky, BS, Gail J. Roboz, MD, RICHARD T. SILVER,

MD, Andrew I Schafer, MD, Joseph Scandura, MD, PhD, Pinkal Desai ... ASH

59th Annual Meeting and Exposition, Atlanta, GA December 7 – 13, 2017

1. Critical Evaluation of Who 2016 Criteria for the Diagnosis of Polycythemia

Vera: Distinction from JAK2V617+ Essential Thrombocythemia. RICHARD T. SILVER, MD and Spencer Krichevsky, BS, ASH 59th Annual Meeting and Exposition, Atlanta, GA December 7 – 13, 2017

1. Dueck A, Mascarenhas J, Kosiorek HE, Yacoub A, Prchal JT, Berenzon D, Baer MR, Ritchie EK, Silver RT, Kessler CM, Winton EF, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz DS, Rondelli D, Arcasoy MO, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Orellana A, Sandy L, Tripodi J, Najfeld V, Salama ME, Weinberg RS, Rampal RK, Hoffman R, Mesa RA: Single-Arm Phase II Trial of Pegylated Interferon Alpha 2a in Patients with High-Risk Essential Thrombocythemia or Polycythemia Vera Resistant or Intolerant to Hydroxyurea: MPN Symptom Impact & Quality of Life Results of the Myeloproliferative Disorders-Research Consortium (MPD- RC) Protocol 111Global Phase II Trial. 59th ASH Annual Meeting & Exposition, American Society of Hematology, Atlanta, GA, December 7-12, 2017.
2. Vikas Gupta, Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, John F. DiPersio, John V. Catalano, Michael W. N. Deininger, Carole B. Miller, RICHARD T. SILVER, Moshe Talpaz, Elliott F. Winton, Jimmie H. Harvey, Jr, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Ronald Paquette, Azra Raza, Deanna Kornacki, Kang Sun, Hagop Kantarjian: Long-Term Outcomes of Ruxolitinib Therapy in Patients with Myelofibrosis: 5-Year Update from Comfort-1. American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, Illonois; June 3-7, 2016.
3. Verstovsek S, Mesa RA. Gotlib JR, Gupta V, DiPersio JF, Catalano JV, Deininger MWN, Miller CB, SILVER RT, Talpaz M, Winton EF, Harvey Jr JH, Arcasoy MO, Hexner EO, Lyons, RM, Paquette R, Raza A, Jones M, Kornacki D, Sun K, Kantarjian H: Long-Term Outcomes of Ruxolitinib (rux) Therapy in Patients (pts) with Myelofibrosis (MF): 5-Year Final Efficacy and Safety Analysis from Comfort-I. Eurpopean Hem,atology Associates (EHA) 21st Congress, Copenhagen, Denmark, June 9 – 12, 2016
4. Margolskee E, Krichevsky S, Orazi A, SILVER RT. Evaluation of Bone Marrowmorphology in Addition to JAK2 Allele Burden Is Essential for Assessing Disease Status in Recombinant Interferon Alpha-Treated Polycythemia Vera Patients. 58th ASH Annual Meeting & Exposition, American Society of Hematology, San Diego, CA, December 3-6, 2016
5. SILVER RT, Barel A, Lascu E, Ritchie EK, Roboz GJ, Christos P, Orazi A, Hassane D, Tam W & Cross NCP: The Effect of Initial Molecular Profile on Response to Recombinant Interferon Alpha (rIFNα) Treatment in Early Myelofibrosis. 58th ASH Annual Meeting & Exposition, American Society of Hematology, San Diego, CA, December 3-6, 2016.
6. Silver RT, Barel A, Lascu E, Ritchie EK, Roboz GJ, Christos P, Orazi A, Hassane D, Tam W & Cross NCP: The Effect of Initial Molecular Profile on Response to Recombinant Interferon Alpha (rIFNα) Treatment in Early Myelofibrosis. 58th ASH Annual Meeting & Exposition, American Society of Hematology, San Diego, CA, December 3-6, 2016.
7. Margolskee E, Krichevsky S, Orazi A, Silver RT: Evaluation of Bone Marrowmorphology in Addition to JAK2 Allele Burden Is Essential for Assessing Disease Status in Recombinant Interferon Alpha-Treated Polycythemia Vera Patients. 58th ASH Annual Meeting & Exposition, American Society of Hematology, San Diego, CA, December 3-6, 2016
8. Verstovsek S, Mesa RA. Gotlib JR, Gupta V, DiPersio JF, Catalano JV, Deininger MWN, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey Jr JH, Arcasoy MO, Hexner EO, Lyons, RM, Paquette R, Raza A, Jones M, Kornacki D, Sun K, Kantarjian H: Long-Term Outcomes of Ruxolitinib (rux) Therapy in Patients (pts) with Myelofibrosis (MF): 5-Year Final Efficacy and Safety Analysis from Comfort-I. Eurpopean Hem,atology Associates (EHA) 21st Congress, Copenhagen, Denmark, June 9 – 12, 2016
9. Vikas Gupta, Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, John F. DiPersio, John V. Catalano, Michael W. N. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, Jimmie H. Harvey, Jr, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Ronald Paquette, Azra Raza, Deanna Kornacki, Kang Sun, Hagop Kantarjian: Long-Term Outcomes of Ruxolitinib Therapy in Patients with Myelofibrosis: 5-Year Update from Comfort-1. American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, Illonois; June 3-7, 2016.
10. Richard T. Silver: Is Polycytmeia Vera Curable with Recombinant Interferon Alfa (RIFNα)? 8th International Hematology Expert Meeting, Cascais, Portugal, May 1-3, 2015.
11. Pozdnyakova O, Hasserjian R, Salama M, Mesa R, Foltz L, Gupta V, Mascarenhas J, Ritchie E, Hoffman R, Silver RT, Kremyanskaya M, Trehu E, Kantarjian H, Gotlib J, Verstovsek S: Bone marrow reticulin fibrosis by WHO Grade and quantitative image analysis is reduced by PRM-151 in patients with myelofibrosis and is associated with normalization of megakaryocyte morphology and improved platelet counts. 56th ASH Annual Meeting & Exposition, American Society of Hematology, San Francisco, CA, December 6-9, 2014.
12. Passamonti F, Alessandro V, MD2\*, Caramazza D, Rambaldi A, Morra E, Kiladjian JJ, Komrokji RS, Maffioli M, Gotlib J, Francisco C, Devos T, Silver RT, Guglielmelli P, Vianelli N, De Stefano V, Ruggeri M, Specchia G, Vitolo U, Rumi E, Mora B, Barbui T, Pieri L, Pascutto C, Cazzola M: A New International Multicenter-Based Model to Predict Survival in Myelofibrosis Secondary to Polycythemia and Thrombocythemia: The Mysec Prognostic Model (MYSEC-PM). . 56th ASH Annual Meeting & Exposition, American Society of Hematology, San Francisco, CA, December 6-9, 2014.
13. Caramazza D, Maffioli M, Cazzola M, Vannucchi AM, Rambaldi A, Morra E, Kiladjian JJ, Komrokji RS, Gotilib J, Cervantes F, Guglielmelli P, Devos T, Silver RT, Vianelli N, De Stefano V, Ruggeri M, Ricco A, Benevolo G, Mora B, Barbui T, Pieri L, Pascutto C, Rumi E, Passamonti F: Post-Polycythemia and Post-Thrombocythemia Myelofibrosis Have Distinctive Clinical Phenotypes: An International Multicenter Study on 718 Patients. 56th ASH Annual Meeting & Exposition, American Society of Hematology, San Francisco, CA, December 6-9, 2014.
14. Hekmatjou H, Roboz GJ, Ritchie EK, Lee S, Desai P, Scandura JM, Allen-Bard S, Christos P, Silver RT, Feldman EJ: Arterial Thrombotic Complications Are Uncommon in Patients without Cardiovascular Risk Factors and Occur at Equivalent Rates in Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib and Nilotinib. 56th ASH Annual Meeting & Exposition, American Society of Hematology, San Francisco, CA, December 6-9, 2014.
15. Larson RA, Conti R, Padula WV, Apperley JF, Baccarani M, Eigendorff E, Guilhot F, Guilhot J, Mahon FX, Martinelli G, Mayer J, Mueller MC, Niederwieser D, Saussele S, Schiffer CA, Silver RT, Simonsson B, Hehlmann R: What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity? 56th ASH Annual Meeting & Exposition, American Society of Hematology, San Francisco, CA, December 6-9, 2014.
16. Verstovsek S, Mesa RA, Foltz LM, Gupta V, Mascarenhas JO, Ritchie EK, Hoffman R, Silver RT, Kremyanskaya M, Pozdnyakova O, Hasserjian RP, Trehu E, Kantarjian HM, Gotlib JR: Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results. 56th ASH Annual Meeting & Exposition, American Society of Hematology, San Francisco, CA, December 6-9, 2014.
17. Verstovsek S, Mesa R, Foltz L, Gupta V, Mascarenhas J, Ritchie J, Hoffman R, Silver RT, Hong WJ, Kremyanskaya M, Trehu E, Kantarjian H, Gotlib J: Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results. American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, Illonois; May 29 to June 2, 2014.
18. Zhou J, Gong, Silver RT, Lascu, E, Orazi, A: Recombinant Interferon Alpha Therapy Decreases Bone Marrow Fibrosis and Cellular and Improves Megakaryocytes Morphology in a Significant Proportion of Patients with Myelofibrosis. 103rd Annual Meeting, United States & Canadian Academy of Pathology, March 1 - 7, 2014. Mod Pathol 2014 27, 389A
19. Fonseca E, Silver RT, Kazis LE, Iqbal SU, Rose M & Khan N: Ruxolitinib Discontinuation In Patients With Myelofibrosis: An Analysis From Clinical Practice. 55th ASH Annual Meeting & Exposition, American Society of Hematology, New Orleans, LA, December 7-10, 2013.
20. Harrison CN, Schaap NPM, Zweegman S, Jourdan E, Kiladjian JJ, Cervantes F, Niederwieser D, Cortes JE, Passamonti F, Reiter A, Recher C, Döhner K, Heidel FH, Silver RT, Winton EF, Gupta V, Ojeda E, Gisslinger H, Vannucchi AM, Talpaz M, Zhang J, Shi W & Mesa RA: Efficacy and Safety Of Fedratinib (SAR302503/TG101348) In Patients With Intermediate- Or High-Risk Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, Or Post-Essential Thrombocythemia (ET) MF Previously Treated With Ruxolitinib: Interim Results From a Phase II Study (JAKARTA-2). 55th ASH Annual Meeting & Exposition, American Society of Hematology, New Orleans, LA, December 7-10, 2013.
21. Verstovsek S, Mesa RA, GotlibJ, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MWN, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey, Jr. JH, Arcasoy MO, Hexner EO, Lyons RM, Raza A, Vaddi K, Sun W, Peng W, Sandor V, & Kantarjian H, for the COMFORT-I investigators: Long-Term Outcomes of Ruxolitinib Therapy in Patients with Myelofibrosis: 3-Year Update From COMFORT-I. 55th ASH Annual Meeting & Exposition, American Society of Hematology, New Orleans, LA, December 7-10, 2013.
22. Silver RT, Lascu E, Feldman EJ, Ritchie E, Roboz GJ, De Sancho MT, Bauman R, & Orazi A: Recombinant Interferon Alpha (rIFN) May Retard Progression of Early Myelofibrosis by Reducing Splenomegaly and By Decreasing Marrow Fibrosis. 55th ASH Annual Meeting & Exposition, American Society of Hematology, New Orleans, LA, December 7-10, 2013.
23. Verstovsek S, Mesa RA, Gotlib JR, Levy, RS, Gupta V, DiPersio, JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Vaddi K, Ericksin-Vitanen S, Sun W, Sandor V, Kantarjian H, for the COMFORT-I investigators: Long-Term Outcime of Ruxolitinib in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I. 54th ASH Annual Meeting & Exposition, Atlanta Georgia; December 8-11, 2012
24. Verstovsek S, Mesa RA, Gotlib JR, Gupta V, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Sun W, Kantarjian H, for the COMFORT-I investigators: Adverse Events and the Return of Myelofibrosis-Related Symptoms After Treatment Interruption or Discontinuation in the COMFORT-I Study. 17th Congress of the European Hematology Association. Amsterdam, The Netherlands; June 14–17, 2012
25. Moshe Talpaz, Solomon I. Hamburg, Katarzyna Jamieson, Howard R. Terebelo, Lawrence Afrin, Elliott F. Winton, Michael A. Scola, Roger M. Lyons, Jimmie Huling Harvey Jr., Chris E. Holmes, Gregory L. Ortega, Josef T. Prchal, Richard T. Silver, Maria R. Baer, Susan Erickson-Viitanen, Peter O’Neill, Wei Peng, Lance Leopold, Hagop Kantarjian, Srdan Verstovsek: Preliminary safety and efficacy from phase II study of rutoxolitinib in patients with primary and secondary myelofibrosis with platelet counts of 50–100x109/L. American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, Illonois; June 2012
26. Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano J, Deininger MW, Shields A, Miller CB, Silver RT, Talpaz M, Winston EF, Harvey JH, Hare T, Erickson-Viitanen S, Sun W, Sandor VA, Levy RS, Kantarjian HM and Verstovsek S: Associations Between Improvements in Myelofibrosis (MF) Symptoms and Quality of Life Measures with Splenomegaly Reduction in COMFORT-I: A Randomized, Double-Blind, Phase III Trial of the JAK1 and JAK2 Inhibitor Ruxolitinib Versus Placebo in Patients with MF. San Diego, CA December 10-13, 2011 (ASH Annual Meeting Abstracts 2011; 118:3842)
27. Mesa R, Kantarjian A, Shields J, Gotlib J, Gupta V, DiPersio J, Catalano J, Deininger M, Miller C, Silver RT, Talpaz M, Winston E, Harvey J, Hare T, Erickson-Viiitanen S, Koumenis L, Sun W, Sandor V, Levy R and Verstovsek: Results using the modified myelofibrosis symptoms assessment form (MFSAF v.2.0) in COMFORT-I: A randomized, double blind, phase III trial of JAK ½ inhibitor ruxolitinib vs Placebo in myelofibrosis. American Society of Clinical Oncology 2011 abstract for INCB 18424-351 (COMFORT-I). Chicago, IL June 2011.
28. Santisakultarm TP, Paduano C, Nishimura N, Stokol T, Skoa RC, Olbricht WL, Schafer AI, Silver RT, and Schaffer CB: Leukocyte plugging and microthrombi in capillaries contribute to decreased brain blood flow in animal models of myeloproliferative neoplasms. Journal of Cerebral Blood Flow & Metabolism 2011.
29. Verstovsek S, Mesa R, Gotlib, JR, Levy RS, Gupta V, DIPersio JF, Catalano J, Deininger M, Miller CT, Silver RT, Talpaz M, Winston E, Harvey J, Vaddi K, Erickson-Viitanen S, Koumenis L, Sun W, Sandor V, and Kantarjian H: Results of COMFORT-I: A randomized, double blind, phase III trial of JAK 1/2 inhibitor INCB (424) versus placebo (PB) for patients with myelofibrosis. American Society of Clinical Oncology Annual Meeting, Chicago, IL June 2011.
30. Santisakultarm T, Paduano C, Nishimura N, Stokol T, Skoda R, Olbricht WL, Schafer AI, Silver RT, and Schaffer C: Two-photo in vivo imaging reveals cerebral circulation disruptions in mouse models of myeloproliferative neoplasms. XXV International Symposium on Cerebral Blood Flow, Metabolism & Function. Barcelona, Spain, May 25-27, 2011.
31. Santiskultarm TP, Nishimura N, Paduano C, Skoda RC, Olbricht WI, Schafer AI, Schaffer CB, and Silver RT: In vivo imaging of cerebral circulation in mouse models of polycythemia vera. 52nd ASH Annual Meeting & Exposition, American Society of Hematology, Orlando FL, December 4-7-2010. (ASH Annual Meeting Abstracts 2010; 116:4091).
32. Schleuning M, Scholten M., Biezen A. V. , Nagler A., Apperley J, Michallet M, Grigg A, Silver RT, Leitner, A, Gratwohl A, Ekblom M, Kouhry J, de Witte T., and Olavarria E.: Allogeneic Stem Cell Transplantation for Patients with Chronic Myeloid Leukemia after Prior Treatment with Nilotinib or Dasatinib. 52nd Annual Meeting & Exposition, American Society of Hematology, Orlando FL, December 4-7, 2010 (ASH Annual Meeting Abstracts 2010; 116:2348).
33. Silver RT. Is A Decrease In JAK2V617F Allele Burden A Prerequisite To Clinical Response in patients With Polycythemia Vera?, 4th Annual Workshop on CML and MPN, Natchez, Mississippi, December 8-10, 2009.
34. Goldman JJ, Vandris K, Adriano F, Bourla M, and Silver RT. Normal Serum-Erythropoeitin (S-epo) Level at Diagnosis of Polycythemia Vera (PV ) Correlates with Low JAK2V617F Mutant Allele Burden and Indicates Mild Phenotype. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 4978.
35. Najfeld V, Tripodi J, Fruchtman S, Silverman LR, Silver RT, Scalise A, and Hoffman R. Jumping Translocations of the Long Arms of Chromosome 1 (1qJT) in Myeloproliferative Neoplasms (MPNs) and Myelodysplastic Syndromes (MDS) Are Associated with High Risk of Transformation to Acute Myelogeneous Leukemia (AML), 51st ASH Annual Meeting , New Orleans, Louisiana, December 5-7, 2009; 1567:627.
36. Alchberger KJ, Fleischman AG, Doratotaj S, Bumm TGP, Silver RT, Deloughery TG, Pahl HL, Druker, BJ, Burns CJ, and Deininger M. Tumor Necrosis Factor-Alpha (TNF) Expression is Elevated in Myelo-Proliferative Neoplasms (MPN) and Modulated by Inhibition of JAK2 V617F. 51st ASH Annual Meeting, New Orleans, Louisiana, December 5-7, 2009; Abstract 2917; pp1140.
37. Silver RT, Vandris K, Goldman JJ, Adriano F, Wang YL, Jones A, Christos P, and Cross NCP. Decrease in JAK2V617F Allele Burden is Not a Prerequisite to Clinical Response in Patients with Polycythemia Vera (PV). 51st ASH Annual Meeting, New Orleans, Louisiana, December 5-7, 2009. Abstract 1908; pp 757.
38. Shieh JH, Silver, RT, Adriano F, and Moore M. A Novel in Vitro Model of Focal Fibrosis in Bone Marrow Stromal Co-Culture of CD34+ Cells From Patients With Idiopathic Myelofibrosis. 51st ASH Annual Meeting, New Orleans, Louisiana, December 5-7, 2009; Abstract 2896; pp1131.
39. Jones A, Campbell P, Beer P, Schnittger S, Vannucchi A, Zoi K, Percy M, McMullin M, Scott L, Tapper W, Silver R, Oscier D, Harrison C, Grallert H, Kisialiou A, Strike P, Chase A, Green A and Cross N. The JAK2 46/1 haplotype predisposes to myeloproliferative neoplasms characterized by diverse mutations. Blood (ASH Annual Meeting Abstracts) November 2009; 114:433.
40. Silver RT. Leukemias, myelodysplasia and transplantation update. News from the 45th Asco Annual meeting (ASCO) 2009, New York, NY, July 25, 2009. Abstracts: 7000, 7002, 7003, 7007, 7010, 7011, 7015, 7044.
41. T.P. Santisakultarm, Cornelius N.R., Nishimura N, Doerschuk P.C., Obricht W.L, Silver RT, Schaffer C.B. Blood flow dynamics in Cortical Microvascular Networks. Brain, June 8, 2009.
42. Paquette RL, Sokol L, Shah NP, Silver RT, List AF, Clary DO, Bui LA, and Talpaz M. A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Polycythemia Vera. Blood (ASH Annual Meeting Abstracts), Nov 2008;112:2810.
43. Silver RT, Vandris K, Adriano F, Goldman J, and Levy BP. Recombinant interferon alpha (rIFNα) may retard progression of early primary myelofibrosis (PM) by reducing splenomegaly and by changing marrow morphology. Blood (ASH Annual Meeting Abstracts), Nov 2008;112:1758.
44. Cross NCP, Jones AV, Silver RT, Oscier D, Metzgeroth G, Wang YL, Collions A, Reiter A, Grand F, Chase A. Development of V617F JAK2 Associated Myeloproliferative Neoplasms is a Non-Random Event that is Strongly Dependent on JAK2 Haplotype. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112:173.
45. Salie R, Silver R. Uncommon or delayed adverse events associated with imatinib treatment for CML. Eurpean LeukemiaNet (ELN) Frontiers Meeting (Abstracts) October 2008 in Cannes, France.
46. Silver RT, Vandris K, Wang YL, Christos PJ, Adriano F, Jones AV, and Cross NCP. JAK2V617F Mutational Load in Patients with Polycythemia Vera (PV) Measured by Peripheral Blood DNA Is Associated with Disease Severity. Blood (ASH Annual Meeting Abstracts) Nov 2007;110:2530.
47. Wang YL, Vandris K, Jones AV, Cross NCP, Christos PJ, Adriano F, and Silver RT. JAK2 Mutations Are Present in All Cases of Polycythemia Vera. Blood (ASH Annual Meeting Abstracts) Nov 2007;110:4669.
48. Silver RT, Baccarani M, Vandris K, Guilhot F, Simonsson B, Hochhaus A, Hehlmann R, and the European LeukemiaNet. Chronic Myeloid Leukemia (CML): A Model Disease for Utilizing Evidence-Based Guidelines in a Decade of Progress. Blood. 2006;108(11):Abstract# 3313. ASH Poster Board #-Session 542-III.
49. Cortes J, Kim DW, Guilhot F, Rosti G, Silver RT, et al. Dasatinib (SPRYCEL) in Patients (pts) with Chronic Myelogenous Leukemia in Accelerated Phase (AP-CML) That Is Imatinib-Resistant (im-r) or –Intolerant (im-i): Updated Results of the CA180-005 ‘Start-A’ Phase II Study. Blood. 2006. Abstract# 2160. Poster Board #-Session:338-II.
50. Yang X-F, Xiong A, Liu E, Yan Y, Silver RT, Verstovsek S, Prachal J, Wang H. A Novel Mechanism in Generation of Self-Antigen Repertoire – An Unconventional Antigen Translated by a Novel Internal Ribosome Entry Site Elicits Anti-Tumor Humoral Immune Responses. Blood. 2006;108(11):Abstract# 3702. ASH Poster Board #-Session 931-III.
51. Hyjek E, Chadburn A, Cross NCP, Jones AV, Chiu A, Mathew S, Sun P, Young A, Knowles DM, Silver RT. Correlation of clinical and molecular response to imatinib in Polycythemia Vera (PV) patients with bone marrow morphologic and immunophenotypic changes. Blood. 2006;108(11):Abstract #4914, ASH Poster Board Session.
52. Silver, RT. Guidelines in CML. First Annual Global CML Workshop, Hamilton, Bermuda, December 15-16, 2006.
53. Silver, RT. Some Clinical Thoughts Regarding Polycythemia Vera in 2006. Madeira, Spain, September 2006.
54. Silver, RT. Some Aspects of Polycythemia Vera in 2006. Grand Rounds. Barcelona, Spain, September 7, 2006.
55. Silver RT, Baccarani M. CML Guidelines. 15th International CML-Workshop, European LeukemiaNet, Mannheim, Germany, June 30-July 1, 2006.
56. Silver RT, Lee S, Jones AV, Rivera M, Feldman EJ, Roboz G, Ritchie E, Allen- Bard S, Cross N. The frequency of JAK2 V617F mutation in patients with polycythemia vera and its correlation with severity of disease. 42nd Annual, American Society of Clinical Oncology Meeting, Atlanta, GA, June 2-6, 2006.
57. Feldman EJ, Spivak JL, Lee S, Rivera M, Fruchtman SM, Salvado A, Silver RT., Imatinib mesylate is effective in the treatment of polycythemia vera: A multi- institutional clinical trial. 42nd Annual American Society of Clinical Oncology Meeting, Atlanta, GA, June 2-6, 2006.
58. Talpaz M, Apperley JF, Kim DW, Silver RT, Bullorsky EO, Cheng S, Iyer M, Guilhot F. Dasatinib (D) in patients with accelerated phase chronic myeloid leukemia (AP-CML) who are resistant or intolerant to imatinib: Results of the CA180005. 42nd Annual American Society of Clinical Oncology Meeting, Atlanta, GA, June 2-6, 2006.
59. Jones AV, Higley K, Curtis…Silver RT, Cross N, et al.:No significant molecular response in polycythemia vera patients treated with imatinib or interferon alpha. 47th American Society of Hematology Annual Meeting, Atlanta, GA, 2005.
60. Silver RT, Jones AV, Feldman EJ, et al.: Validation of JAK2 and new clinical criteria for the diagnosis of polycythemia vera (PV). 47th American Society of Hematology Annual Meeting, Atlanta, GA, 2005.
61. Najfeld V, Silver RT, Hoffman, et al: Pretreatment Cytogenetic Abnormalities in Polycythemia Vera (PV) Determines the Effectiveness of Imatinib Studies From A Multi-Institutional Trial. 46th American Society of Hematology Annual Meeting, San Diego, CA, December, 2004.
62. Silver RT, Fruchtman S, Feldman E, et al.: Imatinib mesylate (GleevecR) is effective in the treatment of polycythemia vera: A multi-institutional clinical trial. 46th American Society of Hematology Annual Meeting, San Diego, CA, December, 2004.
63. Silver RT, Talpaz, Sawyers C, et al.: Four Years of Follow-up of 1027 Patients With Late Chronic Phase (L-CP), Accelerated Phase (AP), or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Treated With Imatinib In Three Large Phase II Trials. 46th American Society of Hematology Annual Meeting, San Diego, CA, December, 2004.
64. Silver RT: Imatinib mesylate (IM) is effective in treating patients with polycythemia vera (PV), Chemotherapy Foundation, Mt. Sinai School of Medicine, New York, NY, November 12, 2004.
65. Silver RT: Use of Guidelines for the Treatment of Chronic Myeloid Leukemia, European LeukemiaNet, Heidelberg, Germany, July 3, 2004.
66. Peerschke E, Weksler B, Silver, RT, et al. Effect of Hematocrit on Platelet Adhesion and Arterial Flow Conditions. Forty-fifth annual meeting program presented at the American Society of Hematology, December 2003. Blood, Vol. 102 No 11 pg. 71b (Part B). November 16, 2003.
67. Sawyers CL, Hochhaus A, Silver RT, et al. High Dose Imatinib (STI571), Gleevec®) Provides Durable Long-Term Outcomes for Patients (Pts) with Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) or Myeloid Blast Crisis (BC): Follow-Up of the Phase II Studies. Forty-fifth annual meeting program presented at the American Society of Hematology, December 2003. Blood, Vol. 102 No 11 pg. 905a. November 16, 2003.
68. Kantarjian HM, Schiffer CA, Silver RT, et al. Imatinib (Gleevec®) Maintains Favorable Long-Term Outcomes in Chronic-Phase Chronic Myeloid Leukemia (CML) for Patients Failing Interferon-Alpha (IFN)-Follow-Up of a Phase II Study. Forty-fifth annual meeting program presented at the American Society of Hematology, December 2003. Blood, Vol. 102 No 11 pg. 905a. November 16, 2003.
69. Feldman EJ, Roboz GJ, Silver RT, et al. Phase I Evaluation of Troxacitabine (TroxatylTM) Administered by Continuous Infusion in Patients with Refractory Acute Myeloid Leukemia (AML). Forty-fifth annual meeting program presented at the American Society of Hematology, December 2003. Blood, Vol. 102 No 11 pg. 873a. November 16, 2003.
70. Pastore YD, Spivak JL, Silver RT, et al: Report on 12 Children with Polycythemia Vera. Forty-fifth annual meeting program presented at the American Society of Hematology, December 2003. Blood, Vol. 102 No 11 pg. 515a. November 16, 2003.
71. Feldman E, Cortes J, Silver RT, et al: Continuous Oral Lonafarnib (SarasarTM) for the Treatment of Patients with Myelodysplastic Syndrome. Forty-fifth annual meeting program presented at the American Society of Hematology, December 2003. Blood, Vol. 102 No 11 pg. 421a. November 2003.
72. Silver RT: The Effect of Imatinib Mesylate (Gleevec) on CML Treatment. The New England Healthcare Institute (NEHI). Cambridge, Massachusetts. November 5, 2003.
73. Silver RT: Treatment of Polycythemia Vera (PV) with Interferon (rIFN-Alpha) and Imatinib Mesylate (IM). XVIIth Meeting of the International Society of Haematology (European & African Division) Abstract book page 17. Graz, Austria September, 2003
74. Silver RT, Current Perspectives in Myeloproliferative Disorders. “New Aspects of Polycythemia Vera”. XVIIth Meeting of the International Society of Haematology (European & African Division). Graz, Austria, September, 2003.
75. Feldman E, Najfeld V, Silver RT, et al. The Emergence of Philadelphia Chromosome (Ph) Negative, Trisomy 8 Positive Cells in Patients with Chronic Myelogenous Leukemia (CML) Treated with Imatinib Mesylate: Clinical Evidence for a Multistep Pathogenesis. 2003
76. Talpaz M, Silver RT, Druker B, et al.: Imatinib (STI571, GleevecTM) achieves prolonged survival in patients with accelerated phase Ph+ chronic myeloid leukemia (CML-AP): up to 36 month follow-up of a phase II study. ASH December 2002.
77. Silver RT: Imatinib Mesylate Reduces Phlebotomy Requirements in Polycythemia Vera. (Abstract presented at the American Society Hematology), December 2002.
78. RT Silver: Treatment of Chronic Myeloid Leukemia, Chemotherapy Foundation Symposium XX Innovative Cancer Therapy for Tomorrow, Cancer Investigation. November 2002
79. Silver RT. New Treatments for Chronic Myeloid Leukemia. Chronic Myeloproliferative Disorders 2002 Hematology Fellows’ Program, Coronado, CA, September 2002.
80. Stein M, Fruchtman S, Silver RT, Najfeld V: Prognostic Implications of Gain of 9p, the Most Frequent Cytogenetic Alteration in Polycythemia Vera (PV). ASH September 2002 (abstract)
81. Silver RT, Chadburn A, Feldman E, Schuster MW, Godwin BA, Berk GI: Importance of Bone Marrow in Blast and Accelerated Phases of Chronic Myeloid Leukemia (CML). ASH 2001
82. M Talpaz, RT Silver, B Druker et al: Gleevec (Formerly STI-571): An active Drug in Patients with PH+ Chronic Myeloid Leukemia in Accelerated Phase – Updated Results of a Phase II Study. MD Anderson Cancer Ct. Tx. Novartis Pharma AG. on behalf of the Int’l Gleevec Study Group, Basel, Switzerland. BLOOD, Vol 98, #11, Abst. 3509. 2001.
83. RT Silver, C Tendler et al: Phase III Trial of PEG Intron vs Interferon Alfa-2b for the Initial Treatment of Chronic Myelogenous Leukemia (CML), Weill Med. College of Cornell Univ. Schering-Plough, Kenilworth, NJ. BLOOD, Vol.98 #11, Nov.2001, Abst. 1467. Poster presentation at ASH 12-2001.
84. RT Silver et al: Treatment of Chronic Myeloid Leukemia (CML) with an Intermittent Schedule of Interferon alfa-2b and ara-C: CALGB 9013; Poster Presentation at 37th ASCO Annual Meeting, May 2001, San Francisco.
85. A.R. Moliterno, R.T. Silver, A Diagnostic Assay for Polycythemia Vera. J.L. Spivak, John Hopkins Univ.School of Med. Baltimore, MD; Weill Med. School of Cornell Univ. NY. Blood, Vol.96 #11, Nov. 2000, Abst. #2204.
86. RT Silver et al: Treatment of Chronic Myeloid Leukemia (CML) with an Intermittent Schedule of Interferon alfa-2b and ara-C: CALGB 9013; Poster Presentation at 37th ASCO Annual Meeting, May 2001, San Francisco.
87. RT Silver, C Tendler et al: Phase III Trial of PEG Intron vs Interferon Alfa-2b for the Initial Treatment of Chronic Myelogenous Leukemia (CML), Weill Med. College of Cornell Univ. Schering-Plough, Kenilworth, NJ. BLOOD, Vol.98 #11, Nov.2001, Abst. 1467. Poster presentation at ASH 12-2001.
88. M Talpaz, RT Silver, B Druker et al: Gleevec (Formerly STI-571): An active Drug in Patients with PH+ Chronic Myeloid Leukemia in Accelerated Phase – Updated Results of a Phase II Study. MD Anderson Cancer Ct. Tx. Novartis Pharma AG. on behalf of the Int’l Gleevec Study Group, Basel, Switzerland. BLOOD, Vol 98, #11, Abst. 3509. 2001.
89. Silver RT, Chadburn A, Feldman E, Schuster MW, Godwin BA, Berk GI: Importance of Bone Marrow in Blast and Accelerated Phases of Chronic Myeloid Leukemia (CML). ASH 2001
90. Stein M, Fruchtman S, Silver RT, Najfeld V: Prognostic Implications of Gain of 9p, the Most Frequent Cytogenetic Alteration in Polycythemia Vera (PV). ASH September 2002
91. Silver RT. New Treatments for Chronic Myeloid Leukemia. Chronic Myeloproliferative Disorders 2002 Hematology Fellows’ Program, Coronado, CA, September 2002.
92. RT Silver: Treatment of Chronic Myeloid Leukemia, Chemotherapy Foundation Symposium XX Innovative Cancer Therapy for Tomorrow, Cancer Investigation. November 2002
93. Silver RT: Imatinib Mesylate Reduces Phlebotomy Requirements in Polycythemia Vera. (Abstract presented at the American Society Hematology), December 2002.
94. Talpaz M, Silver RT, Druker B, et al.: Imatinib (STI571, GleevecTM) achieves prolonged survival in patients with accelerated phase Ph+ chronic myeloid leukemia (CML-AP): up to 36 month follow-up of a phase II study. ASH December 2002.
95. Feldman E, Najfeld V, Silver RT, et al. The Emergence of Philadelphia Chromosome (Ph) Negative, Trisomy 8 Positive Cells in Patients with Chronic Myelogenous Leukemia (CML) Treated with Imatinib Mesylate: Clinical Evidence for a Multistep Pathogenesis. 2003
96. Silver RT, Current Perspectives in Myeloproliferative Disorders. “New Aspects of Polycythemia Vera”. XVIIth Meeting of the International Society of Haematology (European & African Division). Graz, Austria, September, 2003.
97. Silver RT: Treatment of Polycythemia Vera (PV) with Interferon (rIFN-Alpha) and Imatinib Mesylate (IM). XVIIth Meeting of the International Society of Haematology (European & African Division) Abstract book page 17. Graz, Austria September, 2003
98. Silver RT: The Effect of Imatinib Mesylate (Gleevec) on CML Treatment. The New England Healthcare Institute (NEHI). Cambridge, Massachusetts. November 5, 2003.
99. Feldman E, Cortes J, Silver RT, et al: Continuous Oral Lonafarnib (SarasarTM) for the Treatment of Patients with Myelodysplastic Syndrome. Forty-fifth annual meeting program presented at the American Society of Hematology, December 2003. Blood, Vol. 102 No 11 pg. 421a. November 2003.
100. Pastore YD, Spivak JL, Silver RT, et al: Report on 12 Children with Polycythemia Vera. Forty-fifth annual meeting program presented at the American Society of Hematology, December 2003. Blood, Vol. 102 No 11 pg. 515a. November 16, 2003.
101. Feldman EJ, Roboz GJ, Silver RT, et al. Phase I Evaluation of Troxacitabine (TroxatylTM) Administered by Continuous Infusion in Patients with Refractory Acute Myeloid Leukemia (AML). Forty-fifth annual meeting program presented at the American Society of Hematology, December 2003. Blood, Vol. 102 No 11 pg. 873a. November 16, 2003.
102. Kantarjian HM, Schiffer CA, Silver RT, et al. Imatinib (Gleevec®) Maintains Favorable Long-Term Outcomes in Chronic-Phase Chronic Myeloid Leukemia (CML) for Patients Failing Interferon-Alpha (IFN)-Follow-Up of a Phase II Study. Forty-fifth annual meeting program presented at the American Society of Hematology, December 2003. Blood, Vol. 102 No 11 pg. 905a. November 16, 2003.
103. Sawyers CL, Hochhaus A, Silver RT, et al. High Dose Imatinib (STI571), Gleevec®) Provides Durable Long-Term Outcomes for Patients (Pts) with Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) or Myeloid Blast Crisis (BC): Follow-Up of the Phase II Studies. Forty-fifth annual meeting program presented at the American Society of Hematology, December 2003. Blood, Vol. 102 No 11 pg. 905a. November 16, 2003.
104. Peerschke E, Weksler B, Silver, RT, et al. Effect of Hematocrit on Platelet Adhesion and Arterial Flow Conditions. Forty-fifth annual meeting program presented at the American Society of Hematology, December 2003. Blood, Vol. 102 No 11 pg. 71b (Part B). November 16, 2003.
105. Silver RT: Use of Guidelines for the Treatment of Chronic Myeloid Leukemia, European LeukemiaNet, Heidelberg, Germany, July 3, 2004.
106. Silver RT: Imatinib mesylate (IM) is effective in treating patients with polycythemia vera (PV), Chemotherapy Foundation, Mt. Sinai School of Medicine, New York, NY, November 12, 2004.
107. Silver RT, Talpaz, Sawyers C, et al.: Four Years of Follow-up of 1027 Patients With Late Chronic Phase (L-CP), Accelerated Phase (AP), or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Treated With Imatinib In Three Large Phase II Trials. 46th American Society of Hematology Annual Meeting, San Diego, CA, December, 2004.
108. Silver RT, Fruchtman S, Feldman E, et al.: Imatinib mesylate (GleevecR) is effective in the treatment of polycythemia vera: A multi-institutional clinical trial. 46th American Society of Hematology Annual Meeting, San Diego, CA, December, 2004.
109. Najfeld V, Silver RT, Hoffman, et al: Pretreatment Cytogenetic Abnormalities in Polycythemia Vera (PV) Determines the Effectiveness of Imatinib Studies From A Multi-Institutional Trial. 46th American Society of Hematology Annual Meeting, San Diego, CA, December, 2004.
110. Silver RT, Jones AV, Feldman EJ, et al.: Validation of JAK2 and new clinical criteria for the diagnosis of polycythemia vera (PV). 47th American Society of Hematology Annual Meeting, Atlanta, GA, 2005.
111. Jones AV, Higley K, Curtis…Silver RT, Cross N, et al.:No significant molecular response in polycythemia vera patients treated with imatinib or interferon alpha. 47th American Society of Hematology Annual Meeting, Atlanta, GA, 2005.
112. Talpaz M, Apperley JF, Kim DW, Silver RT, Bullorsky EO, Cheng S, Iyer M, Guilhot F. Dasatinib (D) in patients with accelerated phase chronic myeloid leukemia (AP-CML) who are resistant or intolerant to imatinib: Results of the CA180005. 42nd Annual American Society of Clinical Oncology Meeting, Atlanta, GA, June 2-6, 2006.
113. Feldman EJ, Spivak JL, Lee S, Rivera M, Fruchtman SM, Salvado A, Silver RT., Imatinib mesylate is effective in the treatment of polycythemia vera: A multi- institutional clinical trial. 42nd Annual American Society of Clinical Oncology Meeting, Atlanta, GA, June 2-6, 2006.
114. Silver RT, Lee S, Jones AV, Rivera M, Feldman EJ, Roboz G, Ritchie E, Allen- Bard S, Cross N. The frequency of JAK2 V617F mutation in patients with polycythemia vera and its correlation with severity of disease. 42nd Annual, American Society of Clinical Oncology Meeting, Atlanta, GA, June 2-6, 2006.
115. Silver RT, Baccarani M. CML Guidelines. 15th International CML-Workshop, European LeukemiaNet, Mannheim, Germany, June 30-July 1, 2006.
116. Silver, RT. Some Aspects of Polycythemia Vera in 2006. Grand Rounds. Barcelona, Spain, September 7, 2006.
117. Silver, RT. Some Clinical Thoughts Regarding Polycythemia Vera in 2006. Madeira, Spain, September 2006.
118. Silver, RT. Guidelines in CML. First Annual Global CML Workshop, Hamilton, Bermuda, December 15-16, 2006.
119. Hyjek E, Chadburn A, Cross NCP, Jones AV, Chiu A, Mathew S, Sun P, Young A, Knowles DM, Silver RT. Correlation of clinical and molecular response to imatinib in Polycythemia Vera (PV) patients with bone marrow morphologic and immunophenotypic changes. Blood. 2006;108(11):Abstract #4914, ASH Poster Board Session.
120. Yang X-F, Xiong A, Liu E, Yan Y, Silver RT, Verstovsek S, Prachal J, Wang H. A Novel Mechanism in Generation of Self-Antigen Repertoire – An Unconventional Antigen Translated by a Novel Internal Ribosome Entry Site Elicits Anti-Tumor Humoral Immune Responses. Blood. 2006;108(11):Abstract# 3702. ASH Poster Board #-Session 931-III.
121. Cortes J, Kim DW, Guilhot F, Rosti G, Silver RT, et al. Dasatinib (SPRYCEL) in Patients (pts) with Chronic Myelogenous Leukemia in Accelerated Phase (AP-CML) That Is Imatinib-Resistant (im-r) or –Intolerant (im-i): Updated Results of the CA180-005 ‘Start-A’ Phase II Study. Blood. 2006. Abstract# 2160. Poster Board #-Session:338-II.
122. Silver RT, Baccarani M, Vandris K, Guilhot F, Simonsson B, Hochhaus A, Hehlmann R, and the European LeukemiaNet. Chronic Myeloid Leukemia (CML): A Model Disease for Utilizing Evidence-Based Guidelines in a Decade of Progress. Blood. 2006;108(11):Abstract# 3313. ASH Poster Board #-Session 542-III.
123. Wang YL, Vandris K, Jones AV, Cross NCP, Christos PJ, Adriano F, and Silver RT. JAK2 Mutations Are Present in All Cases of Polycythemia Vera. Blood (ASH Annual Meeting Abstracts) Nov 2007;110:4669.
124. Silver RT, Vandris K, Wang YL, Christos PJ, Adriano F, Jones AV, and Cross NCP. JAK2V617F Mutational Load in Patients with Polycythemia Vera (PV) Measured by Peripheral Blood DNA Is Associated with Disease Severity. Blood (ASH Annual Meeting Abstracts) Nov 2007;110:2530.
125. Salie R, Silver R. Uncommon or delayed adverse events associated with imatinib treatment for CML. Eurpean LeukemiaNet (ELN) Frontiers Meeting (Abstracts) October 2008 in Cannes, France.
126. Cross NCP, Jones AV, Silver RT, Oscier D, Metzgeroth G, Wang YL, Collions A, Reiter A, Grand F, Chase A. Development of V617F JAK2 Associated Myeloproliferative Neoplasms is a Non-Random Event that is Strongly Dependent on JAK2 Haplotype. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112:173.
127. Silver RT, Vandris K, Adriano F, Goldman J, and Levy BP. Recombinant interferon alpha (rIFNα) may retard progression of early primary myelofibrosis (PM) by reducing splenomegaly and by changing marrow morphology. Blood (ASH Annual Meeting Abstracts), Nov 2008;112:1758.
128. Paquette RL, Sokol L, Shah NP, Silver RT, List AF, Clary DO, Bui LA, and Talpaz M. A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Polycythemia Vera. Blood (ASH Annual Meeting Abstracts),Nov 2008;112:2810.
129. T.P. Santisakultarm, Cornelius N.R., Nishimura N, Doerschuk P.C., Obricht W.L, Silver RT, Schaffer C.B. Blood flow dynamics in Cortical Microvascular Networks. Brain, June 8, 2009.
130. Silver RT. Leukemias, myelodysplasia and transplantation update. News from the 45th Asco Annual meeting (ASCO) 2009, New York, NY, July 25, 2009. Abstracts: 7000, 7002, 7003, 7007, 7010, 7011, 7015, 7044.
131. Jones A, Campbell P, Beer P, Schnittger S, Vannucchi A, Zoi K, Percy M, McMullin M, Scott L, Tapper W, Silver R, Oscier D, Harrison C, Grallert H, Kisialiou A, Strike P, Chase A, Green A and Cross N. The JAK2 46/1 haplotype predisposes to myeloproliferative neoplasms characterized by diverse mutations. Blood (ASH Annual Meeting Abstracts) November 2009; 114:433.
132. Shieh JH, Silver, RT, Adriano F, and Moore M. A Novel in Vitro Model of Focal Fibrosis in Bone Marrow Stromal Co-Culture of CD34+ Cells From Patients With Idiopathic Myelofibrosis. 51st ASH Annual Meeting, New Orleans, Louisiana, December 5-7, 2009; Abstract 2896; pp1131.
133. Silver RT, Vandris K, Goldman JJ, Adriano F, Wang YL, Jones A, Christos P, and Cross NCP. Decrease in JAK2V617F Allele Burden is Not a Prerequisite to Clinical Response in Patients with Polycythemia Vera (PV). 51st ASH Annual Meeting, New Orleans, Louisiana, December 5-7, 2009. Abstract 1908; pp 757.
134. Alchberger KJ, Fleischman AG, Doratotaj S, Bumm TGP, Silver RT, Deloughery TG, Pahl HL, Druker, BJ, Burns CJ, and Deininger M. Tumor Necrosis Factor-Alpha (TNF) Expression is Elevated in Myelo-Proliferative Neoplasms (MPN) and Modulated by Inhibition of JAK2 V617F. 51st ASH Annual Meeting, New Orleans, Louisiana, December 5-7, 2009; Abstract 2917; pp1140.
135. Najfeld V, Tripodi J, Fruchtman S, Silverman LR, Silver RT, Scalise A, and Hoffman R. Jumping Translocations of the Long Arms of Chromosome 1 (1qJT) in Myeloproliferative Neoplasms (MPNs) and Myelodysplastic Syndromes (MDS) Are Associated with High Risk of Transformation to Acute Myelogeneous Leukemia (AML), 51st ASH Annual Meeting , New Orleans, Louisiana, December 5-7, 2009; 1567:627.
136. Goldman JJ, Vandris K, Adriano F, Bourla M, and Silver RT. Normal Serum-Erythropoeitin (S-epo) Level at Diagnosis of Polycythemia Vera (PV ) Correlates with Low JAK2V617F Mutant Allele Burden and Indicates Mild Phenotype. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 4978.
137. Silver RT. Is A Decrease In JAK2V617F Allele Burden A Prerequisite To Clinical Response in patients With Polycythemia Vera?, 4th Annual Workshop on CML and MPN, Natchez, Mississippi, December 8-10, 2009.
138. Schleuning M, Scholten M., Biezen A. V. , Nagler A., Apperley J, Michallet M, Grigg A, Silver RT, Leitner, A, Gratwohl A, Ekblom M, Kouhry J, de Witte T., and Olavarria E.: Allogeneic Stem Cell Transplantation for Patients with Chronic Myeloid Leukemia after Prior Treatment with Nilotinib or Dasatinib. 52nd Annual Meeting & Exposition, American Society of Hematology, Orlando FL, December 4-7, 2010 (ASH Annual Meeting Abstracts 2010; 116:2348).
139. Santiskultarm TP, Nishimura N, Paduano C, Skoda RC, Olbricht WI, Schafer AI, Schaffer CB, and Silver RT: In vivo imaging of cerebral circulation in mouse models of polycythemia vera. 52nd ASH Annual Meeting & Exposition, American Society of Hematology, Orlando FL, December 4-7-2010. (ASH Annual Meeting Abstracts 2010; 116:4091).
140. Santisakultarm T, Paduano C, Nishimura N, Stokol T, Skoda R, Olbricht WL, Schafer AI, Silver RT, and Schaffer C: Two-photo in vivo imaging reveals cerebral circulation disruptions in mouse models of myeloproliferative neoplasms. XXV International Symposium on Cerebral Blood Flow, Metabolism & Function. Barcelona, Spain, May 25-27, 2011.
141. Verstovsek S, Mesa R, Gotlib, JR, Levy RS, Gupta V, DIPersio JF, Catalano J, Deininger M, Miller CT, Silver RT, Talpaz M, Winston E, Harvey J, Vaddi K, Erickson-Viitanen S, Koumenis L, Sun W, Sandor V, and Kantarjian H: Results of COMFORT-I: A randomized, double blind, phase III trial of JAK 1/2 inhibitor INCB (424) versus placebo (PB) for patients with myelofibrosis. American Society of Clinical Oncology Annual Meeting, Chicago, IL June 2011.
142. Santisakultarm TP, Paduano C, Nishimura N, Stokol T, Skoa RC, Olbricht WL, Schafer AI, Silver RT, and Schaffer CB: Leukocyte plugging and microthrombi in capillaries contribute to decreased brain blood flow in animal models of myeloproliferative neoplasms. Journal of Cerebral Blood Flow & Metabolism 2011.
143. Mesa R, Kantarjian A, Shields J, Gotlib J, Gupta V, DiPersio J, Catalano J, Deininger M, Miller C, Silver RT, Talpaz M, Winston E, Harvey J, Hare T, Erickson-Viiitanen S, Koumenis L, Sun W, Sandor V, Levy R and Verstovsek: Results using the modified myelofibrosis symptoms assessment form (MFSAF v.2.0) in COMFORT-I: A randomized, double blind, phase III trial of JAK ½ inhibitor ruxolitinib vs Placebo in myelofibrosis. American Society of Clinical Oncology 2011 abstract for INCB 18424-351 (COMFORT-I). Chicago, IL June 2011.
144. Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano J, Deininger MW, Shields A, Miller CB, Silver RT, Talpaz M, Winston EF, Harvey JH, Hare T, Erickson-Viitanen S, Sun W, Sandor VA, Levy RS, Kantarjian HM and Verstovsek S: Associations Between Improvements in Myelofibrosis (MF) Symptoms and Quality of Life Measures with Splenomegaly Reduction in COMFORT-I: A Randomized, Double-Blind, Phase III Trial of the JAK1 and JAK2 Inhibitor Ruxolitinib Versus Placebo in Patients with MF. San Diego, CA December 10-13, 2011 (ASH Annual Meeting Abstracts 2011; 118:3842)
145. Moshe Talpaz, Solomon I. Hamburg, Katarzyna Jamieson, Howard R. Terebelo, Lawrence Afrin, Elliott F. Winton, Michael A. Scola, Roger M. Lyons, Jimmie Huling Harvey Jr., Chris E. Holmes, Gregory L. Ortega, Josef T. Prchal, Richard T. Silver, Maria R. Baer, Susan Erickson-Viitanen, Peter O’Neill, Wei Peng, Lance Leopold, Hagop Kantarjian, Srdan Verstovsek: Preliminary safety and efficacy from phase II study of rutoxolitinib in patients with primary and secondary myelofibrosis with platelet counts of 50–100x109/L. American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, Illonois; June 2012
146. Verstovsek S, Mesa RA, Gotlib JR, Gupta V, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Sun W, Kantarjian H, for the COMFORT-I investigators: Adverse Events and the Return of Myelofibrosis-Related Symptoms After Treatment Interruption or Discontinuation in the COMFORT-I Study. 17th Congress of the European Hematology Association. Amsterdam, The Netherlands; June 14–17, 2012
147. Verstovsek S, Mesa RA, Gotlib JR, Levy, RS, Gupta V, DiPersio, JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Vaddi K, Ericksin-Vitanen S, Sun W, Sandor V, Kantarjian H, for the COMFORT-I investigators: Long-Term Outcime of Ruxolitinib in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I. 54th ASH Annual Meeting & Exposition, Atlanta Georgia; December 8-11, 2012
148. Silver RT, Lascu E, Feldman EJ, Ritchie E, Roboz GJ, De Sancho MT, Bauman R, & Orazi A: Recombinant Interferon Alpha (rIFN) May Retard Progression of Early Myelofibrosis by Reducing Splenomegaly and By Decreasing Marrow Fibrosis. 55th ASH Annual Meeting & Exposition, American Society of Hematology, New Orleans, LA, December 7-10, 2013.
149. Verstovsek S, Mesa RA, GotlibJ, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MWN, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey, Jr. JH, Arcasoy MO, Hexner EO, Lyons RM, Raza A, Vaddi K, Sun W, Peng W, Sandor V, & Kantarjian H, for the COMFORT-I investigators: Long-Term Outcomes of Ruxolitinib Therapy in Patients with Myelofibrosis: 3-Year Update From COMFORT-I. 55th ASH Annual Meeting & Exposition, American Society of Hematology, New Orleans, LA, December 7-10, 2013.
150. Harrison CN, Schaap NPM, Zweegman S, Jourdan E, Kiladjian JJ, Cervantes F, Niederwieser D, Cortes JE, Passamonti F, Reiter A, Recher C, Döhner K, Heidel FH, Silver RT, Winton EF, Gupta V, Ojeda E, Gisslinger H, Vannucchi AM, Talpaz M, Zhang J, Shi W & Mesa RA: Efficacy and Safety Of Fedratinib (SAR302503/TG101348) In Patients With Intermediate- Or High-Risk Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, Or Post-Essential Thrombocythemia (ET) MF Previously Treated With Ruxolitinib: Interim Results From a Phase II Study (JAKARTA-2). 55th ASH Annual Meeting & Exposition, American Society of Hematology, New Orleans, LA, December 7-10, 2013.
151. Fonseca E, Silver RT, Kazis LE, Iqbal SU, Rose M & Khan N: Ruxolitinib Discontinuation In Patients With Myelofibrosis: An Analysis From Clinical Practice. 55th ASH Annual Meeting & Exposition, American Society of Hematology, New Orleans, LA, December 7-10, 2013.
152. Zhou J, Gong, Silver RT, Lascu, E, Orazi, A: Recombinant Interferon Alpha Therapy Decreases Bone Marrow Fibrosis and Cellular and Improves Megakaryocytes Morphology in a Significant Proportion of Patients with Myelofibrosis. 103rd Annual Meeting, United States & Canadian Academy of Pathology, March 1 - 7, 2014. Mod Pathol 2014 27, 389A
153. Verstovsek S, Mesa R, Foltz L, Gupta V, Mascarenhas J, Ritchie J, Hoffman R, Silver RT, Hong WJ, Kremyanskaya M, Trehu E, Kantarjian H, Gotlib J: Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results. American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, Illonois; May 29 to June 2, 2014.
154. Verstovsek S, Mesa RA, Foltz LM, Gupta V, Mascarenhas JO, Ritchie EK, Hoffman R, Silver RT, Kremyanskaya M, Pozdnyakova O, Hasserjian RP, Trehu E, Kantarjian HM, Gotlib JR: Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results. 56th ASH Annual Meeting & Exposition, American Society of Hematology, San Francisco, CA, December 6-9, 2014.
155. Larson RA, Conti R, Padula WV, Apperley JF, Baccarani M, Eigendorff E, Guilhot F, Guilhot J, Mahon FX, Martinelli G, Mayer J, Mueller MC, Niederwieser D, Saussele S, Schiffer CA, Silver RT, Simonsson B, Hehlmann R: What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity? 56th ASH Annual Meeting & Exposition, American Society of Hematology, San Francisco, CA, December 6-9, 2014.
156. Hekmatjou H, Roboz GJ, Ritchie EK, Lee S, Desai P, Scandura JM, Allen-Bard S, Christos P, Silver RT, Feldman EJ: Arterial Thrombotic Complications Are Uncommon in Patients without Cardiovascular Risk Factors and Occur at Equivalent Rates in Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib and Nilotinib. 56th ASH Annual Meeting & Exposition, American Society of Hematology, San Francisco, CA, December 6-9, 2014.
157. Caramazza D, Maffioli M, Cazzola M, Vannucchi AM, Rambaldi A, Morra E, Kiladjian JJ, Komrokji RS, Gotilib J, Cervantes F, Guglielmelli P, Devos T, Silver RT, Vianelli N, De Stefano V, Ruggeri M, Ricco A, Benevolo G, Mora B, Barbui T, Pieri L, Pascutto C, Rumi E, Passamonti F: Post-Polycythemia and Post-Thrombocythemia Myelofibrosis Have Distinctive Clinical Phenotypes: An International Multicenter Study on 718 Patients. 56th ASH Annual Meeting & Exposition, American Society of Hematology, San Francisco, CA, December 6-9, 2014.
158. Passamonti F, Alessandro V, MD2\*, Caramazza D, Rambaldi A, Morra E, Kiladjian JJ, Komrokji RS, Maffioli M, Gotlib J, Francisco C, Devos T, Silver RT, Guglielmelli P, Vianelli N, De Stefano V, Ruggeri M, Specchia G, Vitolo U, Rumi E, Mora B, Barbui T, Pieri L, Pascutto C, Cazzola M: A New International Multicenter-Based Model to Predict Survival in Myelofibrosis Secondary to Polycythemia and Thrombocythemia: The Mysec Prognostic Model (MYSEC-PM). . 56th ASH Annual Meeting & Exposition, American Society of Hematology, San Francisco, CA, December 6-9, 2014.
159. Pozdnyakova O, Hasserjian R, Salama M, Mesa R, Foltz L, Gupta V, Mascarenhas J, Ritchie E, Hoffman R, Silver RT, Kremyanskaya M, Trehu E, Kantarjian H, Gotlib J, Verstovsek S: Bone marrow reticulin fibrosis by WHO Grade and quantitative image analysis is reduced by PRM-151 in patients with myelofibrosis and is associated with normalization of megakaryocyte morphology and improved platelet counts. 56th ASH Annual Meeting & Exposition, American Society of Hematology, San Francisco, CA, December 6-9, 2014.
160. Richard T. Silver: Is Polycytmeia Vera Curable with Recombinant Interferon Alfa (RIFNα)? 8th International Hematology Expert Meeting, Cascais, Portugal, May 1-3, 2015.
161. Vikas Gupta, Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, John F. DiPersio, John V. Catalano, Michael W. N. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, Jimmie H. Harvey, Jr, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Ronald Paquette, Azra Raza, Deanna Kornacki, Kang Sun, Hagop Kantarjian: Long-Term Outcomes of Ruxolitinib Therapy in Patients with Myelofibrosis: 5-Year Update from Comfort-1. American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, Illonois; June 3-7, 2016.
162. Verstovsek S, Mesa RA. Gotlib JR, Gupta V, DiPersio JF, Catalano JV, Deininger MWN, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey Jr JH, Arcasoy MO, Hexner EO, Lyons, RM, Paquette R, Raza A, Jones M, Kornacki D, Sun K, Kantarjian H: Long-Term Outcomes of Ruxolitinib (rux) Therapy in Patients (pts) with Myelofibrosis (MF): 5-Year Final Efficacy and Safety Analysis from Comfort-I. Eurpopean Hem,atology Associates (EHA) 21st Congress, Copenhagen, Denmark, June 9 – 12, 2016
163. Margolskee E, Krichevsky S, Orazi A, Silver RT: Evaluation of Bone Marrowmorphology in Addition to JAK2 Allele Burden Is Essential for Assessing Disease Status in Recombinant Interferon Alpha-Treated Polycythemia Vera Patients. 58th ASH Annual Meeting & Exposition, American Society of Hematology, San Diego, CA, December 3-6, 2016
164. Silver RT, Barel A, Lascu E, Ritchie EK, Roboz GJ, Christos P, Orazi A, Hassane D, Tam W & Cross NCP: The Effect of Initial Molecular Profile on Response to Recombinant Interferon Alpha (rIFNα) Treatment in Early Myelofibrosis. 58th ASH Annual Meeting & Exposition, American Society of Hematology, San Diego, CA, December 3-6, 2016.
165. SILVER RT, Barel A, Lascu E, Ritchie EK, Roboz GJ, Christos P, Orazi A, Hassane D, Tam W & Cross NCP: The Effect of Initial Molecular Profile on Response to Recombinant Interferon Alpha (rIFNα) Treatment in Early Myelofibrosis. 58th ASH Annual Meeting & Exposition, American Society of Hematology, San Diego, CA, December 3-6, 2016.
166. Margolskee E, Krichevsky S, Orazi A, SILVER RT. Evaluation of Bone Marrowmorphology in Addition to JAK2 Allele Burden Is Essential for Assessing Disease Status in Recombinant Interferon Alpha-Treated Polycythemia Vera Patients. 58th ASH Annual Meeting & Exposition, American Society of Hematology, San Diego, CA, December 3-6, 2016
167. Verstovsek S, Mesa RA. Gotlib JR, Gupta V, DiPersio JF, Catalano JV, Deininger MWN, Miller CB, SILVER RT, Talpaz M, Winton EF, Harvey Jr JH, Arcasoy MO, Hexner EO, Lyons, RM, Paquette R, Raza A, Jones M, Kornacki D, Sun K, Kantarjian H: Long-Term Outcomes of Ruxolitinib (rux) Therapy in Patients (pts) with Myelofibrosis (MF): 5-Year Final Efficacy and Safety Analysis from Comfort-I. Eurpopean Hem,atology Associates (EHA) 21st Congress, Copenhagen, Denmark, June 9 – 12, 2016
168. Vikas Gupta, Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, John F. DiPersio, John V. Catalano, Michael W. N. Deininger, Carole B. Miller, RICHARD T. SILVER, Moshe Talpaz, Elliott F. Winton, Jimmie H. Harvey, Jr, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Ronald Paquette, Azra Raza, Deanna Kornacki, Kang Sun, Hagop Kantarjian: Long-Term Outcomes of Ruxolitinib Therapy in Patients with Myelofibrosis: 5-Year Update from Comfort-1. American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, Illonois; June 3-7, 2016.
169. Dueck A, Mascarenhas J, Kosiorek HE, Yacoub A, Prchal JT, Berenzon D, Baer MR, Ritchie EK, Silver RT, Kessler CM, Winton EF, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz DS, Rondelli D, Arcasoy MO, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Orellana A, Sandy L, Tripodi J, Najfeld V, Salama ME, Weinberg RS, Rampal RK, Hoffman R, Mesa RA: Single-Arm Phase II Trial of Pegylated Interferon Alpha 2a in Patients with High-Risk Essential Thrombocythemia or Polycythemia Vera Resistant or Intolerant to Hydroxyurea: MPN Symptom Impact & Quality of Life Results of the Myeloproliferative Disorders-Research Consortium (MPD- RC) Protocol 111Global Phase II Trial. 59th ASH Annual Meeting & Exposition, American Society of Hematology, Atlanta, GA, December 7-12, 2017.
170. Critical Evaluation of Who 2016 Criteria for the Diagnosis of Polycythemia

Vera: Distinction from JAK2V617+ Essential Thrombocythemia. RICHARD T. SILVER, MD and Spencer Krichevsky, BS, ASH 59th Annual Meeting and Exposition, Atlanta, GA December 7 – 13, 2017

1. Incidence of Infections and Second Cancers in Philadelphia Chromosome-

Negative Patients with Myeloproliferative Neoplasms Treated with Ruxolitinib. Ellen K Ritchie, MD, Spencer Krichevsky, BS, Gail J. Roboz, MD, RICHARD T. SILVER, MD, Andrew I Schafer, MD, Joseph Scandura, MD, PhD, Pinkal Desai, ... ASH 59th Annual Meeting and Exposition, Atlanta, GA December 7 – 13, 2017

1. Pulmonary Hypertension Independently Shortens Survival of Patients with

Myeloproliferative Neoplasms. Jiwon Kim, MD, Spencer Krichevsky, BS, Neil K Mehta, MD, Sara Rodriguez-Diego, MD, Meridith P Pollie, BS, RICHARD T. SILVER, MD, Andrew I Schafer ... ASH 59th Annual Meeting and Exposition, Atlanta, GA December 7 – 13, 2017

1. Myeloproliferative neoplasms – Clinical. EHA-3957. Gender Effect On

Phenotype And Genotype In Patients With Post-Polycythemia Vera And Post-Essential Thrombocythemia Myelofibrosis: Results From The MYSEC Project. Daniela Barraco, Barbara Mora, Toni Giorgino, Paola Guglielmelli, Elisa Rumi, Margherita Maffioli, Alessandro Rambaldi, Marianna Caramella, Rami Komrokj, Jason Gotlib, Jean Jacques Kiladjian, Francisco Cervantes,Timothy Devos, Francesca Palandri, Valerio De Stefano, Marco Ruggeri, RICHARD T. SILVER, Giulia Benevolo, Francesco Albano, Michele Merli, Daniela Pietra, Tiziano Barbui, Giada Rotunno, Mario Cazzola, Alessandro Maria Vannucchi, Passamonti Francesco. 23rd Congress of the European Hematology Association Stockholm, Sweden; June 14-17, 2017.

1. Distinguishing Essential Thrombocythemia JAK2V617F from Polycythemia Vera:

Clinical and Biological Relevance. RICHARD T. SILVER and Spencer Krichevsky. Dublin, Ireland, May 15, 2018

**INVITED LECTURES: International**

**2019**

Presenter, 4th Annual MPN Asia Symposium, Jeju Island, Korea, April 27, 2019

**2018**

Presenter, 8th ESH International Conference on Myeloproliferative Neoplasms,Dublin, Ireland, May 14 – 17, 2018

Presenter, 11th International Hematology Expert Meeting, Vienna, Austria, April 24 – 29, 2018

Presenter, 3rd Annual International Symposium on MPN, Asia\_Hangzhou, China, March 31, 2018

**2017**

Invited Lecturer, 2nd Annual International Symposium on Myeloproliferative Neoplasms Asia, Treatment of Polycythemia Vera with Recombinant Interferon alpha (rIFNα), Tokyo, Japan, April 1, 2017.

Invited Lecturer, 10th International Hematology Expert Meeting, How I Treat PV in 2017: One Hematologist’s Opinion, Barcelona, Spain, May 11 – 13, 2017.

Invited Lecturer, 25th International CML Workshop, How I Treat PV in 2017: One Hematologist’s Opinion, Mannheim, Germany, July 14 - 15, 2017.

**2016**

Chair and Presenter, 1st Annual International Symposium on Myeloproliferative Neoplasms, Taipei, Taiwan January 9, 2016. Chair:Panel Discussion*, Current Status of the Effect of Treatment on Mutations in MPNs;* Presented: *Is Polycythemia Vera Curable?*

Invited Lecturer, 9th International Hematology Expert Meeting, Can we cure PV with IFN-alfa? Nice, France, April 29 –May 1, 2016

Invited Lecturer, 6th Annual Canadian Hematology Conference, The MPN World in the JAK2 Inhibitor Era, Toronto, Ontario, Canada, September 23 - 24, 2016

Invited Lecturer, European School of Haemotology (ESH) International Conference on Myeloproliferative Neoplasms, Tutored Poster Walk*,* Estoril, Portugal, October 27-29, 2016

**2015**

Invited Lecturer, 12th Annual Symposium of the European LeukemiaNet / 16th Annual Symposium of the German Competence Network "Acute and chronic Leukemias", Capillary Blood Flow in *JAK2V617F* Mouse Models of ET & PV Revealed by *in-vivo*, 2-Photon Imaging: Clinical Implications*,* Mannheim, Germany February 2-4, 2015

Invited Lecturer, 8th International Hematology Expert Meeting, Can we cure polycythemia vera with IFN-alpha? Cascais, Portugal, May 1-3, 2015

**2014**

Invited Lecturer, 11th Annual Symposium of the European LeukemiaNet / 15th Annual Symposium of the German Competence Network "Acute and chronic Leukemias", The Hematocrit Value in Polycythemia Vera: Caveat Utilitor*,* Mannheim, Germany February 2-5, 2014

Invited Lecturer, European School of Haemotology (ESH) International Conference on Myeloproliferative Neoplasms, Tutored Poster Walk*,* Estoril, Portugal, October 23-25, 2014

**2013**

Invited Lecturer, Annual Conference of the Israeli Society of Hematology and Blood Transfusion, *Is PV now Curable?* and *Treatment of Early Phase Myelofibrosis with Interferon,* Kfar Blum, Israel, October 9-12, 2013

**2012**

Invited Lecturer, 9th Annual Symposium of the European LeukemiaNet/13th Annual Symposium of the Germany Competence Network “Acute and Chronic Leukemia”, *Is Polycythemia vera curable?,* Mannheim, Germany, January 31, 2012 – February 1, 2012

Moderator and Presenter, European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Lisbon, Portugal, May 4 – 5, 2012: Moderator:Session*, Clinical Aspects of Polycythemia Vera and Essential Thrombocythemia;* Presented: *Are all interferons the same or MPN?*

Chair and Presenter, 21st International CML Workshop, Mannheim, Germany, June 29-30, 2012: Chair:Session*, Blast Crisis Revisited;* Presented: *Introduction – a historical prospective*

Presenter, ESH International Conference on Myeloproliferative Neoplasms, *The Curability of Polycythemia Vera* Vienna, Austria, October 4-6, 2012

**2010**

Invited lecturer, Investigators board meeting, Update on dasatinib in CML, Bristol Myers Squibb, Prague, Czechoslovakia, May 6-9, 2010.

Invited lecturer, 19th International CML Workshop in Heidelberg, Deutch-American Institute, *A Historical Perspective of Blast Phase Disease”,* Heidelberg, Germany, July 2-3, 2010

Invited lecturer, European School of Hematology International Conference on myeloproliferative disorders, Albufeira, Portugal, September 29, 2010 – October 4, 2010

**2009**

Session Chair, 11th International Conference, Chronic Myeloid Leukemia – Biological Basis of Therapy for the European School of Hematology. Topic was on *The Next Decade for CML,* Bordeaux, France, September 11-13, 2009

Guest lecturer, Hematology Grand Rounds for the Imperial Medical College-Hammersmith, Hospital. Topic was on *Polycythemia Rubra Vera*, London, UK, September 15-16, 2009.

Session Chair, European LeukemiaNet Frontiers-Continuing the Chronic Myeloid Leukemia Revolution. Expanding Options in targeted therapy, Topic was on *Philadelphia chromosome negative chronic myeloproliferatrive disorders,* Barcelona, Spain, September 18-20, 2009.

2008

Invited Lecturer, European School of Hematology Meeting, Athens, Greece. Reccombinant interferon alpha (αIFN2) may retard progression of early primary myelofibrosis (PM) by reducing splenomegaly and changing marrow morphology. September 18-21, 2008.

Session Chair and Presenter, European LeukemiaNet Targeted CMLTherapy Meeting,

Session Chair: Session 1, Evolving targeted CML treatment: what’s new?

Presentation: CML: Late or unexpected side effects with imatinib therapy.

European LeukemiaNet Frontiers Meeting, Cannes, France, October 17-19, 2008.

**2007**

Faculty member and Invited Lecturer, 11th Annual Winter Oncology Conference, Update on theTreatment of Polycythemia Vera and Essential Thrombocythemia, Chateau Whistler, Whistler, BC, Canada, February 14-18, 2007.

Invited Faculty, European School of Hematology, Chronic Myeloid Leukemia: Prospects for the 21st Century, Mandelieu, France, September 28-30, 2007.

Invited Faculty and Lecturer, European LeukemiaNet, Chronic Myeloid Leukemia, Blast Phase, Budapest, Hungary, October 17-24, 2007.

Invited Lecturer, Second Annual Global CML Workshop, Evaluation of the *JAK2* Burden:

The Role of *JAK2V617F* in Polycythemia Vera, San Juan, Puerto Rico, December 12-13, 2007.

Invited Lecturer, Menarini Foundation Meeting, Focus in Hematology: Myeloproliferative and Myelodysplastic Syndromes, Plenary Lecture: Polycythemia Vera - from the PVSG Studies to the *JAK2V617F* Mutation, Bergamo, Italy, September 20-22, 2007.

**2006**

Session Chair, Member, and Invited Lecturer: Evolving concepts in the management of chronic myeloid leukemia,” Expert Panel on Behalf of The European LeukemiaNet, Evolving Concepts in the Management of Chronic Myeloid Leukemia, Venice, Italy, May 8-9.

Invited Lecturer, Plenary Address: “Polycythemia vera in 2006. “ European Society of Haematology, Second ESH Euroconference on Myeloproliferative Disorders:

Molecular Pathogenesis and Therapy. Plenary Address. Madeira, Portugal, September 14-16.

Grand Rounds. Some Aspects of Polycythemia Vera in 2006. Barcelona, Spain,

September 7, 2006.

Lecturer, “Treatment of Polycythemia.” Tenth Annual Winter Oncology Conference, International Congress on Hematological Malignancies Focus on Leukemias, Lymphomas, and Myelomas, Whistler, British Columbia, Canada, February 15-19.

Invited Faculty and Lecturer: “Guidelines in CML.” First Annual Global CML Workshop:

The Future. Hamilton, Bermuda, December 15-16.

**2005**

Invited Guest, Brazilian Hematology Congress, Rio de Janeiro, November 3-6.

Invited Lecturer, International Session Chair, Third European School of Haematology International on Chronic Myeloid Leukaemia in the 21st Century. Genoa, Italy, November 11-13

**2004**

European Workshop on the Myeloproliferative Diseases. Rotterdam, the Netherlands.

May 12-16.

Session Chair, International CML Myeloproliferative Diseases, New Trends in Treating, Diagnosing CML, Germany National Study Group, Heidelberg, Germany, July 1-4.

European LeukemiaNet CML-Workshop on CML-Guidelines-Methods and Goals, Heidelberg, Germany, July 2-3.

European School of Haematology International Conference on Myeloproliferative Disorders. Cascais, Portugal, September 10-12.

**2003**

International Workshop on Chronic Myeloid Leukemia. Invited participant, Rapallo, Italy. September 19-22.

International Society of Hematology, XVII Congress. Session Chair: Myeloproliferative Disease and Participant, Ibid, Graz Austria, September 7-10.

**2002**

The First Como Conference on Myeloproliferative Disorders, Loveno di Menaggio, Italy, September 13-17 2002

European School of Haematology International Conference on chronic myeloid leukemia, Rapallo, Italy, September 26-29.

**2000**

European Society of Hematology Conference on Chronic Myeloid Leukemia, Chairman, Rapallo, (Portifino), Italy, September 22–25, 2000.International Meeting on STI-571, Geneva, November 2000.

**1999**

International Symposium on Chronic Myeloid Leukemia, Biarritz, France, “Chronic Myeloid Leukemia: ASH Practice Guidelines” July 7-9, 1999.

XV th Meeting of the International Society of Hematology, African & European

Division Educational & Symposium Programs. Treatment of Polycythemia Vera with Interferon rIFNα, Durban, South Africa, September 18 – 23, 1999.

**1998**

International Congress on Myeloproliferative Diseases, Rotterdam, Holland, Program: "Treatment of Polycythemia Vera with Interferon", March 13-14, 1998.

"Interferons and Cryoglobulinemias", International Conference on Interferons, Chairman Venice, Italy, March 16-18, 1998.

**1997**

10th Symposium on Molecular Biology of Hematopoiesis and Treatment of Leukemias and Lymphomas, Chairman, Hamburg, Germany, July 2-6, 1997.

**1995**

9th International Symposium Molecular Biology of Hematopoiesis: Interferon in Myeloproliferative Diseases, June 24, 1995; Chaired session on Thrombopoietin II, June 27, 1995. Genoa, Italy.

**1994**

Visiting Professor, Hadassah Hospital, March 22, 1994, Jerusalem, Israel: New Treatment of Polycythemia Vera Israel Hematology Society, Herzlia, Israel, March 21, 1994

- Interferon-Alpha and Low Dose Ara-C or the Treatment of Chronic Myeloid Leukemia

- Use of Anagrelide in Myeloproliferative Disorders

**1992**

Thrombocytosis Refractory to Hydroxyurea in Chronic Myeloid Leukemia (CML) Responds to Anagrelide: International Society of Hematology, London, England, August 21, 1992.

Thrombocytosis Refractory to Hydroxyurea in Chronic Myeloid Leukemia (CML) Responds to Anagrelide: Chronic Myeloid Leukemia – 2nd International Congress, Bologna, Italy, October 5, 1992.

**1987**

XI Brazilian Congress of Cancerology, Florianopolis, Brazil, November 1987,

"Current Treatment of Leukemias and Lymphomas."

**1985**

14th International Congress of Chemotherapy, Kyoto, Japan, June 1985, "Mytoxantrone and Malignant Lymphomas"

“Mitoxantrone in the treatment of non‑Hodgkin's lymphoma: A Phase II study,” 14th International Congress of Chemotherapy, Kyoto, Japan, June 25, 1985.

**1984**

Invited Delegate, International Conference on Mitoxantrone, Monaco, October 1984

Chronic Leukemia, XX Congress of the International Society of Hematology, Buenos Aires, September 3, 1984.

Refractory Anemia, XX Congress of the International Society of Hematology, Buenos Aires, September 4, 1984.

**1981**

VIII Brazilian Hematology Congress, Salvador, Brazil, 1981, "Treatment of Acute Leukemia," "Treatment of Chronic Leukemia," "Treatment of Malignant Lymphomas"

**1979**

Second Medical College of Shanghai, China, "Treatment of Leukemia," October 1979

Medical College of Chengchow, Shanghai, China, "Modern Chemotherapy of Cancer,"

October 1979

Medical School of Wuhan, China, "Treatment of Leukemia," October 1979

**1977**

Third Surgical Clinic, Semmelweill University of Medicine, Budapest, Hungary, "Chemotherapy of Breast Cancer," 1977

**1975**

"Treatment of Leukemia," V Brazilian Hematology Congress, Recife, July, 1975

"Agnogenic Myeloid Metaplasia," Royal Free Hospital, London, England, October 1975

**INVITED LECTURES: (National)**

**2019**

Presenter, 11th Joyce Niblack Memorial Conference on Myeloproliferative Neoplasms, Scottsdale, AZ; March 2-3, 2019

**2018**

Presenter, ASH 60th Annual Meeting and Exposition, San Diego, CA; December 1 -4 2018

Chair and Presenter, 11th International Congress MPN on Myeloproliferative Neoplasms; October 25-26, 2018, NY, NY

Presenter, 4th Annual Levine Cancer Institute Hematology Symposium, Charlotte, NC, October 20, 2018

**2017**

Presenter, 10th Joyce Niblack Memorial Conference on Myeloproliferative Neoplasms, PV Treatment in 2017, Scottsdale, Arizona, February 25 – 26, 2017

Chair and Presenter, 10th International Congress MPN and Chronic Myeloid Leukemia; November 2-3, 2017, NY, NY

Invited Lecturer, American Society of Clinical Oncology, Chicago, IL; June 2-6, 2017

Presenter, ASH 59th Annual Meeting and Exposition, Atlanta, GA; December 7 -12 2017

**2016**

Chair and Presenter, 2nd Annual Think Talk on Integrating New Molecular Targets in Acute Leukemias and Myeloproliferative Neoplasms, Dallas, Texas, January 29 – 30, 2016: Chair: Session, Landscape of MPN*;* Presentation: What’s Wrong with the WHO Classifications.

Chair and Presenter, U.S. focus on MPN & MDS Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Alexandria, Virginia, August 26 – 27, 2016: Chair: Session, Clinical Aspects of Myeloproliferative Neoplasms*;* Presentation: Update on Long-Acting Interferons for MPN.

Invited Lecturer, AOP 6th Annual classical MPN Colloquium at the 18th Annual Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy, Diagnostic and Treatment Enigmas in Polycythemia Vera, Houston, Texas, September 15 - 18, 2016

Invited Lecturer, Women and MPN Conference, Is Polycythemia Curable with Interferon?, New York, New York, September 30, 2016

Chair and Covener, Myeloproliferative Neoplasms for the Practitioner: Diagnosis, Management and New Clinical, New York, New York, November 3 – 5, 2016: Chair: Session, Polycythemia Vera (PV)*;* Presentation: Diagnosis of PV; Meet the Professor Presentation: PV; Co-Chair: CasePresentation.

**2015**

Invited Lecturer, Joyce Niblack Memorial Conference on Myeloproliferative Neoplasms, Mayo Clinic, *PV and ET in 2015,* Scottsdale, AZ, February 21-12, 2015

Invited Lecturer, Expert Reviews in Hematology 2015: Highlights from the Annual Hematology Meeting, *CML and MPNs*, Las Vegas, NV, March 12, 2015.

Chairman, 8th International Patient Symposium on Myeloproliferative Neoplasms, Treatment of Polycythemia vera, Cancer Research & Treatment Foundation, New York, NY, November 4, 2015

Chair and Covener, 8th Biennial International Congress on Myeloproliferative Neoplasms and Myelodysplasia, New York, New York, November 5 – 6, 2015: Chair: Session, Chronic Myeloid Leukemia *(CML);* Presentation: Diagnosis Criteria and Treatment of PV Revisited

**2014**

Invited Lecturer, 9th International CML & MPN Post ASH Workshop: Cerebral Blood Flow in Polycythemic Mice: Implications for the Clinic, New Orleans, LA, December 10, 2014.

**2013**

Invited Lecturer, MPN Patient conference, Mayo Clinic, *On the “Curability” of   
Polycythemia Vera with Interferon,* Scottsdale, AZ, February 9-10, 2013

Invited Lecturer, 17th Annual International Congress on Hematologic Malignancies – Focus on Leukemias, Lymphomas, and Myeloma, *Interferons in the Ph- Myeloproliferative Neoplasms,* New York, NY, February 15-17, 2013

Chairman, 7th International Patient Symposium on Myeloproliferative Neoplasms, Treatment of Polycythemia vera, Cancer Research & Treatment Foundation, New York, NY, November 6, 2013

Chair and Covener, 7th Biennial International Congress on Myeloproliferative Neoplasms and Myelodysplasia, New York, New York, November 7 – 8, 2013: Chair: Session, M*yeloproliferative Diseases (MPN);* Presentation: *An update on the treatment with interferon of low and intermediate-1 risk patients with myelofibrosis*.

Session Co-Chair, Oral Session: Myeloproliferative Syndromes: Clinical: Novel Therapeutic Strategies: 55th ASH Annual Meeting & Exposition, American Society of Hematology, New Orleans, Louisanna, December 7-10, 2013.

**2012**

Grand Rounds, Erythropoetic Stimulatory Agents and Serious Adverse Events: When Physiology and Pharmacology Collide, Jerry Spivak, M.D.., The Richard T. Silver, M.D. Distinguished Visiting Professor in Hematology-Medical Oncology, New York, NY, January 14, 2012

Host, Prime Oncology, *Practical Strategies for the Management of CML,* New York, New York, March 29, 2012

Featured Speaker, Prime Oncology, *Practical Strategies for the Management of CML,* Buffalo, New York, April 5, 2012

Moderator, *MPN/MPDs*, Great Debates and Updates in Hematological Malignancies, New York, New York, April 27 – 28, 2012

Grand Rounds, Myeloproliferative Diseases: What are They and Why are They Important to the Internist, Weill Cornell Medical College, New York, NY, September 25, 2012

Presenter, 8th International Conference on Hematologic Malignancies, Houston, Texas, October 10-14, 2012: Presented: *Are all Interferons the Same as Therapy for ET and PV*

Host, Prime Oncology, *The Evolution of therapy in the Management of CML,* New York, New York, November 7, 2012

**2011**

Grand Rounds, Chronic Myeloid Leukemia – Lessons from the Past and Questions for the Future, John Goldman, M.D., The Richard T. Silver, M.D. Distinguished Visiting Professor in Hematology-Medical Oncology, New York, NY, January 24, 2011

Invited Lecturer, MPN Patient conference, Mayo Clinic, *Treatment of early primary myelofibrosis with interferon,*Scottsdale, AZ, February 26-27, 2011

Invited Lecturer, Incyte Comfort-1 Investigator/Authors’Meeting, Avia-The Woodlands Hotel, The Woodlands, TX, April 8-9, 2011

Invited Lecturer, Great Debates and Updates in Hematologic Malignancies, Imedex, *Myeloproliferative Neoplasm* Session Moderator, The Brooklyn Marriott Hotel, Brooklyn, NY, April 29-30, 2011

Invited Lecturer, American Society of Clinical Oncology annual meeting, *Inaugural Colloquium on the Management of Myeloproliferative Neoplasms with Novel Targeted Agents,* Intermediate Risk – Essential Thrombocythemia, McCormack Place, Chicago, IL,

June 3-7, 2011

Chair and Covener , VIth International Congress of the Myeloproliferative Diseases and Myelodysplastic Syndromes; New York, New York, November 3 – 4, 2011: Chair: Session, *Myeloproliferative Diseases;* Presentation: *Interferon in the treatment of early myelofibrosis*

53rd ASH Annual Meeting & Exposition, American Society of Hematology, *Prospective Evaluation of the World Health Organization Criteria for the Diagnosis of Polycythemia Vera* (Authors include Richard T. Silver, William Chow, Stephen P Arles, Katherine Vandris, Ivy Tam,Anita Narayan, Maria T De Sancho, Attilio Orazi and Stanley J Goldsmith), San Diego, CA, December 10–13, 2011

**2010**

Grand Rounds, Progress in Curing Adult Acute Leukemmia, Clara D. Bloomfield, M.D.,

The Richard T. Silver, M.D. Distinguished Visiting Professor in Hematology-Medical Oncology, New York, NY, January 12, 2010.

Invited Lecturer, CML Fellows Talk, Update on CML, Weill Cornell Medical College, New York, NY, February 4, 2010.

Invited Lecturer, Treatment Evolution in CML: The Past, Present and Future – Investigator meeting, *Nilotinib expanded access study update*, Novartis, Orlando, FL February 11-12, 2010.

Invited Lecturer, Novartis, Treatment Evolution in CML: Follow-Up Novartis Oncology, MDS Advisory Board Meeting. The W Hotel, Fort Lauderdale, Florida, March 26-27, 2010

Invited Lecturer, Duke Debates, Controversies in the Mangement of Patient with Hematologic Malignancies. *JAK2 Polycythemia Vera & Primary Myelofibrosis*, The Grove Park Inn Resort & Spa, Asheville, NC, April 9-11, 2010

Invited Lecturer, 5th Annual Houston Conference on Myelodysplastic syndromes & myeloproliferative neoplasms. *Advancing knowledge in the biology and therapeutic approach of MDS and MPN,* Intercontinental Hotel, Houston, TX, April 24-25, 2010

Invited Lecturer,Great Debates and Updates in Hematologic Malignancies, Imedex, *Myeloproliferative Neoplasm Session,* The Westin New York at Times Square, New York, NY, April 30-May 1, 2010

Guest Speaker, New York MPD patient support group, Weill Cornell Medical Center, New York Blood Center, New York, NY, May 17, 2010

Invited lecturer, CML Advisory Board Meeting during ASCO, *Leukemia, Myelodysplasia and Transplantation*, Hyatt Regency Hotel, Chicago, IL, June 6-8, 2010

Invited lecturer, “Update on CML” Update Your Medicine: Oncology, Cornell University Medical College, Uris Auditorium, New York, NY June 17, 2010

Invited Lecturer, Chemotherapy Foundation Symposium XXVIII, “Treatment of early myelofibrosis with interferon”, *Innovative Cancer Therapy for Tomorrow,* Chemotherapy Foundation, New York, NY November 10, 2010.

Invited Lecturer, 5th International CML & MPN Workshop, Clinical Response in Patients with Polycythemia Vera is not Always Associated with a Decrease in *JAK2V617F* Allele Burden, Orlando, FL., December 7-8, 2010

**2009**

Invited Lecturer, American Society of Hematology Meeting, Cancer Trends in Leukemia, Lymphoma and Myeloma, Treatment of Chronic Myeloid Leukemia - Update, Washington, DC, January 31, 2009.

Invited Lecturer, CML Fellows Talk, Update on CML, Weill Cornell Medical College, New York, NY, January 2009.

Invited Lecturer, Second Year Medical Student Pathophysiology Lecture, Myeloproliferative Diseases, Weill Cornell Medical College, New York, NY, February 2009.

Invited Lecturer, Mayo Clinic Meeting – Patient Support for the MPDs, Polycythemia Vera: From the PVSG to the Present, Scottsdale, AZ, February 27-28, 2009.

Invited Lecturer, House Staff Lecture, Chronic myeloid leukemia update 2009, Weill Cornell Medical College, New York, NY, March 31, 2009.

Invited Lecturer, MPD-Research Consortium Meeting, “Protocol Description”, New York City, April 1-2, 2009.

Invited Lecturer, Celgene Investigator Meeting, Pomalidomide in Myelofibrosis, April 4, 2009.

Invited Lecturer, Hematology-Oncology Grand Rounds, Chronic Myeloid Leukemia Update 2009…and More, Weill Cornell Medical College, New York, NY, April 1, 2009.

Invited Lecturer, Fellows lecture, Polycythemia vera update, Weill Cornell Medical College, New York, NY, April 16, 2009.

Invited Lecturer, 4th annual symposium, on MDS and MPNs, University of Texas MD Anderson Cancer Center, Early treatment of myelofibrosis with interferon may be advantageous, Houston, Texas, April 24-25, 2009.

Invited Lecturer, Hematology Grand Rounds, University of Texas M.D. Anderson Cancer Center,Polycythemia vera Update, Houston, TX. , May 5, 2009.

Invited Lecturer, Cancer Clinics of Excellence hosted by Novartis, Pennsylvania Oncology Hematology Associates, Philadelphia, PA, June 11, 2009

Chairman, 5th International Patient Symposium on Myeloproliferative Diseases, Treatment of Polycythemia vera, Cancer Research & Treatment Foundation, New York, NY, November 4, 2009.

Chairperson, 5th International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes, Cerebral Circulation in Polycythemia Vera, Imedex, New York, NY November 5-7, 2009.

Invited Lecturer, Chemotherapy Foundation Symposium XXVII, JAK2 In Hematopoiesis And Status Of Anti-JAK2 Trials, Chemotherapy Foundation, New York, NY, November 11, 2009.

51st ASH Annual Meeting & Exposition, American Society of Hematology, Pegylated Interferon Trials: Investigators Meeting of the Myeloproliferative Disorders Research Consortrium, New Orleans, LA, December 4-11, 2009

Jumping Translocations of the Long Arms of Chromosome 1 (1aJT) in Myeloproliferative Neoplasms (MPNs) and Myelodysoplastic Syndromes (MDS) Are Associated with High Risk of Transformation to Acute Myelogenous Leukemia (AML), New Orleans, LA, December 5, 2009.

Tumor Necrosis Facotr-Alpha (TNF) Expression is Elevated in Myelo-Proliferative Neoplasms (MPN) and Modulate dby Inhibition of JAK2 V617F, New Orleans, LA, December 5, 2009.

Invited lecturer, 4th International Workshop on CML and MPN, "Is a Decrease in *JAK2V617F* Allele Burden a Prerequisite to Clinical Response in Patients with Polycythemia Vera?", Natchez, Missisippi, December 8-10, 2009.

**2008**

Invited Lecturer, Hematology-Oncology Grand Rounds, New York Medical College, Treating CML in 2008, Westchester, NY, February 14, 2008.

Invited Lecturer, Hematology-Oncology Grand Rounds, Our Lady of Mercy Hospital, Treating CML in 2008, Bronx, New York, March 13, 2008.

Invited Lecturer, Investigator Meeting,The use of oral CEP-701 in treating patients with polycythemia vera or essential thrombocythemia with the JAK2V617F mutation, Houston, TX, May 2008.

Invited Lecturer, ESH Tenth International Conference on CML, CML Blast Phase. Sheraton Boston Hotel, Boston, MA, September 3-7, 2008.

Invited Lecturer, Chemotherapy Foundation Symposium XXVI, Some Aspects of *JAK2* and *MPL* Mutations in 2008, Marriott Marquis Hotel, New York, NY, November 5, 2008.

Invited Lecturer, Dasatinib (Spyrcel) Investigator meeting, AdBoard at ASH, The use of Dasatinib in treating patients with polycythemia vera, Washington DC, December 6, 2008.

Invited Lecturer, Dasatinib (Spyrcel) Investigator meeting, The use of Dasatinib in treating patients with polycythemia vera, Atlanta Hilton & Towers Hotel, Atlanta, GA December 9, 2008.

Invited Lecturer, Myeloproliferative Diseases, Myelodysplastic Syndrome, and Chronic Myeloid Leukemia - Special Invitee, Lecture delivered: “Myeloproliferative Disorders.” Post-ASH meeting, San Francisco, December 8-10, 2008.

Invited Lecturer, Guy’s and St. Thomas’ NH Foundation Trust Meeting, Early treatment of myelofibrosis with interferon may be advantageous, Sonoma California, December 10, 2008.

**2007**

Invited Lecturer, 11th International Congress on Hematological Malignancies

“Optimum Management of ET & PRV”, New York, NY, February 2007

Invited Lecturer, The Fifth CMPD Education Foundation and Mayo Clinic Patient Symposium on the Chronic Myeloproliferative Disorders, Some Thoughts Regarding the Treatment of Polycythemia Vera in 2007, Scottsdale, Arizona, February 23-25, 2007.

Invited Lecturer, Current Trends in Leukemia, Lymphoma, and Myeloma, Management of CML and Ph(-) Myeloproliferative Diseases, The Sofitel, New York, NY, March 3, 2007.

Invited Lecturer, Hematology Oncology Grand Rounds, Some Thoughts Regarding Polycythemia Vera, Weill Cornell Medical College, New York, NY, March 14, 2007.

Lecturer, Lecture to Hematology Oncology Fellows on CML, Weill Cornell Medical College, New York, NY, March 15, 2007.

Invited Lecturer, East Carolina University – Brody School of Medicine, Some Thoughts Regarding Polycythemia Vera, Greenville, NC, March 29, 2007.

Invited Lecturer, Hematology-Oncology Grand Rounds, Weill Cornell Medical College, Polycythemia Vera: from the PVSG Studies to the *JAK2V617F*Mutation. New York, New York, October 31, 2007.

Invited Lecturer, Update on Chronic Myelogenous Leukemia, CML: A Practical Approach to Current Management, Baltimore, Maryland, November 29, 2007.

Invited Lecturer, Dasatinib (Sprycel®) Investigator Meeting, The Use of Dasatinib in Treating Patients with Polycythemia Vera, Atlanta Hilton & Tower Hotel, Atlanta, Georgia, December 9, 2007.

Invited lecturer, BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: Some combinant and contrasting features. Puerto Rico, December 2007.

**2006**

Grand Rounds, Blood and Marrow Transplant City Wide Conference, New Thoughts in the Treatment of CML, University of Rochester, Strong Memorial Hospital, Rochester, NY, January 27, 2006.

Hematology Fellowship Conference, Polycythemia Vera 2006, National Institutes of Health National Heart, Lung, and Blood Institute, Bethesda, MD, February 1, 2006.

Disease State Expert Faculty Presenter, Myelodysplastic Syndromes (MDS), Brookdale Hospital, Brooklyn, NY, February 22, 2006.

Lecturer, International Working Group (IWG) Conference, Myeloproliferative Diseases (MPD), The University of Texas, MD Anderson Cancer Center, Houston, TX, March 4, 2006.

**2005**

Treatment of P. Vera: Chronic Myeloproliferative Disease Symposium, Mayo Clinic, Rochester, MN, February 5.

Some Aspects of the Polycythemia Vera in the 21st Century. Johns Hopkins Hospital, Hematology Grand Rounds, Baltimore, MD, June 9.

The Era of Molecular Therapy: Focus on Chronic Myelogenous Leukemia. Jersey Shore University Medical Center, Neptune, NJ 07754, July 28.

Chairman, 3rd International Congress on the Myeloproliferative Diseases and Myelodysplastic Syndromes, Washington, DC, October 27-29.

Grand Rounds, Leukemia and Myeloproliferative and Myelodysplastic Diseases, New York, NY, December 5.

Myeloproliferative and Myelodysplastic Diseases, Charleston Cancer Center, Charleston, SC, December 15.

**2004**

Myelodysplastic Syndromes: Novel Strategies and Therapeutic Update. The Center for Biomedical Continuing Education. Hematology Grand Rounds, Washington, DC. March 19, 2004.

New Thoughts on the Management of Polycythemia Vera. Hematology Grand Rounds. MD Anderson Cancer Center, Houston, TX. March 24, 2004.

Diagnosis and Management of Polycythemia Vera. Sponsored by an unrestricted educational grant from Shire US Inc., Chicago, IL. March 26-27, 2004.

Chronic Myeloid Leukemia. Columbia Presbyterian Medical Center, Grand Rounds, New York, NY, April 1, 2004.

Myelodysplastic Syndromes: Novel Strategies and Therapeutic Update. Sibley Memorial Hospital, Washington, DC, June 18, 2004.

Myelodysplastic Syndromes: Novel Strategies and Therapeutic Update. Bassett Healthcare. Hematology Grand Rounds, Cooperstown, NY June 24, 2004.

Chronic Myelogenous Leukemia (CML) Educators’ Workshop. Molecular Pathways: Applications in Cancer Therapy. (IMPACT). Dallas, TX. June 25-26, 2004.

Myelodysplastic Syndromes: Novel Strategies and Therapeutic Update. Raleigh Regional Cancer Center, Beckley, WV. July 13, 2004.

**2003**

Mayo Clinic Symposium, Myeloproliferative Diseases, Invited Lecturer, April 20

2nd International Congress on Myeloproliferative and Myelodysplastic Diseases, Chair of the Congress and Speaker, October 16-18, 2003.

**2002**

Grand Rounds: Maimonides Medial Ct. Brooklyn, NY January 16th, 2002

Update on Novel Targeted therapy & the Direction CML Management is Moving

Hematology Grand Round at Weill Medical College on January 22, 2002

Rational Drug Development: Update on STI-571

Grand Rounds: SASS Foundation Meeting at the Garden City Hotel March 6th, 2002

The Current Advances in the Management of CML.

Grand Rounds: New York Methodist Hospital, Brooklyn New York March 14th, 2002

Annual Oncology Update to Hospital Staff, Molecular Targeting in Cancer Therapy

Update your medicine, Weill Cornell Medical Center, June 2002

**2001**

Pennsylvania Soc. Of Oncology & Hematology 2001 Scientific Meeting: Chronic Myeloid Leukemia, September 2001.

Mayo Clinic Cancer Ct.: Myeloproliferative Disorder Conference 2001 at Scottsdale, Az. Overview of Polycythemia Vera, Current Specific Agents in MPD - Interferon. September 2001

First International Congress of the Myeloproliferative Diseases & Myelodysplastic Syndromes, New York City, October 2001. Chair of Congress, Speaker, Northshore University Hospital: Update on CML, November 27, 2001.

Grand Rounds: St. Vincent’s Hospital, Update on CML, New York, NY, November 30, 2001.

**2000**

Grand Rounds, Albert Einstein Medical Center, “Chronic Myeloid Leukemia” February, 2000

Chemotherapy Foundation: Bone marrow rongeur in myelofibrosis. 13th International Symposium on Treatment of Leukemia & Cancer, Chairman, New York City, July 14 -18, 2000.

Lymphoma & Myeloma 2000 at the Turn of the Century, Small B-Cell Lymphoma Chairman, New York City, October 5-7, 2000.

**1998**

Visiting Faculty: Annenberg Center, Palm Springs, California, "Interferon in the Treatment of Polycythemia", April 21, 1998.

First International Conference on MPD (MyeloProliferative Diseases), Interferon alpha for PV. San Diego, CA, October 9-11, 1998.

Cleveland Clinic Cancer Center Experimental Therapeutics, Controversies in the Management of Indolent Lymphomas and Chronic Leukemias, "Interferon for CML", November 6, 1998

American Society of Hematology, 40th Annual Meeting, Miami Beach, Florida, “Chronic Myeloid Leukemia— ASH Practice Guideline and Beyond” December 5, 1998.

**1996**

The Myeloproliferative Diseases and Biologic Modifiers: Medical Grand Rounds, Sarasota Memorial Hospital, Sarasota, FLA, February 2, 1996

Medical World Conferences 1996 Trans-Panama Canal CME cruise. Program: "Taking Better Care of Our Patients", February 24 - March 5, 1996.

Frontiers in Oncology-Hematology III, "Lymphoma Management" Cornell University Medical Center, October 19, 1996.

Oncology Focus: Chronic Myelogenous Leukemia, Four Seasons Hotel, New York, NY, November 13, 1996.

Hematology Grand Rounds, "Treatment of the Myeloproliferative Syndrome", Columbia Presbyterian Hospital, NY, NY, November 14, 1996.

Biologic Reponse Modifiers in the Treatment of Chronic Myeloid Leukemia; Medical Grand Rounds, Memorial Medical Center, Savannah, GA, April 12, 1996.

Medical World Conferences 1996 Rhine River CME cruise, Program: “Health Care

Update", July 1 - 13, 1996.

Annual Seminar of New Therapies and Biologics: The Role of Alpha Interferon in CML.

The Sass Foundation for Medical Research, Inc., Melville, NY, November 18, 1996.

**1995**

Visiting Faculty in Interferons: Interferon in the Treatment of Polycythemia Vera and Chronic Myeloid Leukemia: Medical Grand Rounds, South Nassau Community Hospital, Oceanside, NY, January 31, 1995

SUNY Health and Science Center, Syracuse, NY, February 16, 1995

Woodhull Medical Center, Bklyn, NY, April 5, 1995

Lenox Hill Hospital, New York, NY, April 11, 1995

Medical Grand Round, Saint John's Queens Hospital, Elmhurst, NY, June 9, 1995

Tumor Board, St. Mary's Hospital, Richmond, VA, October 10, 1995

Northern Westchester Hospital, Mt. Kisco, NY, October 20, 1995

Bowman Gray School of Medicine, Winston-Salem, NC, October 27, 1995

Hematology/Oncology Grand Rounds, St. Elizabeth's Hospital of Boston, Boston, MA, December 14, 1995.

Visiting Faculty In Interferon: Annenberg Center, June 2-3, 1995. Moshe Talpaz, M.D., Moderator; Howard Ozer, M.D., Richard T. Silver, M.D.

Update Your Medicine, 1995: Recent Advances in Polycythemia Vera and Chronic Myeloid Leukemia: Medical Grand Rounds, Cornell University Medical College, June 15.

**1994**

Symposium: Epoetin Alfa and 2‑CdA: Advances in Clinical Research and Treatment; Amelia Island, Florida, January 27‑30, 1994.

Interferon in Polycythemia Vera Essential Thrombocytosis: Hematology/Medical Oncology Conference, University of Maryland Cancer Center, Baltimore, February 14, 1994.

The Impact of Health Care Reform on Clinical Practice: Medical Grand Rounds, Mount Sinai Medical Center, New York, February 25, 1994.

Visiting Faculty, Chronic Myeloid Leukemia: Curriculum Development Roundtable. Annenberg Center, Rancho Mirage, California, April 14-15, Francis Giles, M.D., Moderator; Richard T. Silver, M.D., Moshe Talpaz, M.D.

Guest Moderator, Seminars in Oncology, New approaches to the treatment of cancer-related anemia: A panel discussion, Chairman

Visiting Faculty in Interferons, The Use of Interferon in the Treatment of Polycythemia Vera and Chronic Myeloid Leukemia; Montefiore Medical Center, Bronx, New York, June 2.

Polycythemia Vera Study Group, The Use of Interferon in the Treatment of Polycythemia Vera; Mount Sinai Medical Center, June 13.

Guest Lecture Series, Update of Management of Polycythemia Vera and Impact on Results; New York Methodist Hospital, June 15.

Update Your Medicine, New Therapies of Myeloproliferative Disorders; Cornell University Medical College, N.Y., June 16.

Frontiers in Oncology-Hematology: Hematological Malignancies, Cornell University Medical College, New York, NY, October 1.

International Symposium on Myeloproliferative Disorders: New Approaches to the Treatment of Polycythemia Vera: Mayo Clinic, Rochester, MN, October 15.

Understanding Growth Factors and Cytokines: Medical Grand Rounds,

Sarasota Memorial Hospital, Sarasota, FLA, October 21.

Interferon in the Treatment of Chronic Myeloid Leukemia and Polycythemia Vera: St. Mary's Hospital of Brooklyn, N.Y., November 17, White Plains Hospital, White Plains, N.Y., November 21.

Visiting Faculty in Interferons: Interferon in the Treatment of Chronic Myeloid Leukemia: Bethesda, MD, December 14.

**1993**

Novantrone ‑ Overview of Phase II Data: Lymphoma Advisory Board, Lederle Laboratories, New York, NY, February 26, 27, 1993.

New Concepts in the Treatment of Polycythemia Vera: St. Lukes/Roosevelt Hospital Center, NY, April 29, 1993

Mother Cabrini Medical Center, NY, June 18, 1993

St. Vincent's Hospital and Medical Center of New York, July 9, 1993;

Lenox Hill Medical Center,NY, October 19, 1993.

The Impact of Health Care Reform on Clinical Practice: The Impact of Health Care Reform on Cancer Care, The New York State Cancer Assoc. Program, North Shore University Hospital, October 15, 1993.

Special Symposium: New Approaches to the Treatment of Cancer‑Related Anemia, New York Hospital‑Cornell Medical Center and The New York State (Downstate) Society of Medical Oncologists and Hematologists; Cornell University Medical College, N.Y., October 23, 1993, Charmin.

Treatment of Breast Cancer: Medical Grand Rounds, Sarasota Memorial Hospital, Sarasota, FL., October 26, 1993. Invited Lecturer.

**1992**

Update on Myeloproliferative Disorders: Schering Lecture Series, University of Connecticut Health Center, Farmington, CT, March 18, 1992.

Recent Advances in the Treatment of Polycythemia Vera: Hematology‑Oncology Research Seminar, New York University Medical Center, April 3, 1992.

New Thoughts on the Management of Polycythemia Vera: Medical Grand Rounds, Beth Israel, NY, April 15, 1992.

Current Biological and Therapeutic Perspectives in Chronic Myelocytic Leukemia: The Grand Rounds of the Department of Neoplastic Diseases, Mount Sinai Medical Center, NY, April 17, 1992.

Anemia ‑ Chronic Disease: Recombinant Human Erythropoietin: Ortho Biotech Lecture Series, Valley Hospital, Ridgewood, NJ, April 21, 1992.

Anemia ‑ Chronic Disease: Recombinant Human Erythropoietin: Ortho Biotech, Lecture Series, St. Joseph's Hospital, Paterson, NJ, May 6, 1992.

Therapeutic Trials for Myeloproliferative Syndromes: Schering Lecture Series, St. Elizabeth Hospital, Boston, MA, June 4, 1992.

Modern Management of Hematologic Malignancies; the Use of Growth Factors, etc:

Update Your Medicine, Cornell University Medical School, N.Y., June 9, 1992.

Colony Stimulating Factors: From Laboratory to Clinical Applications: Amgen Lecture

Series, St. Vincent's Hospital, NY, June 22, 1992.

Pathogenesis and Treatment of Polycythemia Vera: Grand Rounds, Memorial Sloan‑Kettering Cancer Center, New York, NY, September 29, 1992.

Symposium on Bone Health and Disease: Focus on the Cancer Patient. New York Hospital-Cornell Medical Center, New York, NY, Chairman, December 12.

**1991**

Chronic Myeloid leukemia: An Update, Lederle "Distinguished Lecturer Series in Oncology", Children's Hospital and Adult Medical Center, San Francisco, California, February 14, 1991; Letterman Army Hospital, San Francisco, California, February 15, 1991

Oncology: A Multinational Interface‑Discussion of Treatment Modalities Worldwide: World Congress on Healthcare "The Role of Medical Professionals, Industry and Governments in a Decade of Global Change". World Healthcare Council, National Broadcast Satellite Corp. and Le Jacq Communications, Inc., The Equitable Center, New York, NY, May 23, 1991.

“Molecular Rearrangement within the 5.8 kb-bcr Region in an AML.” 8th International Congress of Human Genetics, Washington, D.C October 6-11, 1991.

Primary Interferon Therapy in Polycythemia Vera: The Chemotherapy Foundation, Advances in Innovative Oncology: Biomodulation,Chemoimmunotherapy and Selected Phase II Drugs", Mt. Sinai School of Med., NYC, November 7, 1991.

Update Oncology, Management of Hematologic Malignancies: Update Your Medicine, New York Hospital‑Cornell University Medical College, November 20, 1991.

Management of Hematologic Malignancies: Cornell at La Guardia Series, La Guardia Hospital, NY, December 4, 1991.

Chronic Myeloid Leukemia: Some Perspectives of the Clinical and Biologic Issues: Bristol‑Myers Squibb Symposium "Highlights in Oncology for the Hematologist", Denver, Colorado, December 6, 1991.

**1990**

Chronic Myeloid Leukemia: An Update, Lederle "Distinguished Lecturer Series in Oncology", Albert Einstein College of Medicine, Bronx, New York, NY, April 18, 1990. St.

Luke's Hospital, New York, NY, April 19, 1990; Mitoxantrone in Cancer Treatment, Lederle Seminar "Recent Advances in Oncology", Bayonne Hospital, Bayonne, NJ, April 24, 1990.

Chronic Myeloid Leukemia: An Update, Lederle Distinguished Lecturer Series in Oncology, Houston Blood Club, Houston, Texas, November 14, 1990.

**1989**

Activity of Novantrone in Breast Cancer, Lederle Seminar "Recent Advances in Oncology", Seattle, WA, April 8, 1989

Some New Thoughts Regarding Chronic Myelogenous Leukemia, Hematology Grand Rounds, The Mount Sinai Medical Center, NY, May 25, 1989

**1988**

Clinical Use of Intereferon in Leukemia, Medical Grand Rounds, Hackensack Medical Center, Hackensack, NJ February 9, 1988

Clinical and Genetic Interactions in Hematologic Disorders: Chronic Myeloid Leukemia, Hematology/Oncology for the 21st. Century, New Rochelle Hospital Medical Center, NY September 28, 1988

**1986**

Treatment of Chronic Myeloid Leukemia, Medical Grand Rounds, Interfaith Hospital, Brooklyn, NY

Update on Chronic Myelogenous Leukemia, Advances in Hematology and Oncology,

New York Hospital and Cornell Medical Center, April 30, 1986

Breast Cancer Update, Update Your Medicine, New York Hospital-Cornell Medical Center, June 10, 1986

Treatment of Chronic Myeloid Leukemia, Medical Grand Rounds, Pennsylvania State Medical College, Hersey, PA, June 19, 1986

Current Status of Chronic Myeloid Leukemia, Medical Grand Rounds, Memorial Medical Center, October 3, 1986

**1985**

Treatment of Non‑Hodgkin's Lymphoma, "Oncology Update," Bayley Seton Hospital,

January 18, 1985

Chronic Myelocytic Leukemia, Medical Grand Rounds New York Hospital – Cornell Medical Center, New York, New York, April 11, 1985, with Dr. Robert Gale

The Management of Carcinoma of the Breast, Clara Mass Medical Center, Belleville,

New Jersey, May 15, 1985

Update on Breast Cancer Management, Silver, R., New Jersey College of Medicine,

May 30, 1985

Chronic Myeloid Leukemia, Update Your Medicine, New York Hospital ‑ Cornell Medical Center, New York, New York, June 13, 1985

Hematology Update, Update your Medicine, New York Hospital‑Cornell Medical Center,

July 13, 1985

Chronic Myelogenous Leukemia, Texas Club of Internists 1985 Fall Clinical Meeting, Cornell Medical Center, New York, New York,October 9, 1985

Breast Cancer Update, Update Your Medicine, New York Hospital‑Cornell Medical Center, Lesnick G, McCormick B, Silver R, New York, NY, October 16, Non‑Hodgkins

Lymphoma, Flushing Hospital and Medical Center, Flushing, New York, November 14, 1985

**1984**

Chronic Leukemia, Lutheran Medical Center, Brooklyn, New York, February 2, 1984

Some Current Studies of CALGB, University Cancer Study Group Update, Tampa, FL, February 18, 1984

Satellite Conference on Mitoxantrone, New York City Moderator, February 23, 1984

Advances in the Pathogenesis and Therapy of Chronic Myelogenous Leukemia,

Downstate Medical Center, Brooklyn, New York, February 28, 1984

Lymphomas: 1984 Update, Flushing Hospital and Medical Center, Flushing, NY,

March 20, 1984

Polycythemia and the Myeloproliferative Syndromes, Long Island College Hospital,

Brooklyn, NY, April 10, 1984

Agnogenic Myeloid Metaplasia, Memorial Medical Center, Treatment of Polycythemia Vera, May, 1984, Savannah, GA

Update on Chronic Myelogenous Leukemia, Cancer Center Clinical Rounds,

The Mount Sinai Medical Center, New York, June 1, 1984

Symposium: Breast Cancer, Moderator; Advances in Hematology and Oncology course sponsored by the American College of Physicians at Cornell University Medical College, October 9, 1984

Chemotherapy of Breast Cancer; Advances in Hematology and Oncology course sponsored by the American College of Physicians at Cornell University Medical College,

October 9, 1984

Satellite Conference on Mitoxantrone, New York City Moderator, February 23, 1984

Current Status of Treatment of Chronic Leukemia, Doctors Hospital, November 15, 1984

**1983**

Treatment of Non‑Hodgkin's Lymphoma, Long Island College Hospital,March 1983

Treatments of Non‑Hodgkin's Lymphomas, White Plains Medical Center, March 1983

Symposium: Treatment of Breast Cancer, Cornell University Medical College, Update, June 1983

New Perspectives for the Hormonal Treatment of Breast Cancer, Program Chairman; participants: Allan Lipton, M.D., Professor of Medicine, Hershey Medical Center, I. Craig Henderson, M.D., Dana‑Farber Cancer Institute; Cornell University Medical College, September 20, 1983

Controversial Aspects in the Treatment of the Non‑Hodgkin's Lymphomas, Program Chairman; participants: George Cannellos, M.D., Dana‑Farber Cancer Institute, John Glick, M.D., University of Pennsylvania, and Morton Coleman, M.D., Cornell Medical Center: Cornell University Medical College, September 27, 1983

Treatment of Breast Cancer, Cabrini Hospital, October 1983

New Concepts in Chronic Myeloid Leukemia, Lenox Hill Hospital, November 1983

**1982**

Leukemia in the Adult: State of the Art, Flushing Hospital and Medical Center, Flushing, NY,

Poorly Differentiated Lymphoma, Mountainside Hospital, NJ

The Scientific Basis for Adjuvant Chemotherapy, American Cancer Society, Clara Mass Hospital, Belleville, NJ

Adjuvant Therapy of Breast Cancer, American Cancer Society, New Jersey Division

Clinical Pathology Conference, The Brooklyn Hospital, Brooklyn, NY

**1981**

Chemotherapy, American College of Physicians Symposium, Philadelphia, PA

Cancer and Leukemia Group B Update, Annual University Cancer Study Group Update, 1981 National Workshop, Clearwater, FL.

Chronic Myeloid Leukemia, Memorial Sloan-Kettering Cancer Center

Myelofibrosis, North Shore University Hospital, Don Monti Memorial Institute

Chronic Myeloid Leukemia, American College of Physicians, New York City

Update on Morphology, American College of Physicians, New York City

Adjuvant Chemotherapy of Breast Cancer, American College of Physicians,Westchester

Caring for the Leukemia Patient, Cornell University Medical College,

Chronic Myeloid Leukemia, Dept. of Neoplastic Diseases, Mount Sinai Hospital

**1980**

Update Your Medicine: Oncology, Cornell University Medical College

Concepts in Cancer Chemotherapy, Grand Rounds, Lenox Hill Hospital

Chronic Myeloid Leukemia, Grand Rounds, Nassau Medical Center

Clinical Concepts in Cancer Chemotherapy, Long Island College Hospital

Current Concepts in Chronic Myeloid Leukemia, Albert Einstein College of Medicine

New Concepts in the Treatment of Chronic Myeloid Leukemia, 5th Annual Symposium on

Advances in Cancer Treatment Research, University of Maryland

Understanding Clinical Cancer Chemotherapy, Metropolitan Hospital

Advances in Oncology: Agnogenic Myeloid Metaplasia, North Shore University Hospital.

New Concepts in the Treatment of CML, Columbia University College of Physicians and Surgeons

The Dying Patient, Death and Dying Seminar, Huron Hospital, Cleveland, OH,

Treatment of Leukemia, United Leukemia Fund Annual Luncheon

Current Concepts in Cancer Chemotherapy, Wycoff Hospital

Adjuvant Chemotherapy and Radiotherapy of Advanced Disease, Cornell University

Medical College Alumni Reunion

Myelofibrosis, Joint Meeting of the 18th Congress of the International Society of Hematology, Montreal Canada

New Thoughts in the Treatment of Blast Phase Chronic Myeloid Leukemia, Leukemia

Update, Leukemia Society of America (Program Chairman)

Clinical Chemotherapy Program in Cancer Control, New York State Cancer

Programs Association Annual Scientific Program, Memorial Sloan-Kettering Cancer Center

**1979**

Medical Management of Breast Cancer, Don Monti Memorial Research Foundation Lecture Series, North Shore University Hospital.

Third Annual Medical Symposium and Awards Luncheon, Leukemia Society of America, New York Medical College.

New Thoughts on the Treatment of Chronic Myeloid Leukemia, Advances in Hematology and Oncology, The Jewish Hospital and Medical Center of Brooklyn ,New Horizons in Colon Cancer, Cornell Unveristy Medical College Symposium

Chemotherapy, T.V. Seminar in Cancer Education, New York Medical College and Archdiocese of New York.

Chemotherapy of Leukemia and Lymphoma, Continuing Education Program, Doctors

Hospital, Death and Dying, Facing the Inevitable, Temple Emanu-El, New York City

Terminal illness, Topics in Medical Ethics, Cornell University Medical College

New Concepts in Chronic Myeloid Leukemia, Leukemia Symposium, Westchester Medical Center.

Symposium on Myeloproliferative Disorders, John Hoover Moon Memorial Lectureship, Medical College of Virginia

**1978**

Medical Grand Rounds: Montefiore Hospital; Mount Sinai Hospital; Beth Israel Hospital;

Lenox Hill Hospital

Myeloproliferative Syndromes, College of Physicians and Surgeons, New York, NY

Hematology-Oncology Course sponsored by the American College of Physicians and Surgeons, Cornell University Medical College, October 4-7: "Breast Cancer Symposium"; "Chemotherapy"; "Chronic Myeloid Leukemia"

Chairman, Leukemia Update Symposium, Leukemia Society of America, Medical Management of Breast Cancer, Don Monti Memorial Research Foundation, North Shore University Hospital.

New Concepts in the Chemotherapy of Acute Leukemia, Fourth Annual Symposium, New Jersey Cancer Society, Englewood Hospital

Update Your Medicine, Cornell University Medical College

New concepts in the Treatment of Chronic Granulocytic Leukemia: Fundamental and Clinical Aspects of Leukemia, Leukemia Research Foundation, Inc.

**1977**

Principles of Cancer Chemotherapy, Our Lady of Lourdes Hospital, Binghamton, NY

Medical Grand Rounds: Lenox Hill Hospital; Beth Israel Hospital

Hematology Grand Rounds, Roosevelt Hospital

Chemotherapy of Acute Leukemia, New Jersey Cancer Society, Englewood Hospital

Hematology Grand Rounds, Roosevelt Hospital

Faculty, Oncology Course, Mount Sinai School of Medicine

**Editorial Activities**

Guest Editor, Supplement News on the Treatment of Myeloproliferative Neoplasms published in Leukemia Research, Volume 44, Supplement 1, May 2016

Journal of Medicine, Journal of Clinical Oncology, Archives of Internal Medicine, Medical Research Council, UK, Hematology

Clinic Proceedings, Blood, Cancer, American Journal of Hematology, New York State

Ad hoc Reviewer: New England Journal of Medicine, Annals of Internal Medicine, Mayo

Member, Editorial Advisory Board, American Journal of Medicine, 1984

Member, Editorial Advisory Board, Cancer Investigation, 1983‑1993

Consultant Editor, American Journal of Medicine, 1974‑1994

Editor, Combined Clinical and Basic Science Seminars published in the American Journal of Medicine, 1973

**Boards and Directorships**

Rectory School Board of Trustees, 2003-present

Arnold R. Krakower Hematology Foundation 1966‑1975

Research for Blood Health, Inc. 1968‑1985

Trustee, Frances & Edwin Cummings Memorial Fund, 1985-1992

Vice President, Leukemia Society of America, New York City Chapter 1968‑1973

Medical Director, Cancer Research and Treatment Fund, 1985-Present Sass Foundation:

The Advisory Board 1985

**Societies and Scientific Organizations**

American College of Physicians

International Society of Hematology

American Society of Hematology

New York Society for the Study of Blood

New York County and State Medical Society

Harvey Society

Society of Sigma XI

American Federation for Clinical Research

American Society of Clinical Oncology

American Association for Cancer Research

New York State Society (Downstate) of Medical Oncologists and Hematologists

Chairman, Scientific Advisory Committee, 1982-85

Board of Directors, 1976‑1978

Explorers Club, 1962

**Visiting Professorships**

East Carolina – Brody School of Medicine, 2007

Hadassah Hospital, Jerusalem, Israel, 1994

Memorial Medical Center, Savannah, GA, September, 1986

New Jersey College of Medicine, May, 1985

University of Georgia, Memorial Medical Center, Savannah, April 1984

New Jersey College of Medicine, New Brunswick, N.J., January 1983

Columbia University Medical School, Post‑Graduate Course, "Current Concepts in Hematopathology," 1982

Medical College of Virginia, 1979

Upstate Medical Center, Binghamton, N.Y., October 1977

Mayo Clinic, July 1977

Pennsylvania State Medical School, Hershey Hospital, June 1976

**Special Listings**

Who's Who in America

Who's Who in the East

American Men of Science

Who's Who in Cancer

Who's Who in Frontier Science and Technology

Who’s Who in Medicine and Healthcare

Who’s Who in the World